{"docstore/data": {"ee6ae5b2-2503-4fa2-8ba9-6ea67573ab57": {"__data__": {"id_": "ee6ae5b2-2503-4fa2-8ba9-6ea67573ab57", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter. ", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db1ed0e1-54e2-4c2d-b916-d6ccd9fc9832", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter. ", "original_text": "Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year. "}, "hash": "ffff9012c90f5f9c81c4de713da4b11279bdd1d8524346d7775adad2cc047836", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion. ", "start_char_idx": 0, "end_char_idx": 639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db1ed0e1-54e2-4c2d-b916-d6ccd9fc9832": {"__data__": {"id_": "db1ed0e1-54e2-4c2d-b916-d6ccd9fc9832", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter. ", "original_text": "Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee6ae5b2-2503-4fa2-8ba9-6ea67573ab57", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter. ", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45b1bfdd2faa9b0ca48a4fdcaae7a8109bb57279f344f2717aa2baa0d76fcc46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92e0c04e-820d-4eee-9f56-c43faab2865a", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 . ", "original_text": "On the basis of U.S. "}, "hash": "09c4679b8bbdc0cddfa08e59806d5e4512d624aee6bd4870a458373005725e0b", "class_name": "RelatedNodeInfo"}}, "text": "Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year. ", "start_char_idx": 639, "end_char_idx": 709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92e0c04e-820d-4eee-9f56-c43faab2865a": {"__data__": {"id_": "92e0c04e-820d-4eee-9f56-c43faab2865a", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 . ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db1ed0e1-54e2-4c2d-b916-d6ccd9fc9832", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter. ", "original_text": "Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3782513879486e4eee5bfbd2c781ee74dbb4f3b6af3b43686bef8a5def0856b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "128f7cbb-d598-4dc1-8ffd-d3aaea15774e", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n", "original_text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter. "}, "hash": "d250a437c4e88cee3f553954da45ba68f53bb157c8a1869a200ea327c73272c2", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 709, "end_char_idx": 730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "128f7cbb-d598-4dc1-8ffd-d3aaea15774e": {"__data__": {"id_": "128f7cbb-d598-4dc1-8ffd-d3aaea15774e", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n", "original_text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92e0c04e-820d-4eee-9f56-c43faab2865a", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 . ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bc05839f261343d10b6e604b86fbcdbfdaceff2afc59ae3ffe858134131737e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32724e6c-0ce1-4427-a280-7dfd48e92f53", "node_type": "1", "metadata": {"window": "Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities. ", "original_text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter. "}, "hash": "d7309d02c37f999097f84c9ff3dc4b87a420ce63cb367881da44ebd47660a823", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter. ", "start_char_idx": 730, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32724e6c-0ce1-4427-a280-7dfd48e92f53": {"__data__": {"id_": "32724e6c-0ce1-4427-a280-7dfd48e92f53", "embedding": null, "metadata": {"window": "Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities. ", "original_text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "128f7cbb-d598-4dc1-8ffd-d3aaea15774e", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n", "original_text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5d7055b5efc37370f3e38dafb9aab29c2bec9bf2a48584f193ac00b2a15e9cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7f5f27c-031e-45ee-9e94-9e99cb14d96e", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n", "original_text": "For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 . "}, "hash": "f4368bb911e068bee215dd38b5fe6632e1291e15dfd68b7be0b128b5a05824dd", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter. ", "start_char_idx": 909, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7f5f27c-031e-45ee-9e94-9e99cb14d96e": {"__data__": {"id_": "b7f5f27c-031e-45ee-9e94-9e99cb14d96e", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n", "original_text": "For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 . ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32724e6c-0ce1-4427-a280-7dfd48e92f53", "node_type": "1", "metadata": {"window": "Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities. ", "original_text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caedc040e576ea15450f5aaacb8500dbbfb2f33fa280811ff364d062fe20fa6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adc2b52c-56f7-48be-8a87-d7b23ef59198", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr. ", "original_text": "For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n"}, "hash": "787cbf64b1dbd02210382927fbff59e1bd71853c8db5f14d611d9114a40f4f45", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 . ", "start_char_idx": 1058, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adc2b52c-56f7-48be-8a87-d7b23ef59198": {"__data__": {"id_": "adc2b52c-56f7-48be-8a87-d7b23ef59198", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr. ", "original_text": "For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7f5f27c-031e-45ee-9e94-9e99cb14d96e", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n", "original_text": "For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 . ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c57c2f0e071ecd233a82f58f680988d92c16fd9c49ade7b61b70be811710933", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f099b2c-5412-43a8-9ac2-cf4e10bdc597", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued. ", "original_text": "\u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities. "}, "hash": "5fb00ae94669756c3daf5185ad945ceaae3157283192b2c90e31370906de969b", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n", "start_char_idx": 1125, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f099b2c-5412-43a8-9ac2-cf4e10bdc597": {"__data__": {"id_": "1f099b2c-5412-43a8-9ac2-cf4e10bdc597", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued. ", "original_text": "\u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adc2b52c-56f7-48be-8a87-d7b23ef59198", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr. ", "original_text": "For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94d213c509ba6f9d7ead72434a8921cc77663c37728ce1547290fad1b0f126c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90b6d25b-e13b-424b-96cb-324c4eaf5a23", "node_type": "1", "metadata": {"window": "For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n"}, "hash": "8c07dda097ff92852a9ae2b1728c4c71584bfa0276a3d5a782bf4191af75002c", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities. ", "start_char_idx": 1202, "end_char_idx": 1360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90b6d25b-e13b-424b-96cb-324c4eaf5a23": {"__data__": {"id_": "90b6d25b-e13b-424b-96cb-324c4eaf5a23", "embedding": null, "metadata": {"window": "For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f099b2c-5412-43a8-9ac2-cf4e10bdc597", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 8.8 percent to $2.60 in the fiscal fourth quarter.  For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued. ", "original_text": "\u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a5a18287f2a1b534d57a787eb34b58cdb07ba669432bfe1869fc9ab5d1944d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1475d67-ae7e-4bf7-aea2-874a11740043", "node_type": "1", "metadata": {"window": "For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "\u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr. "}, "hash": "da320af7b60543f84b4495e6ebab6c82708fc151eb5aa05a600b2d9b279e25c4", "class_name": "RelatedNodeInfo"}}, "text": "Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n", "start_char_idx": 1360, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1475d67-ae7e-4bf7-aea2-874a11740043": {"__data__": {"id_": "c1475d67-ae7e-4bf7-aea2-874a11740043", "embedding": null, "metadata": {"window": "For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "\u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90b6d25b-e13b-424b-96cb-324c4eaf5a23", "node_type": "1", "metadata": {"window": "For fiscal year 2022,\ndiluted EPS increased 8.8 percent to $8.04 .  For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d20dde9d5fe2e7d6f4ca4426710b67913cd739a6e8e9fcb9506f5b4dd8580168", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48ea8a4b-3ea1-4c22-a21b-72354b56689c", "node_type": "1", "metadata": {"window": "\u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "Collis continued. "}, "hash": "5d24da6676a9122e29dabda1d92f7322fb0e8db8b237010fb93966e154178987", "class_name": "RelatedNodeInfo"}}, "text": "\u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr. ", "start_char_idx": 1618, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48ea8a4b-3ea1-4c22-a21b-72354b56689c": {"__data__": {"id_": "48ea8a4b-3ea1-4c22-a21b-72354b56689c", "embedding": null, "metadata": {"window": "\u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1475d67-ae7e-4bf7-aea2-874a11740043", "node_type": "1", "metadata": {"window": "For fiscal year 2022, adjusted diluted EPS increased 19.1 percent to $11.03.\n \u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "\u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d055e3867ef86ccfb8b432c3b209ad02987519d305854126fdf6cefcc3832bd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cb60628-419c-4fab-a98d-cebc8ba02ede", "node_type": "1", "metadata": {"window": "Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "\u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1"}, "hash": "bddc3a5c101246123460ff26295084e4085bc82afe37160c2e6772976844b2c9", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1850, "end_char_idx": 1868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cb60628-419c-4fab-a98d-cebc8ba02ede": {"__data__": {"id_": "4cb60628-419c-4fab-a98d-cebc8ba02ede", "embedding": null, "metadata": {"window": "Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "\u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1b6503173d715661e4a73cd4de222e4827c39341a0a3414dcf7477e14c196", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48ea8a4b-3ea1-4c22-a21b-72354b56689c", "node_type": "1", "metadata": {"window": "\u201cAmerisourceBergen delivered strong performance in our 2022 fiscal year as our team\u2019s execution excellence allowed us to deliver\non our strategic priorities.  Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b25b662cb993e38613dadbbe49647b55e465633ed532079e9c120f7b43e39b93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efce9afa-ac43-4b39-9f8e-0c01557da49e", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S. ", "original_text": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. "}, "hash": "bfc315dbffd92f6c7beeff64892ee1fa263dcb0a4fc068cfb5be212eb6dd00ae", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "start_char_idx": 1868, "end_char_idx": 2472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efce9afa-ac43-4b39-9f8e-0c01557da49e": {"__data__": {"id_": "efce9afa-ac43-4b39-9f8e-0c01557da49e", "embedding": null, "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S. ", "original_text": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cb60628-419c-4fab-a98d-cebc8ba02ede", "node_type": "1", "metadata": {"window": "Our leading capabilities in pharmaceutical distribution and manufacturer solutions enable us to play our\ncore role in advancing pharmaceutical innovation and access,\u201d said Steven H. Collis, Chairman, President & Chief Executive Officer of\nAmerisourceBergen.\n \u201cUnited by our purpose, our team members have positioned us well to execute on our long-term strategic vision of expanding our\nleadership in distribution while continuing to grow our higher-margin and higher-growth businesses,\u201d Mr.  Collis continued.  \u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "original_text": "\u201cAs we\nenter a new fiscal year, we are uniquely positioned to deliver long-term value creation to our stakeholders as we advance our\nfoundation, enhance our capabilities, and invest in innovation to further drive our differentiation.\u201d\nFour th Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $61.2B $61.2B\nGross Pr ofit $2.0B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $455M $741M\nInterest Expense, Net $52M $52M\nEffectiv e Tax Rat e 21.9% 19.8%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $295M $546M\nDilut ed Earnings P er Shar e $1.40 $2.60\n1", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f805fe836cfab2b4669685bb58a0d17f34a5a6b17d5df01215638b7a09e856be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fa95183-63cb-40a9-a312-713ecdc9ed66", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "98b6f77e9328ca31dc39fe197d22caccd8fdeeef89f4d15acf85f60e8208631e", "class_name": "RelatedNodeInfo"}}, "text": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "start_char_idx": 0, "end_char_idx": 180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fa95183-63cb-40a9-a312-713ecdc9ed66": {"__data__": {"id_": "4fa95183-63cb-40a9-a312-713ecdc9ed66", "embedding": null, "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efce9afa-ac43-4b39-9f8e-0c01557da49e", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S. ", "original_text": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28c11b5011b94891090eb379687f4e94f1af407245888194f75d5da40d39db1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06151153-aab5-42e3-87b3-9bb31a3bc800", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year. ", "original_text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n"}, "hash": "d4b1eb92f4c9064d2f95f61d68440ff6c52697b216311133c99a93bb27968a5f", "class_name": "RelatedNodeInfo"}}, "text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 180, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06151153-aab5-42e3-87b3-9bb31a3bc800": {"__data__": {"id_": "06151153-aab5-42e3-87b3-9bb31a3bc800", "embedding": null, "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year. ", "original_text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fa95183-63cb-40a9-a312-713ecdc9ed66", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e26f12f6b1f369524a133b4289989a195cc8de801ea1dd9d0e3e8b276f0575d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e77d2d38-e641-4add-8904-d9549d74e747", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation. ", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S. "}, "hash": "da2fbe7788965de82202a0929059323ed4f74831d424004b82c624863239bfa0", "class_name": "RelatedNodeInfo"}}, "text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n", "start_char_idx": 272, "end_char_idx": 491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e77d2d38-e641-4add-8904-d9549d74e747": {"__data__": {"id_": "e77d2d38-e641-4add-8904-d9549d74e747", "embedding": null, "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation. ", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06151153-aab5-42e3-87b3-9bb31a3bc800", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year. ", "original_text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31343e9134c1fe7da6b2e9d8e595bc576b10215000806c51020aaa09cd1c1d1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8098cf5e-f5bf-43f9-81f1-a86f1861194a", "node_type": "1", "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S. ", "original_text": "Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n"}, "hash": "8c2bb016df10f7f75d4ad75a4baa2854bb2af4581c97c899cca9284d25c336a2", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S. ", "start_char_idx": 491, "end_char_idx": 712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8098cf5e-f5bf-43f9-81f1-a86f1861194a": {"__data__": {"id_": "8098cf5e-f5bf-43f9-81f1-a86f1861194a", "embedding": null, "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S. ", "original_text": "Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e77d2d38-e641-4add-8904-d9549d74e747", "node_type": "1", "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation. ", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5746ff87851dab93084024312d24982c207efb9b265ef89cb6d27bab0c3d3d71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d08a53c-9fb5-4543-8912-b9ab034c0f3f", "node_type": "1", "metadata": {"window": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year. "}, "hash": "8b831e40f1b1e90e742dbbd80076ed3cdf57793c70f6ccacca559a51ae9ba75e", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n", "start_char_idx": 712, "end_char_idx": 881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d08a53c-9fb5-4543-8912-b9ab034c0f3f": {"__data__": {"id_": "1d08a53c-9fb5-4543-8912-b9ab034c0f3f", "embedding": null, "metadata": {"window": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8098cf5e-f5bf-43f9-81f1-a86f1861194a", "node_type": "1", "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S. ", "original_text": "Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bdd3f0fd673f6ec217d26c5ae6aaf17bbfc4ec74e0f0b78ad196c6a7edd53a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b03e6d8-60fa-4842-91d5-926e5ebf2d5f", "node_type": "1", "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n", "original_text": "Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation. "}, "hash": "93d427e96434658db16b09eec8adc9963c27a988e6f39661d330914ec4b3dc48", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year. ", "start_char_idx": 881, "end_char_idx": 1041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b03e6d8-60fa-4842-91d5-926e5ebf2d5f": {"__data__": {"id_": "6b03e6d8-60fa-4842-91d5-926e5ebf2d5f", "embedding": null, "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n", "original_text": "Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d08a53c-9fb5-4543-8912-b9ab034c0f3f", "node_type": "1", "metadata": {"window": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ddeded1911e8c5a3f43669e555097bc936bdef70d454b82f1217c0773c3fb3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9b6cc8e-8090-407a-ab57-4d44dce365f7", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses. ", "original_text": "The decrease was offset in part by an\nincrease in gross profit in U.S. "}, "hash": "3348c642a763fb01144d5594babfbd3226771a1406170ed0f79bac860e7e285b", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation. ", "start_char_idx": 1041, "end_char_idx": 1345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9b6cc8e-8090-407a-ab57-4d44dce365f7": {"__data__": {"id_": "a9b6cc8e-8090-407a-ab57-4d44dce365f7", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses. ", "original_text": "The decrease was offset in part by an\nincrease in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b03e6d8-60fa-4842-91d5-926e5ebf2d5f", "node_type": "1", "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S.  Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n", "original_text": "Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98ff43716cba39c3ec9a43f86c59aa7c5ff145f8708d67bdb80be59ae1e58d5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13ba6ed1-5f06-44cb-a2d0-876d2f7b09a3", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n", "original_text": "Healthcare Solutions. "}, "hash": "364e4fe79a21b7c958f0226d754eabc5a176addba76d1382617c9b7cfdcdabde", "class_name": "RelatedNodeInfo"}}, "text": "The decrease was offset in part by an\nincrease in gross profit in U.S. ", "start_char_idx": 1345, "end_char_idx": 1416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13ba6ed1-5f06-44cb-a2d0-876d2f7b09a3": {"__data__": {"id_": "13ba6ed1-5f06-44cb-a2d0-876d2f7b09a3", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n", "original_text": "Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9b6cc8e-8090-407a-ab57-4d44dce365f7", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue and a 2.7 percent decrease in\nrevenue within International Healthcare Solutions due to the negative impact of foreign currency translation.\n Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses. ", "original_text": "The decrease was offset in part by an\nincrease in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da61ee323cb4f942d1eba0a9572645c33860d07a93b06d2460ce2081551c4cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "565b5fd3-f266-40df-a747-ed3b80e794a7", "node_type": "1", "metadata": {"window": "Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses. ", "original_text": "Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n"}, "hash": "99e1989fa1866482d5a77636723f7af954687afa1fa4956b0eb1aba6fb2ca135", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions. ", "start_char_idx": 1416, "end_char_idx": 1438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "565b5fd3-f266-40df-a747-ed3b80e794a7": {"__data__": {"id_": "565b5fd3-f266-40df-a747-ed3b80e794a7", "embedding": null, "metadata": {"window": "Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses. ", "original_text": "Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13ba6ed1-5f06-44cb-a2d0-876d2f7b09a3", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2022 fourth quarter was $2.0 billion, a 4.1 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n", "original_text": "Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10d74efc18614eda560ee6d0157ff7c79e8f092428dd23444b2b8b2a233c62e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1facaba3-fe33-4505-bb60-97b89257a541", "node_type": "1", "metadata": {"window": "The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses. "}, "hash": "b95b8478a738b135643f1c6f0d491027e57ae15257a9550e58fb4e8eefb0a596", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n", "start_char_idx": 1438, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1facaba3-fe33-4505-bb60-97b89257a541": {"__data__": {"id_": "1facaba3-fe33-4505-bb60-97b89257a541", "embedding": null, "metadata": {"window": "The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "565b5fd3-f266-40df-a747-ed3b80e794a7", "node_type": "1", "metadata": {"window": "Gross profit was unfavorably impacted by LIFO expense of $104.8 million in the current year\nperiod versus a LIFO credit of $42.5 million in the previous fiscal year period and a decline in gross profit within International\nHealthcare Solutions due to the negative impact of foreign currency translation.  The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses. ", "original_text": "Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d16e9d97cb29d6643dd1e14a6103b4149c03a934f1a90db45775ef070c06ea7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c1aa6fc-e4e2-4e6e-8f94-9164d7847bbe", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n", "original_text": "Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n"}, "hash": "98025272ea3030246fb71aee1ea58c372a27d88da52280268c4ca95a4fa5a5c4", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses. ", "start_char_idx": 1554, "end_char_idx": 1794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c1aa6fc-e4e2-4e6e-8f94-9164d7847bbe": {"__data__": {"id_": "8c1aa6fc-e4e2-4e6e-8f94-9164d7847bbe", "embedding": null, "metadata": {"window": "Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n", "original_text": "Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1facaba3-fe33-4505-bb60-97b89257a541", "node_type": "1", "metadata": {"window": "The decrease was offset in part by an\nincrease in gross profit in U.S.  Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ee1389278d88a10961810fee7581fb82670ce5a21cd9cda1358a785fecde997", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2c95d30-2727-4c02-b486-472baed2028e", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022. ", "original_text": "Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses. "}, "hash": "eaf7314d5ddc20e715710dbac6dd6a47c3b8e6fd7ad81abd2ff03ff9379807ac", "class_name": "RelatedNodeInfo"}}, "text": "Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n", "start_char_idx": 1794, "end_char_idx": 1966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2c95d30-2727-4c02-b486-472baed2028e": {"__data__": {"id_": "e2c95d30-2727-4c02-b486-472baed2028e", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022. ", "original_text": "Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c1aa6fc-e4e2-4e6e-8f94-9164d7847bbe", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n", "original_text": "Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1bd7f3e3c322a2598dac7faf02174b054a2a65711f799f5d80589c180e47453", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09b25521-bc96-4f9e-bacf-a98c9566121c", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n", "original_text": "Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n"}, "hash": "856325e98552c86be6e87e053bb03e291e10d59e481ad2fb7e824aa7196c28fc", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses. ", "start_char_idx": 1966, "end_char_idx": 2176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09b25521-bc96-4f9e-bacf-a98c9566121c": {"__data__": {"id_": "09b25521-bc96-4f9e-bacf-a98c9566121c", "embedding": null, "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n", "original_text": "Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2c95d30-2727-4c02-b486-472baed2028e", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.25 percent, a decline of 26\nbasis points from the prior year quarter.\n Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022. ", "original_text": "Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4aabaa964e49ca26b0fa4e6bf26a0115f00133d7792ffd57bb30f7dfb171246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "566b8bd0-bb9c-478d-86b2-9e8240a51012", "node_type": "1", "metadata": {"window": "Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n"}, "hash": "926509117fc70a5c36b46b30ce4f2e26e75a1e7d3613a59eff68b3a0fa497312", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n", "start_char_idx": 2176, "end_char_idx": 2348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "566b8bd0-bb9c-478d-86b2-9e8240a51012": {"__data__": {"id_": "566b8bd0-bb9c-478d-86b2-9e8240a51012", "embedding": null, "metadata": {"window": "Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09b25521-bc96-4f9e-bacf-a98c9566121c", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2022, operating expenses were $1.5 billion, up 1.6 percent from the same\nperiod last fiscal year, primarily a result of an increase in distribution, selling, and administrative expenses.  Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n", "original_text": "Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50419551fe5b2480ccefe400d12f6686369b3ca50e330aa8187c2a2b6ae8bad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55a21817-ccc6-4ac7-b9a5-f8d87fd09841", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022. "}, "hash": "7b5b62fc67a20f777838f3a69394f97a130af4a09996b1d6c51808f9f1627144", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n", "start_char_idx": 2348, "end_char_idx": 2583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55a21817-ccc6-4ac7-b9a5-f8d87fd09841": {"__data__": {"id_": "55a21817-ccc6-4ac7-b9a5-f8d87fd09841", "embedding": null, "metadata": {"window": "Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "566b8bd0-bb9c-478d-86b2-9e8240a51012", "node_type": "1", "metadata": {"window": "Operating\nexpenses as a percentage of revenue in the fiscal 2022 fourth quarter were 2.50 percent compared to 2.56 percent for the\nsame period in the previous fiscal year.\n Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4dd5a5d04e055e162b8b3ec90a4e0a0599058ca0768586a149344253739d787e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbaa7845-620c-44ec-918e-8a66d9412d1e", "node_type": "1", "metadata": {"window": "Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 21.2 percent\nin the prior year quarter.\n"}, "hash": "aa35c82e11bc478c5be0f60af800ecc5ca294f2a856c542a35a79523ca3b823b", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022. ", "start_char_idx": 2583, "end_char_idx": 2683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbaa7845-620c-44ec-918e-8a66d9412d1e": {"__data__": {"id_": "bbaa7845-620c-44ec-918e-8a66d9412d1e", "embedding": null, "metadata": {"window": "Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 21.2 percent\nin the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55a21817-ccc6-4ac7-b9a5-f8d87fd09841", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2022 fourth quarter, operating income was $454.5 million versus $561.9 million in the prior\nyear quarter due to the decrease in gross profit and increase in operating expenses.  Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c42c8aa653e1ad7667fb3b5e6fc9824dc42ec4b846b3aa7f7d6cac112949deba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d361b967-ea7e-4eba-bf48-9db31743d9f4", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n"}, "hash": "7656dec1d2040e0d18a4b63a359572d923ac96f707cfa2b6b482b4663d755ada", "class_name": "RelatedNodeInfo"}}, "text": "This compares to 21.2 percent\nin the prior year quarter.\n", "start_char_idx": 2683, "end_char_idx": 2740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d361b967-ea7e-4eba-bf48-9db31743d9f4": {"__data__": {"id_": "d361b967-ea7e-4eba-bf48-9db31743d9f4", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbaa7845-620c-44ec-918e-8a66d9412d1e", "node_type": "1", "metadata": {"window": "Operating income as a percentage of\nrevenue was 0.74 percent in the fourth quarter of fiscal 2022 compared to 0.95 percent for the same period in the previous\nfiscal year.\n Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 21.2 percent\nin the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a2d569d34b43007ee5acca82f4db3782cd11a36ca7f4958b9d478d2dec4a973", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4658214-60b0-43b8-a5db-bf38c407ef86", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n"}, "hash": "28cfb78e4329e171ada9c600cdeb2f3232e743818a7d4fb26eda5f42e1a4aaba", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n", "start_char_idx": 2740, "end_char_idx": 2905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4658214-60b0-43b8-a5db-bf38c407ef86": {"__data__": {"id_": "c4658214-60b0-43b8-a5db-bf38c407ef86", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d361b967-ea7e-4eba-bf48-9db31743d9f4", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2022 fourth quarter, net interest expense of $51.5 million was down 5.6 percent versus the\nprior year quarter due to an increase in interest income as a result of higher investment interest rates.\n Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48ab6e7bf62b8022396f7d0c9f4d3b78ccaf506067fc4fd1348ab3ecbf56ff91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa9e5732-c343-4196-b2b8-13012845a233", "node_type": "1", "metadata": {"window": "This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S. ", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "edf3da182b2342dd7cb9e541eaeff5b1241a623686b1e019dedccb6b5262ef1b", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n", "start_char_idx": 2905, "end_char_idx": 3211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa9e5732-c343-4196-b2b8-13012845a233": {"__data__": {"id_": "fa9e5732-c343-4196-b2b8-13012845a233", "embedding": null, "metadata": {"window": "This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S. ", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4658214-60b0-43b8-a5db-bf38c407ef86", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 21.9 percent for the fourth quarter of fiscal 2022.  This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1878b3c1dc1b23d083711219998dcb1f3bf823fc935e4fa97b9b949bacbf8405", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "934cc17c-05d9-4e76-83ee-99e10ee7f1e1", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation. ", "original_text": "In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n"}, "hash": "a35403f4e6b164843a98228e9b91240945735d9a80e9e802e49db4e4914a77c5", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3211, "end_char_idx": 3330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "934cc17c-05d9-4e76-83ee-99e10ee7f1e1": {"__data__": {"id_": "934cc17c-05d9-4e76-83ee-99e10ee7f1e1", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation. ", "original_text": "In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa9e5732-c343-4196-b2b8-13012845a233", "node_type": "1", "metadata": {"window": "This compares to 21.2 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S. ", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82680ecdccbec02b4d17a4e7406d0f53b832bd94dbc0c263d36087b956129d78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56d12f6e-9f64-4fca-9783-23b8b04dcde5", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n"}, "hash": "a3d25e734807165eb358db2566791af223a683cec415ce63b3e26c91ef75cfec", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n", "start_char_idx": 3330, "end_char_idx": 3510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56d12f6e-9f64-4fca-9783-23b8b04dcde5": {"__data__": {"id_": "56d12f6e-9f64-4fca-9783-23b8b04dcde5", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "934cc17c-05d9-4e76-83ee-99e10ee7f1e1", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the fourth quarter of fiscal 2022 compared to $2.08 in the\nprevious fiscal year fourth quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation. ", "original_text": "In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92b4c60a01d559ab1027ed8fed135ace331b677b2e14d31f6c12c7c63d144b9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee6d63cf-fb6c-4d1f-b849-5f1d50339264", "node_type": "1", "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S. "}, "hash": "af6877c412e99a5dbbcfeb51629f1074d07d4542bf196ce7f4122a02ad90b27e", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n", "start_char_idx": 3510, "end_char_idx": 3679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee6d63cf-fb6c-4d1f-b849-5f1d50339264": {"__data__": {"id_": "ee6d63cf-fb6c-4d1f-b849-5f1d50339264", "embedding": null, "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56d12f6e-9f64-4fca-9783-23b8b04dcde5", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0\nmillion, a 0.4 percent decline versus the prior fiscal year fourth quarter primarily due to share repurchases, partially offset by\nstock option exercises and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18510a3420f2141563b98dfb808e3ed06b262336388eb3f82dea3348707c7fb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de7b98fc-7c4d-4cc8-a5dc-81e7f2b1455e", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation. "}, "hash": "e30b2cb837a63d2bb4e8c4a633130bf640205152a37e2de1fa7b09a9d7284514", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S. ", "start_char_idx": 3679, "end_char_idx": 3901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de7b98fc-7c4d-4cc8-a5dc-81e7f2b1455e": {"__data__": {"id_": "de7b98fc-7c4d-4cc8-a5dc-81e7f2b1455e", "embedding": null, "metadata": {"window": "In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee6d63cf-fb6c-4d1f-b849-5f1d50339264", "node_type": "1", "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9bd929356210fcab2a3296e0713ad1a8173e6bd2f6bcf6e1c6b2519d1fe1c9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfda1178-e301-4ae3-a628-be03c2a6375f", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n"}, "hash": "d7302e96d5aa73e5048fc9197f56ca3261cc78bb716c824279cfc64d678b963f", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation. ", "start_char_idx": 3901, "end_char_idx": 4071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfda1178-e301-4ae3-a628-be03c2a6375f": {"__data__": {"id_": "bfda1178-e301-4ae3-a628-be03c2a6375f", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de7b98fc-7c4d-4cc8-a5dc-81e7f2b1455e", "node_type": "1", "metadata": {"window": "In the fourth quarter of fiscal 2022, revenue was\n$61.2 billion, up 3.8 percent compared to the same quarter in the previous fiscal year, reflecting a 4.7 percent increase in U.S.\n Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8459b009a0f3b21479aaf693fcc95d97a70dac332aec8892243daa313883dc30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6eb0c918-36cc-4c04-89fa-ed32d28a6ae1", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "2"}, "hash": "8b05d76d1629f0f6134d5f183bb86930043c1aa2088682da6cedad4e9b523520", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n", "start_char_idx": 4071, "end_char_idx": 4243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6eb0c918-36cc-4c04-89fa-ed32d28a6ae1": {"__data__": {"id_": "6eb0c918-36cc-4c04-89fa-ed32d28a6ae1", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "2", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7544e346ec87fd9919443e3527acd3219124225f75fa3bc80fa4b843019d08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfda1178-e301-4ae3-a628-be03c2a6375f", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue and a 2.7 percent decrease in revenue within International Healthcare Solutions due to the\nnegative impact of foreign currency translation.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc31abec3d9b3ca1aad39cdff05572a4b36b2f55ee34b8a8d14664d525c73b45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caeca9e1-6294-4aa2-8cab-a110a16f3167", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation. ", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter. "}, "hash": "6e42b8931ac7c33669d93d7471da03cadcd259a7bed69b7913f8a9907e538ba3", "class_name": "RelatedNodeInfo"}}, "text": "2", "start_char_idx": 29, "end_char_idx": 30, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caeca9e1-6294-4aa2-8cab-a110a16f3167": {"__data__": {"id_": "caeca9e1-6294-4aa2-8cab-a110a16f3167", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation. ", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6eb0c918-36cc-4c04-89fa-ed32d28a6ae1", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2022 fourth quarter was $2.1 billion, which was up 4.8 percent\ncompared to the same period in the previous fiscal year due to an increase in gross profit in U.S.  Healthcare Solutions,\npartially offset by a decline in gross profit within International Healthcare Solutions due to the negative impact of foreign\ncurrency translation.  Adjusted gross profit as a percentage of revenue was 3.44 percent in the fiscal 2022 fourth quarter, an\nincrease of 4 basis points when compared to the prior year quarter.\n 2", "original_text": "2", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "915710563053621c46593931f14e796b7b246d7d17c2574065176a133ef8bf90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bc5add5-e9ba-4615-8ec2-93db69a5800e", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n", "original_text": "Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n"}, "hash": "d498ca90aeea3cf3a935b62587c6b4148f561a0c3b1abb3d2191b0e75c815132", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter. ", "start_char_idx": 0, "end_char_idx": 317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bc5add5-e9ba-4615-8ec2-93db69a5800e": {"__data__": {"id_": "2bc5add5-e9ba-4615-8ec2-93db69a5800e", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n", "original_text": "Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caeca9e1-6294-4aa2-8cab-a110a16f3167", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation. ", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ccbd2dec721ec4a648dea424d23e7d491e00dfae3384f2dc634339c1bcaac0cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ccacf68-1e22-4e7c-a204-005c835df1a6", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S. "}, "hash": "deee39a40b61a5660ec9c975ecb72040193caa32fe7200714505a340dbd96950", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n", "start_char_idx": 317, "end_char_idx": 470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ccacf68-1e22-4e7c-a204-005c835df1a6": {"__data__": {"id_": "9ccacf68-1e22-4e7c-a204-005c835df1a6", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bc5add5-e9ba-4615-8ec2-93db69a5800e", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n", "original_text": "Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59a128933a9c130d0de63e6ee361f9410bae3666f535235a58770020d9fa55ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "794266ea-a583-4b91-ab65-09bebafab231", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n", "original_text": "Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation. "}, "hash": "d24b801f11c47d4f41dce5ad8f15c61485fdb614a72613f533297d2904dca511", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S. ", "start_char_idx": 470, "end_char_idx": 666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "794266ea-a583-4b91-ab65-09bebafab231": {"__data__": {"id_": "794266ea-a583-4b91-ab65-09bebafab231", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n", "original_text": "Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ccacf68-1e22-4e7c-a204-005c835df1a6", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0bb328606e1850623ad76f62b27847bd11defde0ebc65325f84992f3cb7f04a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8754192d-95a4-4f82-924d-6e8140df1749", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n"}, "hash": "0d2324b723f0a06109d09f87afd76bd827829ed1d16d5c7201f5dac1820b4736", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation. ", "start_char_idx": 666, "end_char_idx": 872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8754192d-95a4-4f82-924d-6e8140df1749": {"__data__": {"id_": "8754192d-95a4-4f82-924d-6e8140df1749", "embedding": null, "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "794266ea-a583-4b91-ab65-09bebafab231", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n", "original_text": "Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee664dd9eda597f9954ddf097b6ba6c4db2a73f3c8fd99049cbf703834043be2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37e93c2e-287a-4442-9562-3650ef14946a", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "89cfe57ff028a13500c64c20ea6d8123adbf64c5262868b5d0f0d1682f13f952", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n", "start_char_idx": 872, "end_char_idx": 1048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37e93c2e-287a-4442-9562-3650ef14946a": {"__data__": {"id_": "37e93c2e-287a-4442-9562-3650ef14946a", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8754192d-95a4-4f82-924d-6e8140df1749", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "940ec0db63fd9dca639d1d5b29b5899a3e4ffc726f9d3583b53d316457470307", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac201113-5bc7-4fc9-bc16-9794d8e6c3d0", "node_type": "1", "metadata": {"window": "Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n"}, "hash": "89cc60d2223bca5a86287aaab05ad824f257481de116f7622bf1b502ce51b0b2", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1048, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac201113-5bc7-4fc9-bc16-9794d8e6c3d0": {"__data__": {"id_": "ac201113-5bc7-4fc9-bc16-9794d8e6c3d0", "embedding": null, "metadata": {"window": "Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37e93c2e-287a-4442-9562-3650ef14946a", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6e7757b4053f91147dc612bc85c245de8f02e296f085e67c02374047ef2cd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bc5cbe8-f3e0-4a20-bcf7-50ede04b68b2", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n"}, "hash": "bc4b9ee4f8b1d533dc9214f9f364a4194ed8fb387860ad9336b78ebdac2de4f6", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n", "start_char_idx": 1147, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bc5cbe8-f3e0-4a20-bcf7-50ede04b68b2": {"__data__": {"id_": "9bc5cbe8-f3e0-4a20-bcf7-50ede04b68b2", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac201113-5bc7-4fc9-bc16-9794d8e6c3d0", "node_type": "1", "metadata": {"window": "Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation.  Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd80a5d57a769313878e28801d47ee312e3b4aec00fdc51c3e1d461debd4368a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c9c84be-5c4e-4b58-b3e5-2aa10e83c049", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n"}, "hash": "662f247fa6e0c4af836420cf114c6d8d524dfe599af837675c6f714fc1ec02c4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n", "start_char_idx": 1358, "end_char_idx": 1527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c9c84be-5c4e-4b58-b3e5-2aa10e83c049": {"__data__": {"id_": "9c9c84be-5c4e-4b58-b3e5-2aa10e83c049", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bc5cbe8-f3e0-4a20-bcf7-50ede04b68b2", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.21 percent in the fiscal 2022 fourth\nquarter, an increase of 3 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8f397845e428f3f3676016d79ef390151c6bf8ff3b45fe8b59aae031b64d4a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae0caca5-c84c-48c9-8387-d19e4d1b0849", "node_type": "1", "metadata": {"window": "In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "6cdd4f581bc748c3a811f817d08b3b2a9cfe8adbc3ff9e51cfa3ba0789001cdb", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n", "start_char_idx": 1527, "end_char_idx": 1728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae0caca5-c84c-48c9-8387-d19e4d1b0849": {"__data__": {"id_": "ae0caca5-c84c-48c9-8387-d19e4d1b0849", "embedding": null, "metadata": {"window": "In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c9c84be-5c4e-4b58-b3e5-2aa10e83c049", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f5ae6cef8bdb7d0eea0b222f629e3fbafa4a1a7a8aeba216c5fab47fcec3766", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "421517db-7461-4d7a-a7c1-a4e4142b4d51", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n"}, "hash": "12182ae9a627fd07d8dc9244aa489ea7d4a1652ac0ec094ebc1669dfde223586", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 1728, "end_char_idx": 1838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "421517db-7461-4d7a-a7c1-a4e4142b4d51": {"__data__": {"id_": "421517db-7461-4d7a-a7c1-a4e4142b4d51", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae0caca5-c84c-48c9-8387-d19e4d1b0849", "node_type": "1", "metadata": {"window": "In the fiscal 2022 fourth\nquarter, net interest expense of $51.5 million was down 5.6 percent versus the prior year quarter due to an increase in interest\nincome as a result of higher investment interest rates.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c600a24a80475e97e703fb71d2803960f29022d542fc2e3b173bd9ad5e98139a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "796c0af1-813a-42a8-8a55-51ee1534bb1a", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. "}, "hash": "489a2bb40394f23d63e7d7a13685fd75b8b09a710c34a154176adf7f3c02128a", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n", "start_char_idx": 1838, "end_char_idx": 2115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "796c0af1-813a-42a8-8a55-51ee1534bb1a": {"__data__": {"id_": "796c0af1-813a-42a8-8a55-51ee1534bb1a", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "421517db-7461-4d7a-a7c1-a4e4142b4d51", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.8 percent for the fourth quarter of fiscal 2022 compared to\n20.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f25c1c3309b94c7f0c8033cbccdd4fe5355e5ae213dca1a947dcb855de8cc31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "453131fb-cd5f-4e89-bb21-55e64c1dcdd6", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "original_text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. "}, "hash": "415935a0c915a7fd35a966997d36e2a8d684fed8d80c22e30a9804643ff2869d", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "start_char_idx": 2115, "end_char_idx": 2241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "453131fb-cd5f-4e89-bb21-55e64c1dcdd6": {"__data__": {"id_": "453131fb-cd5f-4e89-bb21-55e64c1dcdd6", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "original_text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "796c0af1-813a-42a8-8a55-51ee1534bb1a", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 8.8 percent to $2.60 in the fourth quarter of\nfiscal 2022 compared to $2.39 in the previous fiscal year fourth quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ae0ab2d763b79a26d0b56c67f67bee7d8b0d9e0d69743c1a562b9f7cabf2bd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46dec6cb-8854-4abf-9a54-8795832d1a67", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. "}, "hash": "e9d2a909b98c4d703ac12629352db2d1938cc22b6c5ef2a1cadd3a1c0c8704a9", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "start_char_idx": 2241, "end_char_idx": 2361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46dec6cb-8854-4abf-9a54-8795832d1a67": {"__data__": {"id_": "46dec6cb-8854-4abf-9a54-8795832d1a67", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "453131fb-cd5f-4e89-bb21-55e64c1dcdd6", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "original_text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27b0fc1c788aded64e94b7bbe3dd55a26c6253d801aa8252b74da9c35167ed2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c9f07f5-8b92-4dcb-a701-c48061ba7645", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "original_text": "U.S. "}, "hash": "21ecaa49aa0217fdb67ba48b3d10bd220b3e99fc08eddf8c340742014e98dd21", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "start_char_idx": 2361, "end_char_idx": 2422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c9f07f5-8b92-4dcb-a701-c48061ba7645": {"__data__": {"id_": "6c9f07f5-8b92-4dcb-a701-c48061ba7645", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46dec6cb-8854-4abf-9a54-8795832d1a67", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the fourth quarter of fiscal 2022 were 210.0 million, a 0.4 percent decline versus the\nprior fiscal year fourth quarter primarily due to share repurchases, partially offset by stock option exercises and restricted\nstock vesting.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bcc060c76c94cd479e8d669cf7bb63f966372ef16332ec6ae0630fab78d17b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b772a7aa-b684-4e44-aa63-f1509d549a08", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S. ", "original_text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. "}, "hash": "5dae5527e9e3701399753bbec2b2aa418ef09f171e511691ad195148caaa6f6b", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 661, "end_char_idx": 666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b772a7aa-b684-4e44-aa63-f1509d549a08": {"__data__": {"id_": "b772a7aa-b684-4e44-aa63-f1509d549a08", "embedding": null, "metadata": {"window": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S. ", "original_text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c9f07f5-8b92-4dcb-a701-c48061ba7645", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4031bb99eadba7f145f61929c0dc487d63f45246f88ff66c7e413f025278b029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81c8d2ce-97df-43a5-98a9-bf808f29c580", "node_type": "1", "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S. ", "original_text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). "}, "hash": "22f1afd2a8cf03f024a12ea20e48c4847c873ea33e2eb5e9fef6d3eaf3a955e9", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "start_char_idx": 2427, "end_char_idx": 2601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81c8d2ce-97df-43a5-98a9-bf808f29c580": {"__data__": {"id_": "81c8d2ce-97df-43a5-98a9-bf808f29c580", "embedding": null, "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S. ", "original_text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b772a7aa-b684-4e44-aa63-f1509d549a08", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S. ", "original_text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55e1487d4a3b0b245582e8ff361e86187e9fe4fcbca2965a5733b5eebda1408e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2479e0b-7cc0-42a4-afca-be404f62dbd1", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments. ", "original_text": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n"}, "hash": "40c7e5bfa011dd04db1a4405f37bc0f52ca4a143074eab91e29eb0bd1857b597", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "start_char_idx": 2601, "end_char_idx": 2764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2479e0b-7cc0-42a4-afca-be404f62dbd1": {"__data__": {"id_": "d2479e0b-7cc0-42a4-afca-be404f62dbd1", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments. ", "original_text": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81c8d2ce-97df-43a5-98a9-bf808f29c580", "node_type": "1", "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S. ", "original_text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6be0ad64d310eb99c59ee77889a7816a4cccdf660dfc0edd6e68d8b23e1d4664", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fff9e945-7bb8-4b0f-9775-7532303b3016", "node_type": "1", "metadata": {"window": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n", "original_text": "U.S. "}, "hash": "7508bfb45ad1a0c9948d0d0b8c50aa9c978eee72d490cdde81371d10d4a0bc2a", "class_name": "RelatedNodeInfo"}}, "text": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "start_char_idx": 2764, "end_char_idx": 2882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fff9e945-7bb8-4b0f-9775-7532303b3016": {"__data__": {"id_": "fff9e945-7bb8-4b0f-9775-7532303b3016", "embedding": null, "metadata": {"window": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2479e0b-7cc0-42a4-afca-be404f62dbd1", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments. ", "original_text": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "112266817f43c01f3e9a46b745ad381abaed9d02fa0b95c5f1119fe7109e4a5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7977de3-bb55-4c68-9919-2924ade42cad", "node_type": "1", "metadata": {"window": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions Segment\nU.S. "}, "hash": "a54365c1d37b0c43ec8d8046d54d2cb70897a4f0dbebba31952de88952905b6f", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 661, "end_char_idx": 666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7977de3-bb55-4c68-9919-2924ade42cad": {"__data__": {"id_": "a7977de3-bb55-4c68-9919-2924ade42cad", "embedding": null, "metadata": {"window": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions Segment\nU.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fff9e945-7bb8-4b0f-9775-7532303b3016", "node_type": "1", "metadata": {"window": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99688f03dc840c77ea321c7fdf38e237ba77ce5abb8837a9cbf325b3c16ec3ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e475589-75a6-499a-b7a8-dc4c4ab00442", "node_type": "1", "metadata": {"window": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022. ", "original_text": "Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments. "}, "hash": "89c4439265f18e3ac07a8c0b623cae3cc1c01c7b636552955937c9b4a2175330", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions Segment\nU.S. ", "start_char_idx": 2887, "end_char_idx": 2921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e475589-75a6-499a-b7a8-dc4c4ab00442": {"__data__": {"id_": "6e475589-75a6-499a-b7a8-dc4c4ab00442", "embedding": null, "metadata": {"window": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022. ", "original_text": "Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7977de3-bb55-4c68-9919-2924ade42cad", "node_type": "1", "metadata": {"window": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022).  The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions Segment\nU.S. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f94c0cd7454bca6410d053fe824aa140e7df8468d90f48f2d59853a2765a420", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "162079fa-64ab-46f9-a359-f18682016f7b", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n", "original_text": "Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n"}, "hash": "3f90b336f259f5b48bf3e5237b1c55d5483a2b211ba86fd7952ff8bd7110cdf8", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments. ", "start_char_idx": 2921, "end_char_idx": 3225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "162079fa-64ab-46f9-a359-f18682016f7b": {"__data__": {"id_": "162079fa-64ab-46f9-a359-f18682016f7b", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n", "original_text": "Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e475589-75a6-499a-b7a8-dc4c4ab00442", "node_type": "1", "metadata": {"window": "The Company\u2019s\npreviously reported segment results have been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022. ", "original_text": "Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06235f3aa14bb8e99c0bcc771a897d758220587f0760381842e5b867e173d897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28f9653b-44ba-484b-9771-c28dd872882a", "node_type": "1", "metadata": {"window": "Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year. "}, "hash": "1a75233cba050791f1bd21cc5506f10edabe20e12e960c93e203ecd5b96d6c4f", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n", "start_char_idx": 3225, "end_char_idx": 3552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28f9653b-44ba-484b-9771-c28dd872882a": {"__data__": {"id_": "28f9653b-44ba-484b-9771-c28dd872882a", "embedding": null, "metadata": {"window": "Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "162079fa-64ab-46f9-a359-f18682016f7b", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n", "original_text": "Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "824edf2bc901314aed2dde8ec6873a47d8e643ab58c2f44a3425a5e8f67b7b5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d86ff64-b35b-4a82-9f8d-781c15f5dc10", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022. "}, "hash": "7ad51bf53ea0f17a177c1ac737258666f5146099d9270c60a31cc8267ef260ba", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year. ", "start_char_idx": 3552, "end_char_idx": 3768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d86ff64-b35b-4a82-9f8d-781c15f5dc10": {"__data__": {"id_": "8d86ff64-b35b-4a82-9f8d-781c15f5dc10", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28f9653b-44ba-484b-9771-c28dd872882a", "node_type": "1", "metadata": {"window": "Healthcare Solutions Segment\nU.S.  Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b27b7a6b3c8794e9a30446e292c7ebd7e45c6f4317df5e3119b68ace3818b3ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf5db6ee-2a3c-429e-a0ca-c24ca6799f4c", "node_type": "1", "metadata": {"window": "Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n"}, "hash": "f2065787f033a81f5bd66d4629fa31d4f95e4b0b07c154c56b2482638fa4cf97", "class_name": "RelatedNodeInfo"}}, "text": "Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022. ", "start_char_idx": 3768, "end_char_idx": 3906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf5db6ee-2a3c-429e-a0ca-c24ca6799f4c": {"__data__": {"id_": "bf5db6ee-2a3c-429e-a0ca-c24ca6799f4c", "embedding": null, "metadata": {"window": "Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d86ff64-b35b-4a82-9f8d-781c15f5dc10", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue was $54.8 billion, an increase of 4.7 percent compared to the same quarter in the prior fiscal year\nprimarily due to overall market growth and increased sales to specialty physician practices, and was partially offset by a decline in\nsales of commercial COVID-19 treatments.  Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3187d41b2116129b35143d08f0dc0100980085cf08fc95ce66073535ae2e8fec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cf2a41b-d4fd-4f94-a520-27163255dc7c", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "Fiscal Y ear 2022 Summar y Results\n3"}, "hash": "35b669d17ab14747ed9d247876a724ab03857d593dd9dd072c15adca917f4174", "class_name": "RelatedNodeInfo"}}, "text": "The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n", "start_char_idx": 3906, "end_char_idx": 4051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cf2a41b-d4fd-4f94-a520-27163255dc7c": {"__data__": {"id_": "5cf2a41b-d4fd-4f94-a520-27163255dc7c", "embedding": null, "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "Fiscal Y ear 2022 Summar y Results\n3", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd20d31bb453527c74b69fd71bca801b77769d7ceb13bff41f3cb902061390d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf5db6ee-2a3c-429e-a0ca-c24ca6799f4c", "node_type": "1", "metadata": {"window": "Segment operating income of $578.4 million in the fourth quarter of fiscal 2022 was up\n14.0 percent compared to the same period in the previous fiscal year due to an increase in gross profit, primarily due to sales to\nspecialty physician practices and fees earned from the distribution of government-owned COVID-19 treatments.\n International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "233fd500e5c12bae5691512f28171c848a7e54badb645b4ef85288dbb84cd2db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c012ccd-c899-43e4-acd4-43383bae0e12", "node_type": "1", "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements. ", "original_text": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year. "}, "hash": "ac10294c959b40ffdd0d8fe99ad539c185f55b47b94f9ab0e2dd1b1241a6d7c6", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2022 Summar y Results\n3", "start_char_idx": 4051, "end_char_idx": 4087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c012ccd-c899-43e4-acd4-43383bae0e12": {"__data__": {"id_": "5c012ccd-c899-43e4-acd4-43383bae0e12", "embedding": null, "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements. ", "original_text": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cf2a41b-d4fd-4f94-a520-27163255dc7c", "node_type": "1", "metadata": {"window": "International Healthcare Solutions\nRevenue in International Healthcare Solutions was $6.4 billion in the fourth quarter of fiscal 2022, a decrease of 2.7 percent\ncompared to the same period in the prior fiscal year.  Operating income within International Healthcare Solutions decreased 12.6\npercent to $163.1 million in the fourth quarter of fiscal 2022.  The period over period declines were due to the negative impact of\nforeign currency translation resulting from our Alliance Healthcare business.\n Fiscal Y ear 2022 Summar y Results\n3", "original_text": "Fiscal Y ear 2022 Summar y Results\n3", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9759958ae3056c5ef4d323ca1ec67dfce1503ce5d865f575143e7d9731488c5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f37dc250-60fc-404f-a2f2-26f15443da1f", "node_type": "1", "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion. "}, "hash": "a63984317e968bf683dec957fde357f55a2ee7d4a443acb82c51b0b0ad26aca1", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year. ", "start_char_idx": 0, "end_char_idx": 489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f37dc250-60fc-404f-a2f2-26f15443da1f": {"__data__": {"id_": "f37dc250-60fc-404f-a2f2-26f15443da1f", "embedding": null, "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c012ccd-c899-43e4-acd4-43383bae0e12", "node_type": "1", "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements. ", "original_text": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4309395dcdd3d78793bc8ecbe9cec8e1db1033b48c582164305afe730b6a0ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b262889-23be-4c2d-b258-17b9da251aea", "node_type": "1", "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses. ", "original_text": "Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n"}, "hash": "7ebd5f4c188558ebbe56a537f1aa9083d2ae0853a75a662fad2bce17f9d1c0d3", "class_name": "RelatedNodeInfo"}}, "text": "Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion. ", "start_char_idx": 489, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b262889-23be-4c2d-b258-17b9da251aea": {"__data__": {"id_": "3b262889-23be-4c2d-b258-17b9da251aea", "embedding": null, "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses. ", "original_text": "Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f37dc250-60fc-404f-a2f2-26f15443da1f", "node_type": "1", "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a606a5a229f15d02f7f2c680f489326baddee7167703c189d873647717ece525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99398746-9c8a-42c4-bc38-54274b13365a", "node_type": "1", "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc. ", "original_text": "Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements. "}, "hash": "6c20cfca3087600f68f35e15a76236d3f3eb8bc57f17b7546e36a4baa13573a9", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n", "start_char_idx": 561, "end_char_idx": 796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99398746-9c8a-42c4-bc38-54274b13365a": {"__data__": {"id_": "99398746-9c8a-42c4-bc38-54274b13365a", "embedding": null, "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc. ", "original_text": "Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b262889-23be-4c2d-b258-17b9da251aea", "node_type": "1", "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses. ", "original_text": "Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5a9424993c36167c8fa4d3ee2833d8f0deb087746ba974a7ccbc3b4e9067b95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93ee77d7-7edd-4890-99b5-ab74f6d209d2", "node_type": "1", "metadata": {"window": "Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n", "original_text": "Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare. "}, "hash": "0ecbdd47c37058d499ebd800faf3375a43f2bfc603a5508cbc880499a7399072", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements. ", "start_char_idx": 796, "end_char_idx": 981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93ee77d7-7edd-4890-99b5-ab74f6d209d2": {"__data__": {"id_": "93ee77d7-7edd-4890-99b5-ab74f6d209d2", "embedding": null, "metadata": {"window": "Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n", "original_text": "Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99398746-9c8a-42c4-bc38-54274b13365a", "node_type": "1", "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc. ", "original_text": "Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b189ae81c0596fb3d10f6007577a6aa641baad2b01c3015ced22aabcae2bd28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b86b146d-f5a4-47dc-b6f8-5f3bbd31baa1", "node_type": "1", "metadata": {"window": "Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year. ", "original_text": "Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses. "}, "hash": "7d7e81cae1574b0a5c7485ae523b0195820912ac1b09a00c82b9a9bf25d6059f", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "start_char_idx": 981, "end_char_idx": 1129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b86b146d-f5a4-47dc-b6f8-5f3bbd31baa1": {"__data__": {"id_": "b86b146d-f5a4-47dc-b6f8-5f3bbd31baa1", "embedding": null, "metadata": {"window": "Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year. ", "original_text": "Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93ee77d7-7edd-4890-99b5-ab74f6d209d2", "node_type": "1", "metadata": {"window": "Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n", "original_text": "Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e0c3ad6a8ac9b05b37fb969b0e0052e8b9ff5c4071a5e7b577e8a4613ec3a1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd054673-0e63-43d2-8098-8a16df09ebdf", "node_type": "1", "metadata": {"window": "Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion. ", "original_text": "Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc. "}, "hash": "f8311ca6e26d6faf07ea1bd873901b3707c3d2d21dc87d3ab108c12ad3c91300", "class_name": "RelatedNodeInfo"}}, "text": "Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses. ", "start_char_idx": 1129, "end_char_idx": 1251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd054673-0e63-43d2-8098-8a16df09ebdf": {"__data__": {"id_": "fd054673-0e63-43d2-8098-8a16df09ebdf", "embedding": null, "metadata": {"window": "Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion. ", "original_text": "Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b86b146d-f5a4-47dc-b6f8-5f3bbd31baa1", "node_type": "1", "metadata": {"window": "Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year. ", "original_text": "Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a602a0e49642415b72a3790c481dc1be6f4071834f713585ae2625f32f7d4e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8379db79-9565-45e6-9e7b-535e90fcfae4", "node_type": "1", "metadata": {"window": "Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S. ", "original_text": "(\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n"}, "hash": "c89f9b4bb5936bad11f71842f73e0032cef7dcce57904721300cdfcd81fc9366", "class_name": "RelatedNodeInfo"}}, "text": "Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc. ", "start_char_idx": 1251, "end_char_idx": 1548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8379db79-9565-45e6-9e7b-535e90fcfae4": {"__data__": {"id_": "8379db79-9565-45e6-9e7b-535e90fcfae4", "embedding": null, "metadata": {"window": "Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S. ", "original_text": "(\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd054673-0e63-43d2-8098-8a16df09ebdf", "node_type": "1", "metadata": {"window": "Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements.  Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion. ", "original_text": "Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cca96f1aa54df1266d55af190d5b59a1d391bdf63e9b3161ab02c6403e637fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c63f97e2-e32a-4274-a2d5-c2006b863803", "node_type": "1", "metadata": {"window": "Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions. ", "original_text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year. "}, "hash": "4266d83819f4069bfb57553da1344fafadc28dd75df2d6be6c7e89a5adb86bbb", "class_name": "RelatedNodeInfo"}}, "text": "(\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n", "start_char_idx": 1548, "end_char_idx": 1654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c63f97e2-e32a-4274-a2d5-c2006b863803": {"__data__": {"id_": "c63f97e2-e32a-4274-a2d5-c2006b863803", "embedding": null, "metadata": {"window": "Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions. ", "original_text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8379db79-9565-45e6-9e7b-535e90fcfae4", "node_type": "1", "metadata": {"window": "Operating expenses increased 29.2 percent primarily due to an increase in\nexpenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S. ", "original_text": "(\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d2e80b1bb9dc4a198a75684d5fe2acd7eccbda67a7447d96ce2c80318036c01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b2b8ba9-816a-47de-8e91-d70f4f115952", "node_type": "1", "metadata": {"window": "Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare. ", "original_text": "Revenue increased 11.5 percent to\n$238.6 billion. "}, "hash": "9bdd47c25696005e18c35750aa9787563de834d0be12ada3ce2059c0b442a68e", "class_name": "RelatedNodeInfo"}}, "text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year. ", "start_char_idx": 1654, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b2b8ba9-816a-47de-8e91-d70f4f115952": {"__data__": {"id_": "4b2b8ba9-816a-47de-8e91-d70f4f115952", "embedding": null, "metadata": {"window": "Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare. ", "original_text": "Revenue increased 11.5 percent to\n$238.6 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c63f97e2-e32a-4274-a2d5-c2006b863803", "node_type": "1", "metadata": {"window": "Operating income increased 0.5 percent due to higher gross\nprofit, which was largely offset by higher operating expenses.  Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions. ", "original_text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4aeefa4ee5031c00b19feadf5921ed4b4a4072f78f9c428359aa3f76d40ee71d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffca696c-79c8-4936-b88f-72c1feb9c5eb", "node_type": "1", "metadata": {"window": "(\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments. ", "original_text": "Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S. "}, "hash": "d9df5cf887acc72a461e77293fc878304708ae1a783743ac844e9b4cf6d28fcb", "class_name": "RelatedNodeInfo"}}, "text": "Revenue increased 11.5 percent to\n$238.6 billion. ", "start_char_idx": 1799, "end_char_idx": 1849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffca696c-79c8-4936-b88f-72c1feb9c5eb": {"__data__": {"id_": "ffca696c-79c8-4936-b88f-72c1feb9c5eb", "embedding": null, "metadata": {"window": "(\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments. ", "original_text": "Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b2b8ba9-816a-47de-8e91-d70f4f115952", "node_type": "1", "metadata": {"window": "Diluted weighted average shares outstanding in fiscal 2022 were 211.2\nmillion, up 1.3 percent from the prior fiscal year resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to Walgreens Boots Alliance, Inc.  (\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare. ", "original_text": "Revenue increased 11.5 percent to\n$238.6 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b425d00f794f2a569250ea200559880abc20c9338ac23b92617b518e4f41593e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76eb3b28-1dd0-49f1-baac-0fad5c893d77", "node_type": "1", "metadata": {"window": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n", "original_text": "Healthcare Solutions. "}, "hash": "a974df43e3786650028cb073ab886d7f03552903c309ef76a0f4f4293949f5d0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S. ", "start_char_idx": 1849, "end_char_idx": 2135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76eb3b28-1dd0-49f1-baac-0fad5c893d77": {"__data__": {"id_": "76eb3b28-1dd0-49f1-baac-0fad5c893d77", "embedding": null, "metadata": {"window": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n", "original_text": "Healthcare Solutions. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffca696c-79c8-4936-b88f-72c1feb9c5eb", "node_type": "1", "metadata": {"window": "(\"WBA\") in connection with the\nacquisition of Alliance Healthcare, partially offset by share repurchases.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments. ", "original_text": "Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd6fee8e2fdccef80f823ec5376d308081e4e76dba6256dd48e0c804232a5fde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63377ddc-e1b6-4e01-bc3a-47127f123eeb", "node_type": "1", "metadata": {"window": "Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022. ", "original_text": "Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare. "}, "hash": "37600f22a2476b34f122dbfd59c59eba5e6e3e8cd65deed5c90075ac5bbf90bd", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions. ", "start_char_idx": 2135, "end_char_idx": 2157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63377ddc-e1b6-4e01-bc3a-47127f123eeb": {"__data__": {"id_": "63377ddc-e1b6-4e01-bc3a-47127f123eeb", "embedding": null, "metadata": {"window": "Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022. ", "original_text": "Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76eb3b28-1dd0-49f1-baac-0fad5c893d77", "node_type": "1", "metadata": {"window": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2022, adjusted diluted EPS was $11.03 compared to $9.26 in the prior fiscal year.  Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n", "original_text": "Healthcare Solutions. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3a80b30c958929c65d40c4f0ec6b7a48c7c9aad4050621ad3b2eb9215dd635d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2787444d-cd35-488d-bd45-633b3d16788e", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President. ", "original_text": "Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments. "}, "hash": "be34d86fdf7e9dc5ce2c4bb4e571a0b1ae51c7fec418dc3a8361c228d3c2049a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare. ", "start_char_idx": 2157, "end_char_idx": 2291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2787444d-cd35-488d-bd45-633b3d16788e": {"__data__": {"id_": "2787444d-cd35-488d-bd45-633b3d16788e", "embedding": null, "metadata": {"window": "Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President. ", "original_text": "Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63377ddc-e1b6-4e01-bc3a-47127f123eeb", "node_type": "1", "metadata": {"window": "Revenue increased 11.5 percent to\n$238.6 billion.  Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022. ", "original_text": "Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "550e3f59203b944fe13089f959350e8d1621153f7631a2e356782e9d01d12d01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42ab8791-5f9c-462b-b498-78929c6e080e", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr. ", "original_text": "Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n"}, "hash": "802cadc91531cfbb88fff980f58c93d320e94530e717ab47eebd3d862bb94cfe", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments. ", "start_char_idx": 2291, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42ab8791-5f9c-462b-b498-78929c6e080e": {"__data__": {"id_": "42ab8791-5f9c-462b-b498-78929c6e080e", "embedding": null, "metadata": {"window": "Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr. ", "original_text": "Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2787444d-cd35-488d-bd45-633b3d16788e", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased by $1.8 billion, or 27.9 percent, from the prior fiscal year to $8.4 billion due to the\nincreases in gross profit within International Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare\nacquisition, and within U.S.  Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President. ", "original_text": "Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95ee30a926084e177eeb5b6c9273aa4e6e401e45b5752d660d4e58e568c33d9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b27fd88a-0cfa-4c40-886f-7a039d83ca2b", "node_type": "1", "metadata": {"window": "Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n", "original_text": "Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022. "}, "hash": "359b1ad68e20e73cc6b42bc3751a158073070e8b616781eb0892792d2b1e5cbf", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n", "start_char_idx": 2587, "end_char_idx": 2754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b27fd88a-0cfa-4c40-886f-7a039d83ca2b": {"__data__": {"id_": "b27fd88a-0cfa-4c40-886f-7a039d83ca2b", "embedding": null, "metadata": {"window": "Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n", "original_text": "Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42ab8791-5f9c-462b-b498-78929c6e080e", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr. ", "original_text": "Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5eff1b542dba9e530576ddcdd965af3a3b847b757d1140ebe2739d64457d7a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d63d00b-09d1-4df1-a913-eb6b7214c4c4", "node_type": "1", "metadata": {"window": "Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit. ", "original_text": "Prior to this,\nhe served as the Company's Executive Vice President and Group President. "}, "hash": "6fbc0a13e46ccf9be1a6aa044401511f0d938bd5f996fcf0b8b64cbaaa4eb627", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022. ", "start_char_idx": 2754, "end_char_idx": 2905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d63d00b-09d1-4df1-a913-eb6b7214c4c4": {"__data__": {"id_": "3d63d00b-09d1-4df1-a913-eb6b7214c4c4", "embedding": null, "metadata": {"window": "Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit. ", "original_text": "Prior to this,\nhe served as the Company's Executive Vice President and Group President. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b27fd88a-0cfa-4c40-886f-7a039d83ca2b", "node_type": "1", "metadata": {"window": "Adjusted operating expenses increased 33.5 percent to $5.2 billion primarily due to\nthe June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n", "original_text": "Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "188f19cb760de96733c33a27c61b89a541fed25c28ec7e5de041a47d2216eccc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "417317ff-a630-4980-aeea-e37c811f58bf", "node_type": "1", "metadata": {"window": "Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "In his new role, Mr. "}, "hash": "a9e973b379808fe008d48c1e93184eb5c85d4066b03364b93e938e9dc3e4fbc2", "class_name": "RelatedNodeInfo"}}, "text": "Prior to this,\nhe served as the Company's Executive Vice President and Group President. ", "start_char_idx": 2905, "end_char_idx": 2993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "417317ff-a630-4980-aeea-e37c811f58bf": {"__data__": {"id_": "417317ff-a630-4980-aeea-e37c811f58bf", "embedding": null, "metadata": {"window": "Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "In his new role, Mr. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d63d00b-09d1-4df1-a913-eb6b7214c4c4", "node_type": "1", "metadata": {"window": "Adjusted operating income increased 19.5 percent to $3.2 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare, increased sales to specialty physician\npractices, and fees earned from the distribution of government-owned COVID-19 treatments.  Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit. ", "original_text": "Prior to this,\nhe served as the Company's Executive Vice President and Group President. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb5f1e79fadf1694666db5560df54e70d2e98e74ea08071ccb7e61c556f73773", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51776c10-44af-4cad-8a9f-0f218c852431", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "Mauch will oversee all\nAmerisourceBergen operations.\n"}, "hash": "a5ff8dc9aed9e29ecaca228a7a111b24f71f8df49a9bdc843fed495efc250d4d", "class_name": "RelatedNodeInfo"}}, "text": "In his new role, Mr. ", "start_char_idx": 2993, "end_char_idx": 3014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51776c10-44af-4cad-8a9f-0f218c852431": {"__data__": {"id_": "51776c10-44af-4cad-8a9f-0f218c852431", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "Mauch will oversee all\nAmerisourceBergen operations.\n", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "417317ff-a630-4980-aeea-e37c811f58bf", "node_type": "1", "metadata": {"window": "Adjusted operating income margin\nincreased 9 basis points to 1.33 percent, primarily due to fees earned from the distribution of government-owned COVID-19\ntreatments.\n Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "In his new role, Mr. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34e5d2774623dcba8b48e98ff2014533c86c2810a3c841e63fe8b173c013b1f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09786442-2438-4122-95b1-bf9d66a9393b", "node_type": "1", "metadata": {"window": "Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit. "}, "hash": "df37317f46944e600f6e11e3295b82608e6a0562cb93b6a332a68ac8f1f1838b", "class_name": "RelatedNodeInfo"}}, "text": "Mauch will oversee all\nAmerisourceBergen operations.\n", "start_char_idx": 3014, "end_char_idx": 3067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09786442-2438-4122-95b1-bf9d66a9393b": {"__data__": {"id_": "09786442-2438-4122-95b1-bf9d66a9393b", "embedding": null, "metadata": {"window": "Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51776c10-44af-4cad-8a9f-0f218c852431", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nRobert P. Mauch was appointed Executive Vice President and Chief Operating Officer effective October 1, 2022.  Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "Mauch will oversee all\nAmerisourceBergen operations.\n", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a6130468c27e6dfa0be0b367effc03b065d7bf442fd7dc41ca8673720d1b2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e80b8a70-6af7-4ef2-9ea2-10e5a935f643", "node_type": "1", "metadata": {"window": "In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "During the event, attendees discussed pressing issues related to\n4"}, "hash": "ed1a904a636d94ff00216f3e54838fe3fac3d154b73e24f9f9b65fb9ecb5d5cc", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit. ", "start_char_idx": 3067, "end_char_idx": 3243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e80b8a70-6af7-4ef2-9ea2-10e5a935f643": {"__data__": {"id_": "e80b8a70-6af7-4ef2-9ea2-10e5a935f643", "embedding": null, "metadata": {"window": "In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "During the event, attendees discussed pressing issues related to\n4", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68152705be1430b3788e2066f2021677cdabe60fcdf901d3ca737c61fdd348ab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09786442-2438-4122-95b1-bf9d66a9393b", "node_type": "1", "metadata": {"window": "Prior to this,\nhe served as the Company's Executive Vice President and Group President.  In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7adfdb4367ed5109ef4e38a498b6e8bac0bb3ba8b9d9ba87fb0a1688df7ca108", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "085869d4-6044-471a-bb88-faec787b50c2", "node_type": "1", "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "health equity in cancer care.\n"}, "hash": "f3658b8a14d1bb3dd3954485e9a4281ac4d9983cf496d3c847ba67414c838846", "class_name": "RelatedNodeInfo"}}, "text": "During the event, attendees discussed pressing issues related to\n4", "start_char_idx": 3243, "end_char_idx": 3309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "085869d4-6044-471a-bb88-faec787b50c2": {"__data__": {"id_": "085869d4-6044-471a-bb88-faec787b50c2", "embedding": null, "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "health equity in cancer care.\n", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e80b8a70-6af7-4ef2-9ea2-10e5a935f643", "node_type": "1", "metadata": {"window": "In his new role, Mr.  Mauch will oversee all\nAmerisourceBergen operations.\n AmerisourceBergen convened healthcare industry executives, community oncology providers, and other patient-care\nadvocates for its first-ever Disparities in Cancer Care Summit.  During the event, attendees discussed pressing issues related to\n4", "original_text": "During the event, attendees discussed pressing issues related to\n4", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32e8272a6283e059330ad697db0b168e57e6cd575e7bb4ffd21e9954ef0818e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae902c71-23c9-4988-99f1-f78c12eecb8b", "node_type": "1", "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share. "}, "hash": "2ff71e99ac13b3cd45e9c44573d7cb418105eb5999f21d14bfd58f03ebb7092a", "class_name": "RelatedNodeInfo"}}, "text": "health equity in cancer care.\n", "start_char_idx": 0, "end_char_idx": 30, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae902c71-23c9-4988-99f1-f78c12eecb8b": {"__data__": {"id_": "ae902c71-23c9-4988-99f1-f78c12eecb8b", "embedding": null, "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "085869d4-6044-471a-bb88-faec787b50c2", "node_type": "1", "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "health equity in cancer care.\n", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7013fb006ea7eb7ab0331bf5ed456184d056e431ec41be1c9556ddf224994919", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6023283-52aa-49a5-a699-99be191d6d84", "node_type": "1", "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day. ", "original_text": "The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n"}, "hash": "ba860d64c38f3fa4393060fe71b31791b5d31b519d9bb188cd1eb5f0f5fac4cc", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share. ", "start_char_idx": 30, "end_char_idx": 235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6023283-52aa-49a5-a699-99be191d6d84": {"__data__": {"id_": "b6023283-52aa-49a5-a699-99be191d6d84", "embedding": null, "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day. ", "original_text": "The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae902c71-23c9-4988-99f1-f78c12eecb8b", "node_type": "1", "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6943058a7a47d8078f1bcff2cb34eed98a2e66db6b7673753696372624a61b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d81ef30-1268-42b3-81a2-f2163dbe5f86", "node_type": "1", "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. "}, "hash": "ebd1f0579085c8c69c1f22d49021355c80d08a989083bd962d730f10dfc6e4f2", "class_name": "RelatedNodeInfo"}}, "text": "The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n", "start_char_idx": 235, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d81ef30-1268-42b3-81a2-f2163dbe5f86": {"__data__": {"id_": "2d81ef30-1268-42b3-81a2-f2163dbe5f86", "embedding": null, "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6023283-52aa-49a5-a699-99be191d6d84", "node_type": "1", "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day. ", "original_text": "The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba4edb06ad102ac50251adf8f1451e9d4d8d507f764922950ec59da09ae4ee17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f034437-825f-4fa4-b630-c145866ec56d", "node_type": "1", "metadata": {"window": "Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "737cf055146a0453b4145b8e7884b2c5daa0e41da7aca8f01ceea148308baa13", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "start_char_idx": 393, "end_char_idx": 638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f034437-825f-4fa4-b630-c145866ec56d": {"__data__": {"id_": "0f034437-825f-4fa4-b630-c145866ec56d", "embedding": null, "metadata": {"window": "Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d81ef30-1268-42b3-81a2-f2163dbe5f86", "node_type": "1", "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1aa31449d4eb4fbbb2b99b84cdc44478acdc20ea2df08d7fb88b1053ca3f5e1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93515638-f16d-4c3e-b046-85208f424f11", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S. ", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day. "}, "hash": "38ff6e09160dba64668bdd1487f2498be5a3bf375bd525010aa8ffa9af87a7b1", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 638, "end_char_idx": 770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93515638-f16d-4c3e-b046-85208f424f11": {"__data__": {"id_": "93515638-f16d-4c3e-b046-85208f424f11", "embedding": null, "metadata": {"window": "The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S. ", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f034437-825f-4fa4-b630-c145866ec56d", "node_type": "1", "metadata": {"window": "Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "692f9e229c011cd45f2931150c178229eabfe16b38969f4091d9999488fb9567", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "384887b7-2218-4902-9994-d069f02d71f4", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S. ", "original_text": "Growth rates are on an as reported basis unless constant currency basis is indicated. "}, "hash": "46b531a03fdd8cc3f1feb73603ddf5f4646e119ffa9bf999de4b07287be984b2", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day. ", "start_char_idx": 770, "end_char_idx": 989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "384887b7-2218-4902-9994-d069f02d71f4": {"__data__": {"id_": "384887b7-2218-4902-9994-d069f02d71f4", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S. ", "original_text": "Growth rates are on an as reported basis unless constant currency basis is indicated. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93515638-f16d-4c3e-b046-85208f424f11", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S. ", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5d1595228bdba71e639165b6e1dc216ef6f5d242770afa19b8d21e460187783", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f17dc73-ab39-439c-8d2d-1454dfd9c77b", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S. "}, "hash": "58c3592ac3f3531d5d20259d9f07ca443f8cf5e7bf3dc22480ff3948e5de342a", "class_name": "RelatedNodeInfo"}}, "text": "Growth rates are on an as reported basis unless constant currency basis is indicated. ", "start_char_idx": 989, "end_char_idx": 1075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f17dc73-ab39-439c-8d2d-1454dfd9c77b": {"__data__": {"id_": "5f17dc73-ab39-439c-8d2d-1454dfd9c77b", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "384887b7-2218-4902-9994-d069f02d71f4", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S. ", "original_text": "Growth rates are on an as reported basis unless constant currency basis is indicated. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf4745846678cb09e677a338e90ff8f436c17f9f101ffd3557ebecc530702992", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db4a5346-ad96-4a30-ac92-8bc5cd221ee7", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S. "}, "hash": "830af842c5651bc53227b8e2d382cccaf0d74e2b9adeb32f11f9a2c5c3e71e4d", "class_name": "RelatedNodeInfo"}}, "text": "The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S. ", "start_char_idx": 1075, "end_char_idx": 1237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db4a5346-ad96-4a30-ac92-8bc5cd221ee7": {"__data__": {"id_": "db4a5346-ad96-4a30-ac92-8bc5cd221ee7", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f17dc73-ab39-439c-8d2d-1454dfd9c77b", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "386e8c086cae9466193b72595d7f4e21755cc3fb4990249ef38c7d9d0ae3e66b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cce00488-3d75-41b2-9056-c5723da91fc9", "node_type": "1", "metadata": {"window": "Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S. "}, "hash": "3d381a6d7fba607686dddeabb94114978fa7ad605fe2dc5f830cb83146787e81", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S. ", "start_char_idx": 1237, "end_char_idx": 2486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cce00488-3d75-41b2-9056-c5723da91fc9": {"__data__": {"id_": "cce00488-3d75-41b2-9056-c5723da91fc9", "embedding": null, "metadata": {"window": "Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db4a5346-ad96-4a30-ac92-8bc5cd221ee7", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2023 financial guidance, which aligns with the initial commentary provided at its\nJune 2022 investor day.  Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94049658bc68fcd26e7b4bf16d97278d86e1b11388b5d1352cb662f9122ba209", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a744504c-f365-4601-88ff-a25f41921f80", "node_type": "1", "metadata": {"window": "The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5"}, "hash": "ab1b1c4606b976d159313dbfb6e9e18a1b1a8e568fdfb5fb5e529ce341d72900", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S. ", "start_char_idx": 2486, "end_char_idx": 2627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a744504c-f365-4601-88ff-a25f41921f80": {"__data__": {"id_": "a744504c-f365-4601-88ff-a25f41921f80", "embedding": null, "metadata": {"window": "The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3293a08e84b1c8a16db78aaf8b16de1a8dd75ef1bccfffc12d89f926c2a996ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cce00488-3d75-41b2-9056-c5723da91fc9", "node_type": "1", "metadata": {"window": "Growth rates are on an as reported basis unless constant currency basis is indicated.  The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S. ", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bef010db383b3d6c496779edccd117ddfcf79eab608fa089ab63cbded283b77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "983613b6-d66f-45fd-9c31-6822e2ea4256", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com. ", "original_text": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n"}, "hash": "70fef2d31b209026aaf80a380df438bbd0553b5535bab798ed18ecd111f93640", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "start_char_idx": 2627, "end_char_idx": 3449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "983613b6-d66f-45fd-9c31-6822e2ea4256": {"__data__": {"id_": "983613b6-d66f-45fd-9c31-6822e2ea4256", "embedding": null, "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com. ", "original_text": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a744504c-f365-4601-88ff-a25f41921f80", "node_type": "1", "metadata": {"window": "The Company expects:\nRevenue growth to be in the range of 5 to 7 percent;\nOn a constant currency basis, revenue growth to be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions revenue growth to be in the range of 6 to 8 percent;\nInternational Healthcare Solutions revenue decline to be in the range of 1 to 5 percent;\nInternational Healthcare Solutions constant currency revenue growth to be in the range of 8 to 12 percent;\nAdjusted diluted earnings per share to be in the range of $11.30 to $11.60, representing growth of 2 to 5 percent;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 7 to 9\npercent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 9 to 11 percent\nAdditional expectations include:\nAdjusted operating income growth to be in the range of 0 to 3 percent;\nOn a constant currency basis, adjusted operating income growth to be in the range of 3 to 6 percent;\nExcluding contributions related to COVID-19, adjusted operating income growth to be in the range of 3 to 5 percent;\nOn a constant currency basis, excluding contributions related to COVID-19, adjusted operating income growth\nto be in the range of 6 to 8 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 2 to 4 percent;\nExcluding contributions related to COVID-19, U.S.  Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "original_text": "Healthcare Solutions segment operating income growth to be\nin the range of 5 to 7 percent;\nInternational Healthcare Solutions segment operating income decline to be in the range of 3 to 7 percent;\nOn a constant currency basis, International Healthcare Solutions segment operating income growth to be in\nrange of 5 to 9 percent;\nExcluding contributions related to COVID-19, International Healthcare Solutions segment operating income\ndecline to be in the range of 1 to 5 percent;\nOn a constant currency basis excluding contributions related to COVID-19, International Healthcare\nSolutions segment operating income growth to be in the range of 7 to 11 percent;\nExcluding the impact of acquisitions and divestitures, International Healthcare Solutions segment operating\nincome decline to be in the range of 7 to 11 percent;\n5", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d6b194ca347233025b2a4b00e0ccbfd4bde8d166c455e292b8ebf94a71eb2d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3d60933-81fe-4f51-a016-5f4be0c27849", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "4695a299fda78c8d6c6e0c2b2e20e97a38572c2e923daecef67cc509e8f64019", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n", "start_char_idx": 0, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3d60933-81fe-4f51-a016-5f4be0c27849": {"__data__": {"id_": "d3d60933-81fe-4f51-a016-5f4be0c27849", "embedding": null, "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "983613b6-d66f-45fd-9c31-6822e2ea4256", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com. ", "original_text": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d3a4eca27cf23d505b7da24619cf0d0930159f41325a95f4c56c8edee632391", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e602a727-786b-449f-8215-b820f699548f", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on November 3, 2022. "}, "hash": "64539eda2e60f07071e6fba4497af6c8faad3a51d9d2f177f6a8181b782edf6b", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 287, "end_char_idx": 402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e602a727-786b-449f-8215-b820f699548f": {"__data__": {"id_": "e602a727-786b-449f-8215-b820f699548f", "embedding": null, "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on November 3, 2022. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3d60933-81fe-4f51-a016-5f4be0c27849", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9160a178d7c0fe113ee23bf7866fe150e99641b53aae5112981df3c09f6d15f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09068d98-3f8a-49ce-a2d3-4cdcae16170b", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465. ", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com. "}, "hash": "29fe1c527f25932f7eb491a6c0400f415994a281c1a4714ba3f181bc97003b6b", "class_name": "RelatedNodeInfo"}}, "text": "ET on November 3, 2022. ", "start_char_idx": 402, "end_char_idx": 426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09068d98-3f8a-49ce-a2d3-4cdcae16170b": {"__data__": {"id_": "09068d98-3f8a-49ce-a2d3-4cdcae16170b", "embedding": null, "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465. ", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e602a727-786b-449f-8215-b820f699548f", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on November 3, 2022. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f5e3f519bf0806114f9dd2f15b04f27b1617472e6bf006748963e80cab4bc1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39169849-65da-4142-9d86-f33cc6c537f7", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "original_text": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. "}, "hash": "341675d1bd0271c05207c4b5b941d6c48229aef0945397f5be460c5ac0481185", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com. ", "start_char_idx": 426, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39169849-65da-4142-9d86-f33cc6c537f7": {"__data__": {"id_": "39169849-65da-4142-9d86-f33cc6c537f7", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "original_text": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09068d98-3f8a-49ce-a2d3-4cdcae16170b", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465. ", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73f463532cdc079ec87cbb92836fd107968936e3d5bfcd69f67d2f7d226f9b7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69fcbc78-1783-49e8-b444-2b77b6f486fe", "node_type": "1", "metadata": {"window": "ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. "}, "hash": "9455e403abf524de769245b0495451fd136928d20fc5788b8a2b5635111cb19f", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "start_char_idx": 542, "end_char_idx": 781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69fcbc78-1783-49e8-b444-2b77b6f486fe": {"__data__": {"id_": "69fcbc78-1783-49e8-b444-2b77b6f486fe", "embedding": null, "metadata": {"window": "ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39169849-65da-4142-9d86-f33cc6c537f7", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "original_text": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa139a0829dce518a2a7b3e8c09ebeb7323063ff7b7cf3cb42ea782c728210f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84682d56-6d77-4dc4-a947-bdaaad64e0e6", "node_type": "1", "metadata": {"window": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 053465. "}, "hash": "16c5a89b22e842809f085fb1ba1aacc41c1db1014271a2b7d775bc052628f145", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "start_char_idx": 781, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84682d56-6d77-4dc4-a947-bdaaad64e0e6": {"__data__": {"id_": "84682d56-6d77-4dc4-a947-bdaaad64e0e6", "embedding": null, "metadata": {"window": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 053465. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69fcbc78-1783-49e8-b444-2b77b6f486fe", "node_type": "1", "metadata": {"window": "ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d618379a9c111c83060801074da7dae1ff64a0979fb256af253893f96e11112", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c03ce97-66db-4e76-9f94-fbb19aeb8d86", "node_type": "1", "metadata": {"window": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. "}, "hash": "36b1e14831a6e154131abfa4e15156b234e6b7a4b237e13a47a208ca1656fee2", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the call will be 053465. ", "start_char_idx": 848, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c03ce97-66db-4e76-9f94-fbb19aeb8d86": {"__data__": {"id_": "8c03ce97-66db-4e76-9f94-fbb19aeb8d86", "embedding": null, "metadata": {"window": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84682d56-6d77-4dc4-a947-bdaaad64e0e6", "node_type": "1", "metadata": {"window": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com.  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 053465. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3a3a0cb36deb47a68092a7425763a9c5f0c1f6710b97a5586c5718f06a30cd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b189b90b-62dd-45c2-bd4a-f7c7c9585057", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n"}, "hash": "697f139b7232d6a934aa6be047d45b48a0fd4ee29d0394177adcd172a6f1689c", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "start_char_idx": 893, "end_char_idx": 989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b189b90b-62dd-45c2-bd4a-f7c7c9585057": {"__data__": {"id_": "b189b90b-62dd-45c2-bd4a-f7c7c9585057", "embedding": null, "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c03ce97-66db-4e76-9f94-fbb19aeb8d86", "node_type": "1", "metadata": {"window": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7d16bb64c29699a613452d1913a4f20e02eed29278be6712196c43c2e97da68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed9bab14-3043-4aa5-9a1f-93b70a1a29f3", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "6e79db9c1774d50a33d9e0efdab6c7927844f9c5d13fa71cfcba71fa1ba6bab4", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "start_char_idx": 989, "end_char_idx": 1112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed9bab14-3043-4aa5-9a1f-93b70a1a29f3": {"__data__": {"id_": "ed9bab14-3043-4aa5-9a1f-93b70a1a29f3", "embedding": null, "metadata": {"window": "The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b189b90b-62dd-45c2-bd4a-f7c7c9585057", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51189bab5e736a3a75d649518474ca1a0efa2e8eb80a8ae4d9be06a129bf4895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50e84f97-cd05-42f4-bf75-58191d20d156", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days. "}, "hash": "063ed6f473de22fc671ed9cdab919dbd5166cea66732084ac96655e4fec612f7", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 1112, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50e84f97-cd05-42f4-bf75-58191d20d156": {"__data__": {"id_": "50e84f97-cd05-42f4-bf75-58191d20d156", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed9bab14-3043-4aa5-9a1f-93b70a1a29f3", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 053465.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1e2d559eaec36c686f5b6f2847cf716ac34c358f07a690aee806d0b4cd2035d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53356fac-8c8a-4e43-80d7-f661ddd8d150", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S. ", "original_text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. "}, "hash": "8e83a80217eaeb93071cff5178aa44b15097f6619662f33e2c54569662c8f038", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days. ", "start_char_idx": 1182, "end_char_idx": 1351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53356fac-8c8a-4e43-80d7-f661ddd8d150": {"__data__": {"id_": "53356fac-8c8a-4e43-80d7-f661ddd8d150", "embedding": null, "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S. ", "original_text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50e84f97-cd05-42f4-bf75-58191d20d156", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e0b685a5076c33b5d8ce4f0b04d9a655bca34f34672530d672055161f50227a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b89874f-3ee0-4e72-aba4-5b490dfec1c4", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658. ", "original_text": "To access the telephone replay from within the U.S. "}, "hash": "5cdbd10c0d059833d7af0c939b3ff7723ca61fdd686f4f56f8564c5b6f7d1a83", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 1351, "end_char_idx": 1494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b89874f-3ee0-4e72-aba4-5b490dfec1c4": {"__data__": {"id_": "8b89874f-3ee0-4e72-aba4-5b490dfec1c4", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658. ", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53356fac-8c8a-4e43-80d7-f661ddd8d150", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S. ", "original_text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b1c04f0536c592e40beacf321aa8c8d0b94f35d3592c3c99bfe18c44cb797b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0bc1075-274a-4c9c-8325-37dfdaac9804", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n", "original_text": "and Canada, dial (866) 813-9403. "}, "hash": "398487a4f0fc84bae45595396a509e28ca8febaddabb591fa322e18132ca2e3f", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S. ", "start_char_idx": 1494, "end_char_idx": 1546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0bc1075-274a-4c9c-8325-37dfdaac9804": {"__data__": {"id_": "c0bc1075-274a-4c9c-8325-37dfdaac9804", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b89874f-3ee0-4e72-aba4-5b490dfec1c4", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658. ", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9715151ec48761ba5f15c4ee8a7864910838675d49d3d68788394a77c8b109c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cfd7e93-fa6a-4d00-8174-c64ef3a29902", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "From outside the U.S. "}, "hash": "08d4bb10ee24fa5e350377ea0ac7e05cc045ed2483effc5ee2f6196299794859", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial (866) 813-9403. ", "start_char_idx": 1546, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cfd7e93-fa6a-4d00-8174-c64ef3a29902": {"__data__": {"id_": "2cfd7e93-fa6a-4d00-8174-c64ef3a29902", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "From outside the U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0bc1075-274a-4c9c-8325-37dfdaac9804", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51f9e556708ce336067e28de9b34917885f4dd0cdb0b9aee4df336e015cea189", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9545b10f-2f3c-4a78-8fac-878ee957a41f", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n", "original_text": "and Canada, dial\n+44 (204) 525-0658. "}, "hash": "8137ee14b4672717de692fdf8f76c373aa7841a098bb59fc420873633d22a6b7", "class_name": "RelatedNodeInfo"}}, "text": "From outside the U.S. ", "start_char_idx": 1579, "end_char_idx": 1601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9545b10f-2f3c-4a78-8fac-878ee957a41f": {"__data__": {"id_": "9545b10f-2f3c-4a78-8fac-878ee957a41f", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n", "original_text": "and Canada, dial\n+44 (204) 525-0658. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cfd7e93-fa6a-4d00-8174-c64ef3a29902", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "From outside the U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fe11a16c98ae3514c2eeeb1a2e2546f47dff77ed89939b416b6e0beecd686e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e9d8bca-9a65-431c-a894-778e48fc90ad", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The access code for the replay is 997664.\n"}, "hash": "f40f64276d4e09cd37242e6ab756bb305b97ca06ebdf496e41cddd641a131814", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial\n+44 (204) 525-0658. ", "start_char_idx": 1601, "end_char_idx": 1638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e9d8bca-9a65-431c-a894-778e48fc90ad": {"__data__": {"id_": "2e9d8bca-9a65-431c-a894-778e48fc90ad", "embedding": null, "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The access code for the replay is 997664.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9545b10f-2f3c-4a78-8fac-878ee957a41f", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n", "original_text": "and Canada, dial\n+44 (204) 525-0658. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aac69f738b8426bf432dce791dd2608020e714f2eb50d9b7b699ce6cbe27c891", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8226164-c034-475d-b562-4c4d8b285ba4", "node_type": "1", "metadata": {"window": "From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. "}, "hash": "c30179d7dc1a68622ff6b9e816a2294fd51c23192b39024ab13e43ec4b65521d", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 997664.\n", "start_char_idx": 1638, "end_char_idx": 1680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8226164-c034-475d-b562-4c4d8b285ba4": {"__data__": {"id_": "d8226164-c034-475d-b562-4c4d8b285ba4", "embedding": null, "metadata": {"window": "From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e9d8bca-9a65-431c-a894-778e48fc90ad", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The access code for the replay is 997664.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a34d9bb1b49acea69ba295070bc7c2e368c44680dbe57896ad307df437d1938a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc8cb903-75d5-4edc-a1e7-46d0612c6c6a", "node_type": "1", "metadata": {"window": "and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "Morgan Healthcare Conference, January 9-12, 2023.\n"}, "hash": "61625f007327134b00b5b7cfc944bc0b1b45dbab619d9e56de0b214ba62df970", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "start_char_idx": 1680, "end_char_idx": 1815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc8cb903-75d5-4edc-a1e7-46d0612c6c6a": {"__data__": {"id_": "dc8cb903-75d5-4edc-a1e7-46d0612c6c6a", "embedding": null, "metadata": {"window": "and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "Morgan Healthcare Conference, January 9-12, 2023.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8226164-c034-475d-b562-4c4d8b285ba4", "node_type": "1", "metadata": {"window": "From outside the U.S.  and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "586cda7e4acc553b18ff47ac1c7c9f392613880589400708936aeb7898dc0dab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a85f1d7-b0dc-498f-b623-62d0f2f83018", "node_type": "1", "metadata": {"window": "The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "0ed2a77eebeda87c9ea00696e5c97c8604c2d93dafe74c72371923a79f15a82b", "class_name": "RelatedNodeInfo"}}, "text": "Morgan Healthcare Conference, January 9-12, 2023.\n", "start_char_idx": 1815, "end_char_idx": 1865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a85f1d7-b0dc-498f-b623-62d0f2f83018": {"__data__": {"id_": "2a85f1d7-b0dc-498f-b623-62d0f2f83018", "embedding": null, "metadata": {"window": "The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc8cb903-75d5-4edc-a1e7-46d0612c6c6a", "node_type": "1", "metadata": {"window": "and Canada, dial\n+44 (204) 525-0658.  The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "Morgan Healthcare Conference, January 9-12, 2023.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "741ef2d19ececeadbaf5c2ca811c6a8f85139f95ba27c4feb4b046f94cae51ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e86fa7da-8421-4f88-8a82-e016bd0ccf9b", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. "}, "hash": "e8ea0465b9232ea05a0e6798a5038966b9e52779b647914f2e1ddc5e5e402f38", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 1865, "end_char_idx": 1994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e86fa7da-8421-4f88-8a82-e016bd0ccf9b": {"__data__": {"id_": "e86fa7da-8421-4f88-8a82-e016bd0ccf9b", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a85f1d7-b0dc-498f-b623-62d0f2f83018", "node_type": "1", "metadata": {"window": "The access code for the replay is 997664.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c62857f31880f3cf0c012d193ebc0f4fc77aad6f211be078c16ee78cfe64420", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "430005e8-b05b-4071-9d08-4787237e2ca6", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. "}, "hash": "1fe29c560b08a0a007dcf494d9158c0e8ceee274346f9e50942291d38a884055", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "start_char_idx": 1994, "end_char_idx": 2207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "430005e8-b05b-4071-9d08-4787237e2ca6": {"__data__": {"id_": "430005e8-b05b-4071-9d08-4787237e2ca6", "embedding": null, "metadata": {"window": "Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e86fa7da-8421-4f88-8a82-e016bd0ccf9b", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f410e33bb1866c158e57a045468afc4a0210fd0fec70851539be3c5ee3463b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c09c9cc-abea-4ead-bc49-00251edd7fab", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. "}, "hash": "702441fbbcb2fcc4de4526a234d410abf4deddc208292e80e9153d02101538c2", "class_name": "RelatedNodeInfo"}}, "text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "start_char_idx": 2207, "end_char_idx": 2442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c09c9cc-abea-4ead-bc49-00251edd7fab": {"__data__": {"id_": "7c09c9cc-abea-4ead-bc49-00251edd7fab", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "430005e8-b05b-4071-9d08-4787237e2ca6", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference, January 9-12, 2023.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2e5f9f140faacc71a30da7735d44372e98c0f51dd29689276f771b410e8d8dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71a8cad6-948d-4155-954c-97f0311f0f0c", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. "}, "hash": "38cedfc113c827b594f20cd7dd747249c9fcd218f21768bfe9c3359334692758", "class_name": "RelatedNodeInfo"}}, "text": "Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 2442, "end_char_idx": 2567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71a8cad6-948d-4155-954c-97f0311f0f0c": {"__data__": {"id_": "71a8cad6-948d-4155-954c-97f0311f0f0c", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c09c9cc-abea-4ead-bc49-00251edd7fab", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8bf3d6719659bba5febcb3ff5c6137d4af224bff71954165379760d8182e56c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb1bd276-5ecd-4322-81e7-2b048c30d3a7", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com.\n"}, "hash": "a4e8f602cfd5f2040c4b26cfd476d753dffa008c4d0772ee890cad887ef43770", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "start_char_idx": 2567, "end_char_idx": 2665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb1bd276-5ecd-4322-81e7-2b048c30d3a7": {"__data__": {"id_": "eb1bd276-5ecd-4322-81e7-2b048c30d3a7", "embedding": null, "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71a8cad6-948d-4155-954c-97f0311f0f0c", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55525c2db218b192cf3b7a12d4354642b3ea628e35a7fbf6eeae434d35c9c0f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fb4a642-a52b-47b3-8de0-ed7f5a55d98a", "node_type": "1", "metadata": {"window": "Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). "}, "hash": "01c4f66504b3c4b808b5912234a0f51160dea1bb01e456f27136e89838578a79", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com.\n", "start_char_idx": 2665, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fb4a642-a52b-47b3-8de0-ed7f5a55d98a": {"__data__": {"id_": "8fb4a642-a52b-47b3-8de0-ed7f5a55d98a", "embedding": null, "metadata": {"window": "Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb1bd276-5ecd-4322-81e7-2b048c30d3a7", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9db5f0b7dfc4304d584c01da95c576491423868842ea8e6d2e06b9c230390b64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ea7b245-413e-494b-a65d-3e049cf8f9ee", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. "}, "hash": "37d09b7dc0ee07e2fe8e8e57ad27d52ffd495f6670dde48cbf2ff5c25f767eee", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "start_char_idx": 2711, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ea7b245-413e-494b-a65d-3e049cf8f9ee": {"__data__": {"id_": "6ea7b245-413e-494b-a65d-3e049cf8f9ee", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fb4a642-a52b-47b3-8de0-ed7f5a55d98a", "node_type": "1", "metadata": {"window": "Our more than 43,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0e641d5f14afd61b0ec6f447daed9f39f57d31502cf02f6822fc10a7c82f44a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26b7256b-97f5-410b-b548-3473605bd39c", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "77c468c1622d5bc9a94e564f52f989c21c00d03b52b93c917083ead658c293d4", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "start_char_idx": 3058, "end_char_idx": 3407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26b7256b-97f5-410b-b548-3473605bd39c": {"__data__": {"id_": "26b7256b-97f5-410b-b548-3473605bd39c", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ea7b245-413e-494b-a65d-3e049cf8f9ee", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d35e7c90336e8af1f31ace0368bc17fb4a8f92fbcbcc296dbf04fb3d11210682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3117a402-5c07-4088-b8e5-8c96082ccc5b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6"}, "hash": "c6eba73bce2bd352529483a6096a093379a784b48cde167688ba383c01fc42b8", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 3407, "end_char_idx": 3569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3117a402-5c07-4088-b8e5-8c96082ccc5b": {"__data__": {"id_": "3117a402-5c07-4088-b8e5-8c96082ccc5b", "embedding": null, "metadata": {"window": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6992a1ae-ddce-4057-9717-e74ff527ad43", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1fcf04afad0dc41f2ad93f523657cd3119174ec19a2f466105c096b010796b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26b7256b-97f5-410b-b548-3473605bd39c", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58687230f1a6960a947930a3cd984b058829535bd3dae1d379b5c1e6b82794ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ffaa400-3c20-4848-aa03-7d5205a26089", "node_type": "1", "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "original_text": "actual results to vary materially from those indicated. "}, "hash": "930faad0295e15f176dbcec536912ec8e11e50dac33f8857d8f95c5b8dbcda70", "class_name": "RelatedNodeInfo"}}, "text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "start_char_idx": 3569, "end_char_idx": 3713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ffaa400-3c20-4848-aa03-7d5205a26089": {"__data__": {"id_": "0ffaa400-3c20-4848-aa03-7d5205a26089", "embedding": null, "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "original_text": "actual results to vary materially from those indicated. ", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17781516435a9f5effdf3d2afed060e92efa44f489a2ed7833f6453b7af95cf4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3117a402-5c07-4088-b8e5-8c96082ccc5b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\n6", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0c321422aa55eacda0cc701ec05a7837331c1a90ec0886065a32cbf7d6836ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0aae783-7b6e-439b-88cf-a5f8a33728e0", "node_type": "1", "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. "}, "hash": "f5b92844f0e91a9cda131bc94ef62ff03ab346098983cda0ca6b0335d7e4af51", "class_name": "RelatedNodeInfo"}}, "text": "actual results to vary materially from those indicated. ", "start_char_idx": 0, "end_char_idx": 56, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0aae783-7b6e-439b-88cf-a5f8a33728e0": {"__data__": {"id_": "d0aae783-7b6e-439b-88cf-a5f8a33728e0", "embedding": null, "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17781516435a9f5effdf3d2afed060e92efa44f489a2ed7833f6453b7af95cf4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ffaa400-3c20-4848-aa03-7d5205a26089", "node_type": "1", "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "original_text": "actual results to vary materially from those indicated. ", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2da5cc23a5d29053239262d75db25a836cbad928790a8381d1599903f44bc6fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "013745d6-b250-4019-b172-4d3ec30d489d", "node_type": "1", "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "original_text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n"}, "hash": "9a1eaa36ac379c137a3c36e1bca7725cba1e34dafcc0f2d7554a0ae940d38c1c", "class_name": "RelatedNodeInfo"}}, "text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "start_char_idx": 56, "end_char_idx": 4020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "013745d6-b250-4019-b172-4d3ec30d489d": {"__data__": {"id_": "013745d6-b250-4019-b172-4d3ec30d489d", "embedding": null, "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "original_text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17781516435a9f5effdf3d2afed060e92efa44f489a2ed7833f6453b7af95cf4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0aae783-7b6e-439b-88cf-a5f8a33728e0", "node_type": "1", "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6129dc55a45983499c05956e3ee7260bd1cde374fdd46b50a5e1bb4ddca93a08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee7f9945-f7bd-46ed-a90a-6361a8e3ea58", "node_type": "1", "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n"}, "hash": "a20c53454746afd2d9ee3f9f79f3bc11f813fd4e3231497b5377e6c471278ac7", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n", "start_char_idx": 4020, "end_char_idx": 4230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee7f9945-f7bd-46ed-a90a-6361a8e3ea58": {"__data__": {"id_": "ee7f9945-f7bd-46ed-a90a-6361a8e3ea58", "embedding": null, "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17781516435a9f5effdf3d2afed060e92efa44f489a2ed7833f6453b7af95cf4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "013745d6-b250-4019-b172-4d3ec30d489d", "node_type": "1", "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "original_text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98ec2c4e429edfd78115f50e00a8216b3b3398f33a7a67d53bbd8c28a65b7af0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "965a8e3b-d85d-45a1-bf23-80d91571a15f", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. "}, "hash": "7805afc82dbb11368178bbc6e5cd0e63c9be52bef2117f5a8cc44f7a256db32c", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "start_char_idx": 4230, "end_char_idx": 6174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "965a8e3b-d85d-45a1-bf23-80d91571a15f": {"__data__": {"id_": "965a8e3b-d85d-45a1-bf23-80d91571a15f", "embedding": null, "metadata": {"window": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17781516435a9f5effdf3d2afed060e92efa44f489a2ed7833f6453b7af95cf4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee7f9945-f7bd-46ed-a90a-6361a8e3ea58", "node_type": "1", "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "866ce8e3ab63dbea04162ca8352bd52b58253e83cbd1b0d0bdc2f6e5949ff80d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f892e518-be5c-4685-b2e5-1a0cba42d6b7", "node_type": "1", "metadata": {"window": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n"}, "hash": "7804d7b8dd44e7ef701551c727e2b12e7754263d7907170302d0a9959086338f", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "start_char_idx": 6174, "end_char_idx": 6589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f892e518-be5c-4685-b2e5-1a0cba42d6b7": {"__data__": {"id_": "f892e518-be5c-4685-b2e5-1a0cba42d6b7", "embedding": null, "metadata": {"window": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17781516435a9f5effdf3d2afed060e92efa44f489a2ed7833f6453b7af95cf4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "965a8e3b-d85d-45a1-bf23-80d91571a15f", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f82b7f03888313d0e1afda456d3a28eba1ba760ce404243f147dd6806a3e5b1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "814e7ba7-d166-4dc0-b641-fad8cfd04452", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "7"}, "hash": "a9590615051e48141e73b85912f6daca2a7dff0e3e5cc9e9de1e6ba0f82c1242", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "start_char_idx": 6589, "end_char_idx": 6738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "814e7ba7-d166-4dc0-b641-fad8cfd04452": {"__data__": {"id_": "814e7ba7-d166-4dc0-b641-fad8cfd04452", "embedding": null, "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "7", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17781516435a9f5effdf3d2afed060e92efa44f489a2ed7833f6453b7af95cf4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f892e518-be5c-4685-b2e5-1a0cba42d6b7", "node_type": "1", "metadata": {"window": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46319dcd90022933783135ae1fa789d9af8c8a380b2f717153e3ff88e6949b87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc454161-9825-4277-9f0a-70e20fa32242", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a03.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a0\u00a056,843,010 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a0\u00a02,069,411 \u00a0\u00a03.51 %\u00a0(4.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a0\u00a01,215,688 \u00a0\u00a02.06 %\u00a03.9 %\nDepreciation and amortization \u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a0\u00a0177,721 \u00a0\u00a00.30 %\u00a0(4.0 )%\nLitigation and opioid-related expenses \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a045,348 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a081,992 \u00a0\u00a0\u00a0 \u00a0\u00a051,062 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a0\u00a01,507,516 \u00a0\u00a02.56 %\u00a01.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a0\u00a0561,895 \u00a0\u00a00.95 %\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 2 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0(46,637 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a0\u00a054,596 \u00a0\u00a0\u00a0 \u00a0(5.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a0\u00a0553,936 \u00a0\u00a00.94 %\u00a0(31.0 )%\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a03.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a0\u00a056,843,010 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a0\u00a02,069,411 \u00a0\u00a03.51 %\u00a0(4.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a0\u00a01,215,688 \u00a0\u00a02.06 %\u00a03.9 %\nDepreciation and amortization \u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a0\u00a0177,721 \u00a0\u00a00.30 %\u00a0(4.0 )%\nLitigation and opioid-related expenses \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a045,348 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a081,992 \u00a0\u00a0\u00a0 \u00a0\u00a051,062 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a0\u00a01,507,516 \u00a0\u00a02.56 %\u00a01.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a0\u00a0561,895 \u00a0\u00a00.95 %\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 2 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0(46,637 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a0\u00a054,596 \u00a0\u00a0\u00a0 \u00a0(5.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a0\u00a0553,936 \u00a0\u00a00.94 %\u00a0(31.0 )%\n8"}, "hash": "988a840ec0631700580f60a6919e8733e9cbaed857a3ac7938f2ad5fe5d35e91", "class_name": "RelatedNodeInfo"}}, "text": "7", "start_char_idx": 6738, "end_char_idx": 6739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc454161-9825-4277-9f0a-70e20fa32242": {"__data__": {"id_": "dc454161-9825-4277-9f0a-70e20fa32242", "embedding": null, "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a03.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a0\u00a056,843,010 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a0\u00a02,069,411 \u00a0\u00a03.51 %\u00a0(4.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a0\u00a01,215,688 \u00a0\u00a02.06 %\u00a03.9 %\nDepreciation and amortization \u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a0\u00a0177,721 \u00a0\u00a00.30 %\u00a0(4.0 )%\nLitigation and opioid-related expenses \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a045,348 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a081,992 \u00a0\u00a0\u00a0 \u00a0\u00a051,062 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a0\u00a01,507,516 \u00a0\u00a02.56 %\u00a01.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a0\u00a0561,895 \u00a0\u00a00.95 %\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 2 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0(46,637 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a0\u00a054,596 \u00a0\u00a0\u00a0 \u00a0(5.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a0\u00a0553,936 \u00a0\u00a00.94 %\u00a0(31.0 )%\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a03.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a0\u00a056,843,010 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a0\u00a02,069,411 \u00a0\u00a03.51 %\u00a0(4.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a0\u00a01,215,688 \u00a0\u00a02.06 %\u00a03.9 %\nDepreciation and amortization \u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a0\u00a0177,721 \u00a0\u00a00.30 %\u00a0(4.0 )%\nLitigation and opioid-related expenses \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a045,348 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a081,992 \u00a0\u00a0\u00a0 \u00a0\u00a051,062 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a0\u00a01,507,516 \u00a0\u00a02.56 %\u00a01.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a0\u00a0561,895 \u00a0\u00a00.95 %\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 2 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0(46,637 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a0\u00a054,596 \u00a0\u00a0\u00a0 \u00a0(5.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a0\u00a0553,936 \u00a0\u00a00.94 %\u00a0(31.0 )%\n8", "page_label": "8", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e1149a58-9120-4328-8ded-2fd5ae3e7f68", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8d15eda47a05a0692d0345701b917f73b036aa29efe764b3f1845e2ff039290", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "814e7ba7-d166-4dc0-b641-fad8cfd04452", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2021 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 7", "original_text": "7", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9eeeca33641354d1ddc57c360a22386feea07980277309351f189b76d73efa3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35117da4-e247-4b9f-9eaf-31256f098c41", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022. "}, "hash": "fcc2b66d74d01065f4fab1cb9907f0bffa8fefcbedab4e3eba0d8435d42ae7b6", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a03.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a0\u00a056,843,010 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a0\u00a02,069,411 \u00a0\u00a03.51 %\u00a0(4.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a0\u00a01,215,688 \u00a0\u00a02.06 %\u00a03.9 %\nDepreciation and amortization \u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a0\u00a0177,721 \u00a0\u00a00.30 %\u00a0(4.0 )%\nLitigation and opioid-related expenses \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a045,348 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a081,992 \u00a0\u00a0\u00a0 \u00a0\u00a051,062 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a0\u00a01,507,516 \u00a0\u00a02.56 %\u00a01.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a0\u00a0561,895 \u00a0\u00a00.95 %\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 2 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0(46,637 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a0\u00a054,596 \u00a0\u00a0\u00a0 \u00a0(5.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a0\u00a0553,936 \u00a0\u00a00.94 %\u00a0(31.0 )%\n8", "start_char_idx": 0, "end_char_idx": 1261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35117da4-e247-4b9f-9eaf-31256f098c41": {"__data__": {"id_": "35117da4-e247-4b9f-9eaf-31256f098c41", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022. ", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63b6f30f1533fedc748b26f7144aec46966d01cba5542a64bf9cb451f72fec5c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc454161-9825-4277-9f0a-70e20fa32242", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a03.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a0\u00a056,843,010 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a0\u00a02,069,411 \u00a0\u00a03.51 %\u00a0(4.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a0\u00a01,215,688 \u00a0\u00a02.06 %\u00a03.9 %\nDepreciation and amortization \u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a0\u00a0177,721 \u00a0\u00a00.30 %\u00a0(4.0 )%\nLitigation and opioid-related expenses \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a045,348 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a081,992 \u00a0\u00a0\u00a0 \u00a0\u00a051,062 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a0\u00a01,507,516 \u00a0\u00a02.56 %\u00a01.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a0\u00a0561,895 \u00a0\u00a00.95 %\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 2 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0(46,637 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a0\u00a054,596 \u00a0\u00a0\u00a0 \u00a0(5.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a0\u00a0553,936 \u00a0\u00a00.94 %\u00a0(31.0 )%\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a03.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a0\u00a056,843,010 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a0\u00a02,069,411 \u00a0\u00a03.51 %\u00a0(4.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a0\u00a01,215,688 \u00a0\u00a02.06 %\u00a03.9 %\nDepreciation and amortization \u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a0\u00a0177,721 \u00a0\u00a00.30 %\u00a0(4.0 )%\nLitigation and opioid-related expenses \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a045,348 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a081,992 \u00a0\u00a0\u00a0 \u00a0\u00a051,062 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a0\u00a01,507,516 \u00a0\u00a02.56 %\u00a01.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a0\u00a0561,895 \u00a0\u00a00.95 %\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 2 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0(46,637 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a0\u00a054,596 \u00a0\u00a0\u00a0 \u00a0(5.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a0\u00a0553,936 \u00a0\u00a00.94 %\u00a0(31.0 )%\n8", "page_label": "8", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff63db0848c3ceb8dd542fa5da873cb3e78c7e8afda3624e85ef6259c880322b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21fd5879-28b5-4f14-8ea5-6c57bc27f652", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n"}, "hash": "61c909cfb965286c784d5d1c14240f10844c6a6e67e8074f76ba74d786e304bd", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022. ", "start_char_idx": 0, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21fd5879-28b5-4f14-8ea5-6c57bc27f652": {"__data__": {"id_": "21fd5879-28b5-4f14-8ea5-6c57bc27f652", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63b6f30f1533fedc748b26f7144aec46966d01cba5542a64bf9cb451f72fec5c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35117da4-e247-4b9f-9eaf-31256f098c41", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022. ", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b403aeaded55dfadfd793cafb079fb9dae764e25068bc9574d6be0edcfd25d3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d68a3fec-2571-4a10-8f1e-9aa6acbceec0", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022. "}, "hash": "03e68fb0959f1d74a7577cbee9ea70b73513d362ca110096cfdc32fd38541419", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n", "start_char_idx": 853, "end_char_idx": 1001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d68a3fec-2571-4a10-8f1e-9aa6acbceec0": {"__data__": {"id_": "d68a3fec-2571-4a10-8f1e-9aa6acbceec0", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022. ", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63b6f30f1533fedc748b26f7144aec46966d01cba5542a64bf9cb451f72fec5c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21fd5879-28b5-4f14-8ea5-6c57bc27f652", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce0faf2f9dfcf0037cdb41ec65b4c598ea7c7e75bb24cada55114f0af1fef1e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ca2f1e8-9c32-4350-b926-bde0da1516b4", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n"}, "hash": "f6542f060fca03021a35cfd4d3496efb6256c0b279ab3d43f50895ca96982ab7", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022. ", "start_char_idx": 1001, "end_char_idx": 1374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ca2f1e8-9c32-4350-b926-bde0da1516b4": {"__data__": {"id_": "9ca2f1e8-9c32-4350-b926-bde0da1516b4", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63b6f30f1533fedc748b26f7144aec46966d01cba5542a64bf9cb451f72fec5c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d68a3fec-2571-4a10-8f1e-9aa6acbceec0", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022. ", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9e45407043c8b00b8cf8a32a103c165a1fc8a80ad229e2247b7b968f66ae5c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "734d6a59-d8c9-4628-9408-41370d5b95e5", "node_type": "1", "metadata": {"window": "Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9"}, "hash": "00d7bca12296e5f7283257755395371ea5bee664b941d60156215a4a7a992b28", "class_name": "RelatedNodeInfo"}}, "text": "Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n", "start_char_idx": 1374, "end_char_idx": 1664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "734d6a59-d8c9-4628-9408-41370d5b95e5": {"__data__": {"id_": "734d6a59-d8c9-4628-9408-41370d5b95e5", "embedding": null, "metadata": {"window": "Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63b6f30f1533fedc748b26f7144aec46966d01cba5542a64bf9cb451f72fec5c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ca2f1e8-9c32-4350-b926-bde0da1516b4", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d5e74e0a384b9122d7114f13775a156d007b3a33adde85d29c7cb51aafdf6df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc632b4f-6379-4fee-8a53-97c1b3e91152", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Fiscal Y ear Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a0\u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a011.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a0\u00a06,943,228 \u00a0\u00a03.24 %\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a0\u00a03,594,251 \u00a0\u00a01.68 %\u00a034.9 %\nDepreciation and amortization \u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a0\u00a0505,172 \u00a0\u00a00.24 %\u00a037.4 %\nLitigation and opioid-related expenses \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0272,623 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0183,059 \u00a0\u00a0\u00a0 \u00a0\u00a0199,288 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 2 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a0\u00a04,589,031 \u00a0\u00a02.14 %\u00a029.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0\u00a02,354,197 \u00a0\u00a01.10 %\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  3 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0(41,736 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a0\u00a0174,074 \u00a0\u00a0\u00a0 \u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0\u00a02,221,859 \u00a0\u00a01.04 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0677,251 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a0\u00a01,544,608 \u00a0\u00a00.72 %\u00a07.9 %\n10", "original_text": "\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Fiscal Y ear Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a0\u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a011.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a0\u00a06,943,228 \u00a0\u00a03.24 %\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a0\u00a03,594,251 \u00a0\u00a01.68 %\u00a034.9 %\nDepreciation and amortization \u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a0\u00a0505,172 \u00a0\u00a00.24 %\u00a037.4 %\nLitigation and opioid-related expenses \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0272,623 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0183,059 \u00a0\u00a0\u00a0 \u00a0\u00a0199,288 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 2 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a0\u00a04,589,031 \u00a0\u00a02.14 %\u00a029.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0\u00a02,354,197 \u00a0\u00a01.10 %\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  3 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0(41,736 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a0\u00a0174,074 \u00a0\u00a0\u00a0 \u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0\u00a02,221,859 \u00a0\u00a01.04 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0677,251 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a0\u00a01,544,608 \u00a0\u00a00.72 %\u00a07.9 %\n10"}, "hash": "2e22d524c0eea0c43f7619712b87dc8175bed8c361d07e66621bc53e0c20adee", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "start_char_idx": 1664, "end_char_idx": 1769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc632b4f-6379-4fee-8a53-97c1b3e91152": {"__data__": {"id_": "fc632b4f-6379-4fee-8a53-97c1b3e91152", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Fiscal Y ear Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a0\u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a011.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a0\u00a06,943,228 \u00a0\u00a03.24 %\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a0\u00a03,594,251 \u00a0\u00a01.68 %\u00a034.9 %\nDepreciation and amortization \u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a0\u00a0505,172 \u00a0\u00a00.24 %\u00a037.4 %\nLitigation and opioid-related expenses \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0272,623 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0183,059 \u00a0\u00a0\u00a0 \u00a0\u00a0199,288 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 2 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a0\u00a04,589,031 \u00a0\u00a02.14 %\u00a029.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0\u00a02,354,197 \u00a0\u00a01.10 %\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  3 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0(41,736 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a0\u00a0174,074 \u00a0\u00a0\u00a0 \u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0\u00a02,221,859 \u00a0\u00a01.04 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0677,251 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a0\u00a01,544,608 \u00a0\u00a00.72 %\u00a07.9 %\n10", "original_text": "\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Fiscal Y ear Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a0\u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a011.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a0\u00a06,943,228 \u00a0\u00a03.24 %\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a0\u00a03,594,251 \u00a0\u00a01.68 %\u00a034.9 %\nDepreciation and amortization \u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a0\u00a0505,172 \u00a0\u00a00.24 %\u00a037.4 %\nLitigation and opioid-related expenses \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0272,623 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0183,059 \u00a0\u00a0\u00a0 \u00a0\u00a0199,288 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 2 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a0\u00a04,589,031 \u00a0\u00a02.14 %\u00a029.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0\u00a02,354,197 \u00a0\u00a01.10 %\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  3 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0(41,736 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a0\u00a0174,074 \u00a0\u00a0\u00a0 \u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0\u00a02,221,859 \u00a0\u00a01.04 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0677,251 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a0\u00a01,544,608 \u00a0\u00a00.72 %\u00a07.9 %\n10", "page_label": "10", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a94cd0c-cd36-4d4d-8bac-0dd7accd2040", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55b707becab6878398954978b14f77ba73b444436d512d40223901d90587c43f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "734d6a59-d8c9-4628-9408-41370d5b95e5", "node_type": "1", "metadata": {"window": "Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n9", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b0daf64ed70e4d7439c0561d7af2f7749fb11ae3109e127dcc8852c312e3baa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf21c2a0-2b5d-4872-a92a-5db23c692665", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022. "}, "hash": "3c5d4f02db5c15b8d4fee6ea1d04904f849af4b1ab09931f1210b840f1f846ac", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Fiscal Y ear Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a0\u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a011.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a0\u00a06,943,228 \u00a0\u00a03.24 %\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a0\u00a03,594,251 \u00a0\u00a01.68 %\u00a034.9 %\nDepreciation and amortization \u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a0\u00a0505,172 \u00a0\u00a00.24 %\u00a037.4 %\nLitigation and opioid-related expenses \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0272,623 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0183,059 \u00a0\u00a0\u00a0 \u00a0\u00a0199,288 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 2 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a0\u00a04,589,031 \u00a0\u00a02.14 %\u00a029.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0\u00a02,354,197 \u00a0\u00a01.10 %\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  3 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0(41,736 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a0\u00a0174,074 \u00a0\u00a0\u00a0 \u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0\u00a02,221,859 \u00a0\u00a01.04 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0677,251 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a0\u00a01,544,608 \u00a0\u00a00.72 %\u00a07.9 %\n10", "start_char_idx": 0, "end_char_idx": 1321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf21c2a0-2b5d-4872-a92a-5db23c692665": {"__data__": {"id_": "bf21c2a0-2b5d-4872-a92a-5db23c692665", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022. ", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db64afe0a04f224fd93f2d6f3469aea53a10f4c787f95bae2f7a37bc570751ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc632b4f-6379-4fee-8a53-97c1b3e91152", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Fiscal Y ear Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a0\u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a011.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a0\u00a06,943,228 \u00a0\u00a03.24 %\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a0\u00a03,594,251 \u00a0\u00a01.68 %\u00a034.9 %\nDepreciation and amortization \u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a0\u00a0505,172 \u00a0\u00a00.24 %\u00a037.4 %\nLitigation and opioid-related expenses \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0272,623 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0183,059 \u00a0\u00a0\u00a0 \u00a0\u00a0199,288 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 2 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a0\u00a04,589,031 \u00a0\u00a02.14 %\u00a029.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0\u00a02,354,197 \u00a0\u00a01.10 %\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  3 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0(41,736 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a0\u00a0174,074 \u00a0\u00a0\u00a0 \u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0\u00a02,221,859 \u00a0\u00a01.04 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0677,251 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a0\u00a01,544,608 \u00a0\u00a00.72 %\u00a07.9 %\n10", "original_text": "\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Fiscal Y ear Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a0\u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a011.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a0\u00a06,943,228 \u00a0\u00a03.24 %\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a0\u00a03,594,251 \u00a0\u00a01.68 %\u00a034.9 %\nDepreciation and amortization \u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a0\u00a0505,172 \u00a0\u00a00.24 %\u00a037.4 %\nLitigation and opioid-related expenses \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0272,623 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0183,059 \u00a0\u00a0\u00a0 \u00a0\u00a0199,288 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 2 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a0\u00a04,589,031 \u00a0\u00a02.14 %\u00a029.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0\u00a02,354,197 \u00a0\u00a01.10 %\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  3 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0(41,736 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a0\u00a0174,074 \u00a0\u00a0\u00a0 \u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0\u00a02,221,859 \u00a0\u00a01.04 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0677,251 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a0\u00a01,544,608 \u00a0\u00a00.72 %\u00a07.9 %\n10", "page_label": "10", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af195127efac4e6fdef59a6421d45dd554b27e1acce378875a751a823a93c9bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50548cc3-2908-4040-886d-bad174a64657", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n", "original_text": "Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n"}, "hash": "88c1d53f8b45af92b263b157c63e0ccf2aa272c4ae1e780a175dabf067656758", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022. ", "start_char_idx": 0, "end_char_idx": 764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50548cc3-2908-4040-886d-bad174a64657": {"__data__": {"id_": "50548cc3-2908-4040-886d-bad174a64657", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n", "original_text": "Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db64afe0a04f224fd93f2d6f3469aea53a10f4c787f95bae2f7a37bc570751ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf21c2a0-2b5d-4872-a92a-5db23c692665", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022. ", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9415889256acea9bf2423dbf20a3146f2bee156f93c23dd3acd5386b3d12521", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4d0d221-016e-428d-a1c6-c111ecf928bf", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n", "original_text": "2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n"}, "hash": "ec9223372714e581c1b75c1e3e336401a6d738c8132ec6c517a7059ea2991f4a", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n", "start_char_idx": 764, "end_char_idx": 913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4d0d221-016e-428d-a1c6-c111ecf928bf": {"__data__": {"id_": "a4d0d221-016e-428d-a1c6-c111ecf928bf", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n", "original_text": "2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db64afe0a04f224fd93f2d6f3469aea53a10f4c787f95bae2f7a37bc570751ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50548cc3-2908-4040-886d-bad174a64657", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n", "original_text": "Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2744dbc46a7b3b4857bf0acda0b289917a07501ab1d91173e29df025206d17d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbcd44ad-fea7-4116-a485-7e62bd46faa8", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022. "}, "hash": "339bf5c196ecfe8bb1d694882e58fee788fdcabeaa3c7a9e46d740531433f658", "class_name": "RelatedNodeInfo"}}, "text": "2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n", "start_char_idx": 913, "end_char_idx": 1004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbcd44ad-fea7-4116-a485-7e62bd46faa8": {"__data__": {"id_": "cbcd44ad-fea7-4116-a485-7e62bd46faa8", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022. ", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db64afe0a04f224fd93f2d6f3469aea53a10f4c787f95bae2f7a37bc570751ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4d0d221-016e-428d-a1c6-c111ecf928bf", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n", "original_text": "2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4bcdfe760f3e4c6d4acf1693360c7c74808c14c990b3bbf750444031cc2643e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a71e440d-0bf9-4c52-9800-6fbc8a2e6817", "node_type": "1", "metadata": {"window": "Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n"}, "hash": "a36ce310d5cbb76c3a5463ee9c47f31fac01c160ffd1183827687298f6ddbc29", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022. ", "start_char_idx": 1004, "end_char_idx": 1354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a71e440d-0bf9-4c52-9800-6fbc8a2e6817": {"__data__": {"id_": "a71e440d-0bf9-4c52-9800-6fbc8a2e6817", "embedding": null, "metadata": {"window": "Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db64afe0a04f224fd93f2d6f3469aea53a10f4c787f95bae2f7a37bc570751ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbcd44ad-fea7-4116-a485-7e62bd46faa8", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022. ", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "332b71478d3fd48f7ee6f576dba03ed5f9c5e6ecfd5dfb55a768a8f8769699d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90e779a3-e4a2-4312-8d4a-916dddd57c6b", "node_type": "1", "metadata": {"window": "2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n"}, "hash": "64b2baeaf1fdced896a0a3ef7d97ab2c0c2d0503dc101ddd5072c4c05ea6fadc", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n", "start_char_idx": 1354, "end_char_idx": 1643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90e779a3-e4a2-4312-8d4a-916dddd57c6b": {"__data__": {"id_": "90e779a3-e4a2-4312-8d4a-916dddd57c6b", "embedding": null, "metadata": {"window": "2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db64afe0a04f224fd93f2d6f3469aea53a10f4c787f95bae2f7a37bc570751ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a71e440d-0bf9-4c52-9800-6fbc8a2e6817", "node_type": "1", "metadata": {"window": "Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48fea89d4cf51a2aaa4221b795243cf1020935463822005f281c1c6da034b228", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1753da94-41de-4fc0-9542-b5f41e7a4ecb", "node_type": "1", "metadata": {"window": "3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11"}, "hash": "76733f2496e99d6d12b1273b7af5295703708fd53d12c6e2470ff5bd98c15e4c", "class_name": "RelatedNodeInfo"}}, "text": "4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n", "start_char_idx": 1643, "end_char_idx": 1980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1753da94-41de-4fc0-9542-b5f41e7a4ecb": {"__data__": {"id_": "1753da94-41de-4fc0-9542-b5f41e7a4ecb", "embedding": null, "metadata": {"window": "3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db64afe0a04f224fd93f2d6f3469aea53a10f4c787f95bae2f7a37bc570751ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90e779a3-e4a2-4312-8d4a-916dddd57c6b", "node_type": "1", "metadata": {"window": "2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "985b540bce36fb09aa638309680706e4fb96ebd0d48480fdc1f6038cc32f76c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d2d1ef6-4b5e-4fc9-ae4e-82ffe65f5748", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0\u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0\u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a012,415 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a0\u00a015,024 \u00a0\u00a0\u00a02,184 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,840 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,992 )\u00a0\u00a081,992 \u00a0\u00a0\u00a081,992 \u00a0\u00a0\u00a011,920 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a070,072 \u00a0\u00a0\u00a00.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n12", "original_text": "\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0\u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0\u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a012,415 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a0\u00a015,024 \u00a0\u00a0\u00a02,184 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,840 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,992 )\u00a0\u00a081,992 \u00a0\u00a0\u00a081,992 \u00a0\u00a0\u00a011,920 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a070,072 \u00a0\u00a0\u00a00.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n12"}, "hash": "5a6f34cf4f2715281bbcec3678bac5c2e2f8226c18ddb139ba097d984417a954", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "start_char_idx": 1980, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d2d1ef6-4b5e-4fc9-ae4e-82ffe65f5748": {"__data__": {"id_": "8d2d1ef6-4b5e-4fc9-ae4e-82ffe65f5748", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0\u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0\u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a012,415 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a0\u00a015,024 \u00a0\u00a0\u00a02,184 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,840 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,992 )\u00a0\u00a081,992 \u00a0\u00a0\u00a081,992 \u00a0\u00a0\u00a011,920 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a070,072 \u00a0\u00a0\u00a00.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n12", "original_text": "\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0\u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0\u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a012,415 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a0\u00a015,024 \u00a0\u00a0\u00a02,184 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,840 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,992 )\u00a0\u00a081,992 \u00a0\u00a0\u00a081,992 \u00a0\u00a0\u00a011,920 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a070,072 \u00a0\u00a0\u00a00.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "643c5de3-bf96-41f7-ab20-836813ab4085", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcb6a2764a1bdabefe59496558b7eb90667ecaa52922b5733e6005efd0f07500", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1753da94-41de-4fc0-9542-b5f41e7a4ecb", "node_type": "1", "metadata": {"window": "3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022.  Includes a $64.7 million gain on the\nremeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable, and a $3.4 million loss on\nthe currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.\n 4 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n11", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37623488db9cc66e5870c474e456190b523b611dd2052ff7d21ec84f1aab242f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b014156f-c852-4d11-987f-91bbca1155cd", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n"}, "hash": "ae36cde51f2ddd677f5a893db9d4c62bf3080824f110921896e8704db14522b3", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0\u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0\u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a012,415 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a0\u00a015,024 \u00a0\u00a0\u00a02,184 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,840 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,992 )\u00a0\u00a081,992 \u00a0\u00a0\u00a081,992 \u00a0\u00a0\u00a011,920 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a070,072 \u00a0\u00a0\u00a00.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n12", "start_char_idx": 0, "end_char_idx": 1413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b014156f-c852-4d11-987f-91bbca1155cd": {"__data__": {"id_": "b014156f-c852-4d11-987f-91bbca1155cd", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61f14a0f-0815-4592-af87-d8fb20bb8d9f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9246b9dc2c9f4e2cfa7a36c6b7924433e478ea3ab73ca1297eeb57d52ba0dc1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d2d1ef6-4b5e-4fc9-ae4e-82ffe65f5748", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0\u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0\u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a012,415 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a0\u00a015,024 \u00a0\u00a0\u00a02,184 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,840 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,992 )\u00a0\u00a081,992 \u00a0\u00a0\u00a081,992 \u00a0\u00a0\u00a011,920 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a070,072 \u00a0\u00a0\u00a00.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n12", "original_text": "\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0\u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0\u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a012,415 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a0\u00a015,024 \u00a0\u00a0\u00a02,184 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,840 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,992 )\u00a0\u00a081,992 \u00a0\u00a0\u00a081,992 \u00a0\u00a0\u00a011,920 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a070,072 \u00a0\u00a0\u00a00.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16216f0c08e1caa1533d882cd5f279cc3ec02186b3277462bd86c017764f4346", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62b66616-5f91-4aaa-97b6-8a4e0647a75f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n"}, "hash": "5c98080b31197b88330df9634456194dd0352d50368e919d9753fcd8dbe8e610", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62b66616-5f91-4aaa-97b6-8a4e0647a75f": {"__data__": {"id_": "62b66616-5f91-4aaa-97b6-8a4e0647a75f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n", "page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61f14a0f-0815-4592-af87-d8fb20bb8d9f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9246b9dc2c9f4e2cfa7a36c6b7924433e478ea3ab73ca1297eeb57d52ba0dc1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b014156f-c852-4d11-987f-91bbca1155cd", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c5b696634170840c12a45c82dca2b2d2518effbdf006abd1a78f4d062e097e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40baa716-cb56-42fa-b564-b61131464dbf", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "cf9817e11d26173c00dabdaa632c5f4b8d781a34eab0567a07dc84a076321674", "class_name": "RelatedNodeInfo"}}, "text": "prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n", "start_char_idx": 410, "end_char_idx": 860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40baa716-cb56-42fa-b564-b61131464dbf": {"__data__": {"id_": "40baa716-cb56-42fa-b564-b61131464dbf", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61f14a0f-0815-4592-af87-d8fb20bb8d9f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9246b9dc2c9f4e2cfa7a36c6b7924433e478ea3ab73ca1297eeb57d52ba0dc1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62b66616-5f91-4aaa-97b6-8a4e0647a75f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n", "page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a79b5c80fefe94f32cd09733f466e7ad10573cc96a6c33a5b306e309f023efb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a81dbff1-2a3e-46db-90fa-d9cd2c9b961c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13"}, "hash": "3ae3dd43dac36c0d43b671440583cf4753ca24ecfc4146e1096107d14a119c16", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 860, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a81dbff1-2a3e-46db-90fa-d9cd2c9b961c": {"__data__": {"id_": "a81dbff1-2a3e-46db-90fa-d9cd2c9b961c", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61f14a0f-0815-4592-af87-d8fb20bb8d9f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9246b9dc2c9f4e2cfa7a36c6b7924433e478ea3ab73ca1297eeb57d52ba0dc1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40baa716-cb56-42fa-b564-b61131464dbf", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f1e4b681333fe00e60a01b60d2c3e925f7bddeefa4a4295c04cb305b8437802", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b57f805-671b-4f3d-bf2c-83d9a34b7299", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Befor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(21,362 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,362 )\u00a0\u00a0(21,362 )\u00a0\u00a0(32,251 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,889 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(42,463 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(42,463 )\u00a0\u00a0(42,463 )\u00a0\u00a0(40,529 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,934 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,932 )\u00a0\u00a081,932 \u00a0\u00a0\u00a081,932 \u00a0\u00a0\u00a043,830 \u00a0\u00a0\u00a0(5,734 )\u00a0\u00a032,368 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(45,348 )\u00a0\u00a045,348 \u00a0\u00a0\u00a045,348 \u00a0\u00a0\u00a023,896 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,452 \u00a0\u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(51,062 )\u00a0\u00a051,062 \u00a0\u00a0\u00a051,062 \u00a0\u00a0\u00a026,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,156 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n14", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Befor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(21,362 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,362 )\u00a0\u00a0(21,362 )\u00a0\u00a0(32,251 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,889 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(42,463 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(42,463 )\u00a0\u00a0(42,463 )\u00a0\u00a0(40,529 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,934 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,932 )\u00a0\u00a081,932 \u00a0\u00a0\u00a081,932 \u00a0\u00a0\u00a043,830 \u00a0\u00a0\u00a0(5,734 )\u00a0\u00a032,368 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(45,348 )\u00a0\u00a045,348 \u00a0\u00a0\u00a045,348 \u00a0\u00a0\u00a023,896 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,452 \u00a0\u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(51,062 )\u00a0\u00a051,062 \u00a0\u00a0\u00a051,062 \u00a0\u00a0\u00a026,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,156 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n14"}, "hash": "32982a865207b4f46d52c3054cdb58ffe73676f99fa7efca8e0a15032ec823f4", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "start_char_idx": 1037, "end_char_idx": 1285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b57f805-671b-4f3d-bf2c-83d9a34b7299": {"__data__": {"id_": "6b57f805-671b-4f3d-bf2c-83d9a34b7299", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Befor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(21,362 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,362 )\u00a0\u00a0(21,362 )\u00a0\u00a0(32,251 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,889 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(42,463 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(42,463 )\u00a0\u00a0(42,463 )\u00a0\u00a0(40,529 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,934 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,932 )\u00a0\u00a081,932 \u00a0\u00a0\u00a081,932 \u00a0\u00a0\u00a043,830 \u00a0\u00a0\u00a0(5,734 )\u00a0\u00a032,368 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(45,348 )\u00a0\u00a045,348 \u00a0\u00a0\u00a045,348 \u00a0\u00a0\u00a023,896 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,452 \u00a0\u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(51,062 )\u00a0\u00a051,062 \u00a0\u00a0\u00a051,062 \u00a0\u00a0\u00a026,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,156 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n14", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Befor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(21,362 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,362 )\u00a0\u00a0(21,362 )\u00a0\u00a0(32,251 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,889 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(42,463 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(42,463 )\u00a0\u00a0(42,463 )\u00a0\u00a0(40,529 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,934 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,932 )\u00a0\u00a081,932 \u00a0\u00a0\u00a081,932 \u00a0\u00a0\u00a043,830 \u00a0\u00a0\u00a0(5,734 )\u00a0\u00a032,368 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(45,348 )\u00a0\u00a045,348 \u00a0\u00a0\u00a045,348 \u00a0\u00a0\u00a023,896 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,452 \u00a0\u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(51,062 )\u00a0\u00a051,062 \u00a0\u00a0\u00a051,062 \u00a0\u00a0\u00a026,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,156 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5ce78148-080b-4415-842a-92e7402300a6", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e0662d8282933172ab2e7cab9b0ff46ba11ce019ed6a7cfcee8e91356fe63a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a81dbff1-2a3e-46db-90fa-d9cd2c9b961c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1384f1a0d891b8c5e2ca7865ce66137adc28a998debccfd55adb8e8100602c0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15866567-8c1f-4b0e-8df1-b634856d10e0", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n"}, "hash": "b381c2920adff5db16dbc78d827d34961be99772332ed27be3b031be8734597b", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Befor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(21,362 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,362 )\u00a0\u00a0(21,362 )\u00a0\u00a0(32,251 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,889 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(42,463 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(42,463 )\u00a0\u00a0(42,463 )\u00a0\u00a0(40,529 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,934 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,932 )\u00a0\u00a081,932 \u00a0\u00a0\u00a081,932 \u00a0\u00a0\u00a043,830 \u00a0\u00a0\u00a0(5,734 )\u00a0\u00a032,368 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(45,348 )\u00a0\u00a045,348 \u00a0\u00a0\u00a045,348 \u00a0\u00a0\u00a023,896 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,452 \u00a0\u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(51,062 )\u00a0\u00a051,062 \u00a0\u00a0\u00a051,062 \u00a0\u00a0\u00a026,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,156 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n14", "start_char_idx": 0, "end_char_idx": 1471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15866567-8c1f-4b0e-8df1-b634856d10e0": {"__data__": {"id_": "15866567-8c1f-4b0e-8df1-b634856d10e0", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n", "page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab64f157-079e-46a0-9ad1-6d073684e00e", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a2ef3ac7afd7766fe32046bfc3eedfaef0b395838803617559c41d2008e0025", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b57f805-671b-4f3d-bf2c-83d9a34b7299", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Befor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(21,362 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,362 )\u00a0\u00a0(21,362 )\u00a0\u00a0(32,251 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,889 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(42,463 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(42,463 )\u00a0\u00a0(42,463 )\u00a0\u00a0(40,529 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,934 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,932 )\u00a0\u00a081,932 \u00a0\u00a0\u00a081,932 \u00a0\u00a0\u00a043,830 \u00a0\u00a0\u00a0(5,734 )\u00a0\u00a032,368 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(45,348 )\u00a0\u00a045,348 \u00a0\u00a0\u00a045,348 \u00a0\u00a0\u00a023,896 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,452 \u00a0\u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(51,062 )\u00a0\u00a051,062 \u00a0\u00a0\u00a051,062 \u00a0\u00a0\u00a026,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,156 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n14", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Befor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(21,362 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,362 )\u00a0\u00a0(21,362 )\u00a0\u00a0(32,251 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,889 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(42,463 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(42,463 )\u00a0\u00a0(42,463 )\u00a0\u00a0(40,529 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,934 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,932 )\u00a0\u00a081,932 \u00a0\u00a0\u00a081,932 \u00a0\u00a0\u00a043,830 \u00a0\u00a0\u00a0(5,734 )\u00a0\u00a032,368 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(45,348 )\u00a0\u00a045,348 \u00a0\u00a0\u00a045,348 \u00a0\u00a0\u00a023,896 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,452 \u00a0\u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(51,062 )\u00a0\u00a051,062 \u00a0\u00a0\u00a051,062 \u00a0\u00a0\u00a026,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,156 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7895a6f618f264f6728adcbfddb3130e0ccafe5b33e0b69caeebe72494018195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aa031bd-5f30-4032-96fb-283b87c607da", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "2 The sum of the components does not equal the total due to rounding.\n"}, "hash": "ad6f358b55d6aaa447bd3f549ec03caa527d598268b401ee526bc6e83069363e", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n", "start_char_idx": 0, "end_char_idx": 614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aa031bd-5f30-4032-96fb-283b87c607da": {"__data__": {"id_": "9aa031bd-5f30-4032-96fb-283b87c607da", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "2 The sum of the components does not equal the total due to rounding.\n", "page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab64f157-079e-46a0-9ad1-6d073684e00e", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a2ef3ac7afd7766fe32046bfc3eedfaef0b395838803617559c41d2008e0025", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15866567-8c1f-4b0e-8df1-b634856d10e0", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n", "page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa37199c1bc2b6a08f73e76e11de173e1402f85203fbad471799c12ab867d6b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86712c93-ed13-4a14-8216-c2d608b4bc53", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "5764aceabeaa1b34e1ed5508bb4cc59d866eb1d564e9124fc7fc0ede6d18aa51", "class_name": "RelatedNodeInfo"}}, "text": "2 The sum of the components does not equal the total due to rounding.\n", "start_char_idx": 614, "end_char_idx": 684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86712c93-ed13-4a14-8216-c2d608b4bc53": {"__data__": {"id_": "86712c93-ed13-4a14-8216-c2d608b4bc53", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab64f157-079e-46a0-9ad1-6d073684e00e", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a2ef3ac7afd7766fe32046bfc3eedfaef0b395838803617559c41d2008e0025", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aa031bd-5f30-4032-96fb-283b87c607da", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "2 The sum of the components does not equal the total due to rounding.\n", "page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "231d6aee6553cfbd855e24ef82dbc738e64eea48edf48d56f19d633e50692b6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f95fc91-b011-46d1-880f-02d56ad4f146", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15"}, "hash": "9bb0d15d04fe1ab24a12df6413235458c91b51bdc0d6ee1df5974f07ea8b8fcc", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 684, "end_char_idx": 861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f95fc91-b011-46d1-880f-02d56ad4f146": {"__data__": {"id_": "1f95fc91-b011-46d1-880f-02d56ad4f146", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab64f157-079e-46a0-9ad1-6d073684e00e", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a2ef3ac7afd7766fe32046bfc3eedfaef0b395838803617559c41d2008e0025", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86712c93-ed13-4a14-8216-c2d608b4bc53", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d7f15a80954d55f8be61effcae8fee5f3e2e21acb1d1e5e09386ac231527240", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1dffebf-1082-411e-9dd6-dda4e3375938", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,059 )\u00a0\u00a0183,059 \u00a0\u00a0\u00a0183,059 \u00a0\u00a0\u00a035,829 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,230 \u00a0\u00a0\u00a00.70 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,059 )\u00a0\u00a0183,059 \u00a0\u00a0\u00a0183,059 \u00a0\u00a0\u00a035,829 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,230 \u00a0\u00a0\u00a00.70 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n16"}, "hash": "7bd72215a95d228ae36a936128d28c9d23412883f786e7ec03e591840e074521", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "start_char_idx": 861, "end_char_idx": 1500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1dffebf-1082-411e-9dd6-dda4e3375938": {"__data__": {"id_": "d1dffebf-1082-411e-9dd6-dda4e3375938", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,059 )\u00a0\u00a0183,059 \u00a0\u00a0\u00a0183,059 \u00a0\u00a0\u00a035,829 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,230 \u00a0\u00a0\u00a00.70 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,059 )\u00a0\u00a0183,059 \u00a0\u00a0\u00a0183,059 \u00a0\u00a0\u00a035,829 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,230 \u00a0\u00a0\u00a00.70 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fe3ce5-de37-4ebc-bd71-9bfe9e54f708", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f67f4bc9a154e348dcc90a4e6bdec5a9f5a51962dff15a1dcdc2bb1a4a2f7486", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f95fc91-b011-46d1-880f-02d56ad4f146", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f0d41a88dec0fea47a2f93ba8097c5f1907eab27025a8b9f6520c6d5a3ad193", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe0fcd7e-abf8-44d3-bbaa-3a971a984c8e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n"}, "hash": "771592a241d4827ed2d3e47e41ba1968c6217b82ad00c96883f013265d5c546b", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,059 )\u00a0\u00a0183,059 \u00a0\u00a0\u00a0183,059 \u00a0\u00a0\u00a035,829 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,230 \u00a0\u00a0\u00a00.70 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n16", "start_char_idx": 0, "end_char_idx": 1298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe0fcd7e-abf8-44d3-bbaa-3a971a984c8e": {"__data__": {"id_": "fe0fcd7e-abf8-44d3-bbaa-3a971a984c8e", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8319279-d7f5-4758-99a9-1ab39219839d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "293822210e2243f929aeae2bcb9223f1acbb49fa3db7a3d3a7d0c39dc6e4c448", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1dffebf-1082-411e-9dd6-dda4e3375938", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,059 )\u00a0\u00a0183,059 \u00a0\u00a0\u00a0183,059 \u00a0\u00a0\u00a035,829 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,230 \u00a0\u00a0\u00a00.70 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,059 )\u00a0\u00a0183,059 \u00a0\u00a0\u00a0183,059 \u00a0\u00a0\u00a035,829 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,230 \u00a0\u00a0\u00a00.70 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "220322b45e55fb9936da8e3e9cfce9a1f555466d7ccc1ac044c6c58605e338b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97bc5cb2-38d8-4f00-a7eb-e0a9bca9ace5", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n"}, "hash": "ae366f500f9dc4d32525d591306cae8b3d7ad0fc390571cd07e6a64d31350419", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97bc5cb2-38d8-4f00-a7eb-e0a9bca9ace5": {"__data__": {"id_": "97bc5cb2-38d8-4f00-a7eb-e0a9bca9ace5", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8319279-d7f5-4758-99a9-1ab39219839d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "293822210e2243f929aeae2bcb9223f1acbb49fa3db7a3d3a7d0c39dc6e4c448", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe0fcd7e-abf8-44d3-bbaa-3a971a984c8e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a09ceaa863ef1e72485accf485d5d4be5a2ab672e0f15108dea1af5a6e9808d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01b2d000-ee8e-48d3-8fc4-f9b5d083447a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "2 The sum of the components does not equal the total due to rounding.\n"}, "hash": "85c8cc30f4862c21ab229022e644b1444c76bb707f79f7731dc372bf4df6793f", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "start_char_idx": 306, "end_char_idx": 748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01b2d000-ee8e-48d3-8fc4-f9b5d083447a": {"__data__": {"id_": "01b2d000-ee8e-48d3-8fc4-f9b5d083447a", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "2 The sum of the components does not equal the total due to rounding.\n", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8319279-d7f5-4758-99a9-1ab39219839d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "293822210e2243f929aeae2bcb9223f1acbb49fa3db7a3d3a7d0c39dc6e4c448", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97bc5cb2-38d8-4f00-a7eb-e0a9bca9ace5", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08f32579906c6f56e903ff26d05e5ea40040ab240fbe96556d89538cf53de402", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02e4c9c9-206c-4f6a-a3f9-14cf7f8da3aa", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "016642bf6bd9d31dc148c4281e3ef52a00680aa92882bed36c093699063eaed7", "class_name": "RelatedNodeInfo"}}, "text": "2 The sum of the components does not equal the total due to rounding.\n", "start_char_idx": 748, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02e4c9c9-206c-4f6a-a3f9-14cf7f8da3aa": {"__data__": {"id_": "02e4c9c9-206c-4f6a-a3f9-14cf7f8da3aa", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8319279-d7f5-4758-99a9-1ab39219839d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "293822210e2243f929aeae2bcb9223f1acbb49fa3db7a3d3a7d0c39dc6e4c448", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01b2d000-ee8e-48d3-8fc4-f9b5d083447a", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "2 The sum of the components does not equal the total due to rounding.\n", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b8ab2df919248510b06eb06c3e0164a346a68de923cff2ed40909629ca6fd92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31c0fcf2-5ce2-4e0a-82f6-860a515d20db", "node_type": "1", "metadata": {"window": "prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17"}, "hash": "c0c53aad2f289f2e4271fb61d1c91a2a6b68b20d7739e585f2cd7cd26cc2deb2", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 818, "end_char_idx": 995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31c0fcf2-5ce2-4e0a-82f6-860a515d20db": {"__data__": {"id_": "31c0fcf2-5ce2-4e0a-82f6-860a515d20db", "embedding": null, "metadata": {"window": "prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b8319279-d7f5-4758-99a9-1ab39219839d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "293822210e2243f929aeae2bcb9223f1acbb49fa3db7a3d3a7d0c39dc6e4c448", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02e4c9c9-206c-4f6a-a3f9-14cf7f8da3aa", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7bd6f876a4e87e4a5b8b44e82b2a7e03843f3037c0932e13aa524d0ff4451ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d76c12a0-f2a8-4141-8b13-654626f216a4", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,794 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,794 )\u00a0\u00a0(168,794 )\u00a0\u00a0(47,517 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(121,277 )\u00a0\u00a0(0.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(203,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(203,028 )\u00a0\u00a0(203,028 )\u00a0\u00a0(57,154 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(145,874 )\u00a0\u00a0(0.70 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(176,221 )\u00a0\u00a0176,221 \u00a0\u00a0\u00a0176,221 \u00a0\u00a0\u00a046,873 \u00a0\u00a0\u00a0(7,498 )\u00a0\u00a0121,850 \u00a0\u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(272,623 )\u00a0\u00a0272,623 \u00a0\u00a0\u00a0272,623 \u00a0\u00a0\u00a050,436 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222,187 \u00a0\u00a0\u00a01.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(199,288 )\u00a0\u00a0199,288 \u00a0\u00a0\u00a0199,288 \u00a0\u00a0\u00a036,868 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0162,420 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\n f\n18", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,794 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,794 )\u00a0\u00a0(168,794 )\u00a0\u00a0(47,517 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(121,277 )\u00a0\u00a0(0.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(203,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(203,028 )\u00a0\u00a0(203,028 )\u00a0\u00a0(57,154 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(145,874 )\u00a0\u00a0(0.70 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(176,221 )\u00a0\u00a0176,221 \u00a0\u00a0\u00a0176,221 \u00a0\u00a0\u00a046,873 \u00a0\u00a0\u00a0(7,498 )\u00a0\u00a0121,850 \u00a0\u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(272,623 )\u00a0\u00a0272,623 \u00a0\u00a0\u00a0272,623 \u00a0\u00a0\u00a050,436 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222,187 \u00a0\u00a0\u00a01.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(199,288 )\u00a0\u00a0199,288 \u00a0\u00a0\u00a0199,288 \u00a0\u00a0\u00a036,868 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0162,420 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\n f\n18"}, "hash": "eb24a15ff006e072191c1caba541b721b03f9051997ca79bbe521fbb0da90fcf", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "start_char_idx": 995, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d76c12a0-f2a8-4141-8b13-654626f216a4": {"__data__": {"id_": "d76c12a0-f2a8-4141-8b13-654626f216a4", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,794 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,794 )\u00a0\u00a0(168,794 )\u00a0\u00a0(47,517 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(121,277 )\u00a0\u00a0(0.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(203,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(203,028 )\u00a0\u00a0(203,028 )\u00a0\u00a0(57,154 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(145,874 )\u00a0\u00a0(0.70 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(176,221 )\u00a0\u00a0176,221 \u00a0\u00a0\u00a0176,221 \u00a0\u00a0\u00a046,873 \u00a0\u00a0\u00a0(7,498 )\u00a0\u00a0121,850 \u00a0\u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(272,623 )\u00a0\u00a0272,623 \u00a0\u00a0\u00a0272,623 \u00a0\u00a0\u00a050,436 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222,187 \u00a0\u00a0\u00a01.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(199,288 )\u00a0\u00a0199,288 \u00a0\u00a0\u00a0199,288 \u00a0\u00a0\u00a036,868 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0162,420 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\n f\n18", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,794 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,794 )\u00a0\u00a0(168,794 )\u00a0\u00a0(47,517 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(121,277 )\u00a0\u00a0(0.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(203,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(203,028 )\u00a0\u00a0(203,028 )\u00a0\u00a0(57,154 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(145,874 )\u00a0\u00a0(0.70 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(176,221 )\u00a0\u00a0176,221 \u00a0\u00a0\u00a0176,221 \u00a0\u00a0\u00a046,873 \u00a0\u00a0\u00a0(7,498 )\u00a0\u00a0121,850 \u00a0\u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(272,623 )\u00a0\u00a0272,623 \u00a0\u00a0\u00a0272,623 \u00a0\u00a0\u00a050,436 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222,187 \u00a0\u00a0\u00a01.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(199,288 )\u00a0\u00a0199,288 \u00a0\u00a0\u00a0199,288 \u00a0\u00a0\u00a036,868 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0162,420 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\n f\n18", "page_label": "18", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5050269a-d340-4cc9-abc1-4dc55fbe0f9d", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83a3e50463e6b65c8d163ca21253eaf851ccfe114b142e2f4607456a05ea8660", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31c0fcf2-5ce2-4e0a-82f6-860a515d20db", "node_type": "1", "metadata": {"window": "prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676 )\u00a0$1,539,932 \u00a0\u00a0$7.39 \u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebe5788c238f1bc136f66dab52de83b3d7ce3106f6103d20a62f919bb89661f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d803435-382b-410d-a6df-a941311e8a56", "node_type": "1", "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "original_text": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n"}, "hash": "403289ec02b7967ab0a535fed8ea1c564843990419c7fac0728f87148e6edd33", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,794 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,794 )\u00a0\u00a0(168,794 )\u00a0\u00a0(47,517 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(121,277 )\u00a0\u00a0(0.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(203,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(203,028 )\u00a0\u00a0(203,028 )\u00a0\u00a0(57,154 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(145,874 )\u00a0\u00a0(0.70 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(176,221 )\u00a0\u00a0176,221 \u00a0\u00a0\u00a0176,221 \u00a0\u00a0\u00a046,873 \u00a0\u00a0\u00a0(7,498 )\u00a0\u00a0121,850 \u00a0\u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(272,623 )\u00a0\u00a0272,623 \u00a0\u00a0\u00a0272,623 \u00a0\u00a0\u00a050,436 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222,187 \u00a0\u00a0\u00a01.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(199,288 )\u00a0\u00a0199,288 \u00a0\u00a0\u00a0199,288 \u00a0\u00a0\u00a036,868 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0162,420 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\n f\n18", "start_char_idx": 0, "end_char_idx": 1254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d803435-382b-410d-a6df-a941311e8a56": {"__data__": {"id_": "9d803435-382b-410d-a6df-a941311e8a56", "embedding": null, "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "original_text": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe4e39af80eda3aace0e7d4e958efd6e485c939ea6af3984d9bba9175db93127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d76c12a0-f2a8-4141-8b13-654626f216a4", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,794 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,794 )\u00a0\u00a0(168,794 )\u00a0\u00a0(47,517 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(121,277 )\u00a0\u00a0(0.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(203,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(203,028 )\u00a0\u00a0(203,028 )\u00a0\u00a0(57,154 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(145,874 )\u00a0\u00a0(0.70 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(176,221 )\u00a0\u00a0176,221 \u00a0\u00a0\u00a0176,221 \u00a0\u00a0\u00a046,873 \u00a0\u00a0\u00a0(7,498 )\u00a0\u00a0121,850 \u00a0\u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(272,623 )\u00a0\u00a0272,623 \u00a0\u00a0\u00a0272,623 \u00a0\u00a0\u00a050,436 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222,187 \u00a0\u00a0\u00a01.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(199,288 )\u00a0\u00a0199,288 \u00a0\u00a0\u00a0199,288 \u00a0\u00a0\u00a036,868 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0162,420 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\n f\n18", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,794 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,794 )\u00a0\u00a0(168,794 )\u00a0\u00a0(47,517 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(121,277 )\u00a0\u00a0(0.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(203,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(203,028 )\u00a0\u00a0(203,028 )\u00a0\u00a0(57,154 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(145,874 )\u00a0\u00a0(0.70 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(176,221 )\u00a0\u00a0176,221 \u00a0\u00a0\u00a0176,221 \u00a0\u00a0\u00a046,873 \u00a0\u00a0\u00a0(7,498 )\u00a0\u00a0121,850 \u00a0\u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(272,623 )\u00a0\u00a0272,623 \u00a0\u00a0\u00a0272,623 \u00a0\u00a0\u00a050,436 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222,187 \u00a0\u00a0\u00a01.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(199,288 )\u00a0\u00a0199,288 \u00a0\u00a0\u00a0199,288 \u00a0\u00a0\u00a036,868 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0162,420 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\n f\n18", "page_label": "18", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eaa783d78615c6726ee116dcea03efa1e2cc275e28f8d6a7d9b8369f74feb20f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2594edb9-b0d8-4d50-a9fb-18209c3029f6", "node_type": "1", "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n"}, "hash": "4f62d5752f4d24259df7450e7bf593e1b11225881e14343d6dce0219093c6e36", "class_name": "RelatedNodeInfo"}}, "text": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "start_char_idx": 0, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2594edb9-b0d8-4d50-a9fb-18209c3029f6": {"__data__": {"id_": "2594edb9-b0d8-4d50-a9fb-18209c3029f6", "embedding": null, "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe4e39af80eda3aace0e7d4e958efd6e485c939ea6af3984d9bba9175db93127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d803435-382b-410d-a6df-a941311e8a56", "node_type": "1", "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "original_text": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22b2dac800f691eb8244ea54a02052cd4b4db65af7a288ca1f26428f148b84b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3001d95-73af-493d-9582-446603dd874a", "node_type": "1", "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "450162dc47e123e4e68d7f09a9b620a5d14853f58c6c203f0309779617498c2c", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n", "start_char_idx": 672, "end_char_idx": 939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3001d95-73af-493d-9582-446603dd874a": {"__data__": {"id_": "b3001d95-73af-493d-9582-446603dd874a", "embedding": null, "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe4e39af80eda3aace0e7d4e958efd6e485c939ea6af3984d9bba9175db93127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2594edb9-b0d8-4d50-a9fb-18209c3029f6", "node_type": "1", "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9d975a4aebcb10c0f35d0b2f217f4241410cc55293a968dd7fd20387de5bbfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6555165-d0c2-4689-9173-633b58b8f3fc", "node_type": "1", "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. "}, "hash": "c35130af2429e8f0a50b854207364f7051a77b2b1fd7a620da739220cc8c0f5a", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 939, "end_char_idx": 1116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6555165-d0c2-4689-9173-633b58b8f3fc": {"__data__": {"id_": "c6555165-d0c2-4689-9173-633b58b8f3fc", "embedding": null, "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe4e39af80eda3aace0e7d4e958efd6e485c939ea6af3984d9bba9175db93127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3001d95-73af-493d-9582-446603dd874a", "node_type": "1", "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f49a53b5a24ce14e93c36f8037e7290bb8015989eb17569f08c106f42f0d0b53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "499c8f1e-54d9-44f3-8f33-40fe9a554778", "node_type": "1", "metadata": {"window": "2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19"}, "hash": "a293ea3f4ac47eac1b15c3ba1b255fee894f2fca08f33bac5bcbbf418a144470", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "start_char_idx": 1116, "end_char_idx": 1291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "499c8f1e-54d9-44f3-8f33-40fe9a554778": {"__data__": {"id_": "499c8f1e-54d9-44f3-8f33-40fe9a554778", "embedding": null, "metadata": {"window": "2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe4e39af80eda3aace0e7d4e958efd6e485c939ea6af3984d9bba9175db93127", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6555165-d0c2-4689-9173-633b58b8f3fc", "node_type": "1", "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85a6f8f58f678d7e3d06e22fa4a5697a5edb28b7ee49e4ad6e9dea1389535b55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e110c59-a06f-4e3b-88de-5cf74f261109", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. "}, "hash": "fdfc8fd635d3b5c8382de612d49ccc30b169d1102ab52d3340ec7edc6d178d73", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "start_char_idx": 1291, "end_char_idx": 1466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e110c59-a06f-4e3b-88de-5cf74f261109": {"__data__": {"id_": "5e110c59-a06f-4e3b-88de-5cf74f261109", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "afcc3826-a4b0-4087-90ec-de9cc9b180d8", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4a7400dd2e529983ad0033dc000d705349b1ddd98db91170a8e90f81cc27943", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "499c8f1e-54d9-44f3-8f33-40fe9a554778", "node_type": "1", "metadata": {"window": "2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$54,788,447 \u00a0\u00a0$52,347,535 \u00a0\u00a04.7 %\nInternational Healthcare Solutions \u00a0\u00a06,387,474 \u00a0\u00a0\u00a06,565,517 \u00a0\u00a0(2.7 )%\nIntersegment eliminations \u00a0\u00a0(1,772 )\u00a0\u00a0(631 )\u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adeda5f6f24ae142237f3bba732f8809f905e89c7e84154e5ec16f9f40b4bcfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0452d29a-b32f-4d92-8e5e-f02d22550777", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "d2eda499df37b575e5c6c3d527c9d7e994770c5a987a156f57857085273652ca", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "start_char_idx": 0, "end_char_idx": 139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0452d29a-b32f-4d92-8e5e-f02d22550777": {"__data__": {"id_": "0452d29a-b32f-4d92-8e5e-f02d22550777", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "afcc3826-a4b0-4087-90ec-de9cc9b180d8", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4a7400dd2e529983ad0033dc000d705349b1ddd98db91170a8e90f81cc27943", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e110c59-a06f-4e3b-88de-5cf74f261109", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42be30f300b0a3e96b8fe65b82b1b2e05e5140d4bc44342148c2a8f1da940dd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0e58ed2-59c0-4b11-8bd8-456666ee7475", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20"}, "hash": "e46635f50a21b228a10f6bd4240c5ddd395e4646b25d55885dc925e1ea213b0d", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 139, "end_char_idx": 889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0e58ed2-59c0-4b11-8bd8-456666ee7475": {"__data__": {"id_": "c0e58ed2-59c0-4b11-8bd8-456666ee7475", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "afcc3826-a4b0-4087-90ec-de9cc9b180d8", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4a7400dd2e529983ad0033dc000d705349b1ddd98db91170a8e90f81cc27943", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0452d29a-b32f-4d92-8e5e-f02d22550777", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1dee62453d3347b7e5d1ed023273cc7181714f05c6f0520c688f656c20099fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4cb7e74-ba4a-43da-9a17-bacec4d4c976", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "24b78926a8db2f6c4436a35b918a3bbbf48e90932e99e3fe1b9ee8cf74ffd735", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "start_char_idx": 889, "end_char_idx": 1038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4cb7e74-ba4a-43da-9a17-bacec4d4c976": {"__data__": {"id_": "d4cb7e74-ba4a-43da-9a17-bacec4d4c976", "embedding": null, "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3262805-6b48-4a9b-98ba-48044b9da8d5", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ca5547221810bee6672c94fea158ed432de634eae002336d1edfa30fd161314", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0e58ed2-59c0-4b11-8bd8-456666ee7475", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f77e144669412a20afc4bfe343065e59ead1bbcc8eccf0d5b223b0e44e36b2be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2a5d8c7-81d4-4051-b2ab-bc388748af9d", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. "}, "hash": "f65a9fb20fb4f706303558c7807902094273108b2667ba6f088ef3ae3ccfed1a", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2a5d8c7-81d4-4051-b2ab-bc388748af9d": {"__data__": {"id_": "e2a5d8c7-81d4-4051-b2ab-bc388748af9d", "embedding": null, "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3262805-6b48-4a9b-98ba-48044b9da8d5", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ca5547221810bee6672c94fea158ed432de634eae002336d1edfa30fd161314", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4cb7e74-ba4a-43da-9a17-bacec4d4c976", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15bde3d76dfb08c37372444c6af5bd8c1a0d65bbe0130b9245de73b1f3bafcf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4d0d37c-9065-4517-9ee1-f11ea04a1ef9", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21"}, "hash": "8b7c7f2200281369d7d064101119066ec421d777995d1ddf85b1a31adae64a2f", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "start_char_idx": 686, "end_char_idx": 861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4d0d37c-9065-4517-9ee1-f11ea04a1ef9": {"__data__": {"id_": "c4d0d37c-9065-4517-9ee1-f11ea04a1ef9", "embedding": null, "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b3262805-6b48-4a9b-98ba-48044b9da8d5", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ca5547221810bee6672c94fea158ed432de634eae002336d1edfa30fd161314", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2a5d8c7-81d4-4051-b2ab-bc388748af9d", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "955ffd26947e8e8dfa38a4a21eb370f8a0b5068aafcf9fa44877108b179fdf03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "672a5eb2-6413-4b50-bb65-c8dafd41a2ba", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. "}, "hash": "90844f1dc450af2eb5940d7b3627f08d67a617a902a2784ce803e78c026a2cf0", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "start_char_idx": 861, "end_char_idx": 1099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "672a5eb2-6413-4b50-bb65-c8dafd41a2ba": {"__data__": {"id_": "672a5eb2-6413-4b50-bb65-c8dafd41a2ba", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2318ecbc-dea3-4801-b07e-f006195958ad", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae8af0c5eaa8046ebc52e2df9b50dfa96779d6a40a7d58cf310500b73f292f57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4d0d37c-9065-4517-9ee1-f11ea04a1ef9", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abf4227c7b3c50f6cf02203f70fa59b4f0723b7f0b98680af41756fc7fad2d2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4dfe92c-2eb0-4563-8b69-784d09d72b41", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "955cb4588ea0b8e0adf96278b09172740fbaa38888c87ed3d9dc533d80cdb664", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "start_char_idx": 0, "end_char_idx": 85, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4dfe92c-2eb0-4563-8b69-784d09d72b41": {"__data__": {"id_": "b4dfe92c-2eb0-4563-8b69-784d09d72b41", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2318ecbc-dea3-4801-b07e-f006195958ad", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae8af0c5eaa8046ebc52e2df9b50dfa96779d6a40a7d58cf310500b73f292f57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "672a5eb2-6413-4b50-bb65-c8dafd41a2ba", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "635a582c202e7d7718ebaf6de8c785c94373471dcc8d30ed14604d1efffe3beb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95cb331c-bbbd-4f9f-af33-f8200daae153", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22"}, "hash": "ed0682ac905fbd902f3bcaf45dcc4792297195cab9bcb5ae80154a10b31ab275", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 85, "end_char_idx": 864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95cb331c-bbbd-4f9f-af33-f8200daae153": {"__data__": {"id_": "95cb331c-bbbd-4f9f-af33-f8200daae153", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2318ecbc-dea3-4801-b07e-f006195958ad", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae8af0c5eaa8046ebc52e2df9b50dfa96779d6a40a7d58cf310500b73f292f57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4dfe92c-2eb0-4563-8b69-784d09d72b41", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc5da103bf6856c02a4e812b2bfa18a6ceeb8ec89e6a2d8e65ce35bd06531cdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9116171c-75d8-4141-bd39-61fd58b9731e", "node_type": "1", "metadata": {"window": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "original_text": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "937e226a0d34652f298c0845d8418a0a97f1f4888f4cc3bc6d8a6efcb63c071d", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "start_char_idx": 864, "end_char_idx": 1129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9116171c-75d8-4141-bd39-61fd58b9731e": {"__data__": {"id_": "9116171c-75d8-4141-bd39-61fd58b9731e", "embedding": null, "metadata": {"window": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "original_text": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "23", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0995082e-f5f9-4a7e-ac46-943fd94c69fe", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c09eb6775aabf0ebd10c5c1d124df71303e03bf124c90f230feb067c402fa749", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95cb331c-bbbd-4f9f-af33-f8200daae153", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e32d6f108d1a25b1caddc4609c10f67cd91e76b4aa6ddb43ac91ccbb260bb4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4d7afbe-c740-4fda-9ff2-c39b783a906f", "node_type": "1", "metadata": {"window": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23"}, "hash": "427ac48f0ac516c5f9b17a65967f82176e458ffb4d7cf10077e900487aa8b99e", "class_name": "RelatedNodeInfo"}}, "text": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4d7afbe-c740-4fda-9ff2-c39b783a906f": {"__data__": {"id_": "e4d7afbe-c740-4fda-9ff2-c39b783a906f", "embedding": null, "metadata": {"window": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "page_label": "23", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0995082e-f5f9-4a7e-ac46-943fd94c69fe", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c09eb6775aabf0ebd10c5c1d124df71303e03bf124c90f230feb067c402fa749", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9116171c-75d8-4141-bd39-61fd58b9731e", "node_type": "1", "metadata": {"window": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "original_text": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "23", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5964110d3ac9798ad312fe569f6238524724de93f44cfca5aabc4387b9c3bb84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07584643-a945-44d9-862d-c1bfa42bb778", "node_type": "1", "metadata": {"window": "Total current assets \u00a039,589,758 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,003 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a012,836,623 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0237,571 \u00a0\u00a0290,791\nOther long-term assets \u00a01,761,661 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $56,560,616 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $40,192,890 \u00a0$38,009,954\nOther current liabilities \u00a02,214,592 \u00a0\u00a03,048,474\nShort-term debt \u00a01,070,473 \u00a0\u00a0300,213\nTotal current liabilities \u00a043,477,955 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,632,360 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0320,274 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,620,413 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a0976,583 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,461,758 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a071,273 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $56,560,616 \u00a0$57,337,805\n24", "original_text": "Total current assets \u00a039,589,758 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,003 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a012,836,623 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0237,571 \u00a0\u00a0290,791\nOther long-term assets \u00a01,761,661 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $56,560,616 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $40,192,890 \u00a0$38,009,954\nOther current liabilities \u00a02,214,592 \u00a0\u00a03,048,474\nShort-term debt \u00a01,070,473 \u00a0\u00a0300,213\nTotal current liabilities \u00a043,477,955 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,632,360 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0320,274 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,620,413 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a0976,583 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,461,758 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a071,273 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $56,560,616 \u00a0$57,337,805\n24"}, "hash": "d18b0e7445ca1b66e646b126923d910a05812260f833edcb9befb5474d9cdc29", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "start_char_idx": 570, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07584643-a945-44d9-862d-c1bfa42bb778": {"__data__": {"id_": "07584643-a945-44d9-862d-c1bfa42bb778", "embedding": null, "metadata": {"window": "Total current assets \u00a039,589,758 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,003 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a012,836,623 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0237,571 \u00a0\u00a0290,791\nOther long-term assets \u00a01,761,661 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $56,560,616 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $40,192,890 \u00a0$38,009,954\nOther current liabilities \u00a02,214,592 \u00a0\u00a03,048,474\nShort-term debt \u00a01,070,473 \u00a0\u00a0300,213\nTotal current liabilities \u00a043,477,955 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,632,360 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0320,274 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,620,413 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a0976,583 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,461,758 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a071,273 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $56,560,616 \u00a0$57,337,805\n24", "original_text": "Total current assets \u00a039,589,758 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,003 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a012,836,623 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0237,571 \u00a0\u00a0290,791\nOther long-term assets \u00a01,761,661 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $56,560,616 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $40,192,890 \u00a0$38,009,954\nOther current liabilities \u00a02,214,592 \u00a0\u00a03,048,474\nShort-term debt \u00a01,070,473 \u00a0\u00a0300,213\nTotal current liabilities \u00a043,477,955 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,632,360 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0320,274 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,620,413 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a0976,583 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,461,758 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a071,273 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $56,560,616 \u00a0$57,337,805\n24", "page_label": "24", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f513770-0913-43ba-9ec8-09122efc9214", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50603d4b3241377f7735cc7edd7ec98a986171b5f7da4ef2842754cb1c0e30ed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4d7afbe-c740-4fda-9ff2-c39b783a906f", "node_type": "1", "metadata": {"window": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "page_label": "23", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e78b462df5bb7cff03a51066fa9fe0fcddb855f8598f360656c8f72a5c82245", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49b2f2eb-7d36-4997-95fd-0d73056d494b", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,666,540 \u00a0\u00a0$1,544,608 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,176,210 \u00a0\u00a0\u00a0754,656 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,659,525 )\u00a0\u00a0(930,078 )\nInventories \u00a0(665,370 )\u00a0\u00a0(1,116,344 )\nAccounts payable \u00a03,320,725 \u00a0\u00a0\u00a02,049,167 \u00a0\nOther, net \u00a0(1,135,492 )\u00a0\u00a0364,577 \u00a0\nNet cash provided by operating activities \u00a02,703,088 \u00a0\u00a0\u00a02,666,586 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(496,318 )\u00a0\u00a0(438,217 )\nCost of acquired companies, net of cash acquired \u00a0(133,814 )\u00a0\u00a0(5,563,040 )\nCost of equity investments \u00a0(18,491 )\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0272,586 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a07,600 \u00a0\u00a0\u00a022,300 \u00a0\nNet cash used in investing activities \u00a0(368,437 )\u00a0\u00a0(6,141,577 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(923,103 )\u00a0\u00a02,216,552 \u00a0\nPurchases of common stock 1 \u00a0(483,704 )\u00a0\u00a0(82,150 )\n25", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,666,540 \u00a0\u00a0$1,544,608 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,176,210 \u00a0\u00a0\u00a0754,656 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,659,525 )\u00a0\u00a0(930,078 )\nInventories \u00a0(665,370 )\u00a0\u00a0(1,116,344 )\nAccounts payable \u00a03,320,725 \u00a0\u00a0\u00a02,049,167 \u00a0\nOther, net \u00a0(1,135,492 )\u00a0\u00a0364,577 \u00a0\nNet cash provided by operating activities \u00a02,703,088 \u00a0\u00a0\u00a02,666,586 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(496,318 )\u00a0\u00a0(438,217 )\nCost of acquired companies, net of cash acquired \u00a0(133,814 )\u00a0\u00a0(5,563,040 )\nCost of equity investments \u00a0(18,491 )\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0272,586 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a07,600 \u00a0\u00a0\u00a022,300 \u00a0\nNet cash used in investing activities \u00a0(368,437 )\u00a0\u00a0(6,141,577 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(923,103 )\u00a0\u00a02,216,552 \u00a0\nPurchases of common stock 1 \u00a0(483,704 )\u00a0\u00a0(82,150 )\n25"}, "hash": "f81365df79f54d4cfd6b376aec88e251eee8d93665871e5eb58126ceafc06bff", "class_name": "RelatedNodeInfo"}}, "text": "Total current assets \u00a039,589,758 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,003 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a012,836,623 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0237,571 \u00a0\u00a0290,791\nOther long-term assets \u00a01,761,661 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $56,560,616 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $40,192,890 \u00a0$38,009,954\nOther current liabilities \u00a02,214,592 \u00a0\u00a03,048,474\nShort-term debt \u00a01,070,473 \u00a0\u00a0300,213\nTotal current liabilities \u00a043,477,955 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,632,360 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0320,274 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,620,413 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a0976,583 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,461,758 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a071,273 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $56,560,616 \u00a0$57,337,805\n24", "start_char_idx": 0, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49b2f2eb-7d36-4997-95fd-0d73056d494b": {"__data__": {"id_": "49b2f2eb-7d36-4997-95fd-0d73056d494b", "embedding": null, "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,666,540 \u00a0\u00a0$1,544,608 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,176,210 \u00a0\u00a0\u00a0754,656 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,659,525 )\u00a0\u00a0(930,078 )\nInventories \u00a0(665,370 )\u00a0\u00a0(1,116,344 )\nAccounts payable \u00a03,320,725 \u00a0\u00a0\u00a02,049,167 \u00a0\nOther, net \u00a0(1,135,492 )\u00a0\u00a0364,577 \u00a0\nNet cash provided by operating activities \u00a02,703,088 \u00a0\u00a0\u00a02,666,586 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(496,318 )\u00a0\u00a0(438,217 )\nCost of acquired companies, net of cash acquired \u00a0(133,814 )\u00a0\u00a0(5,563,040 )\nCost of equity investments \u00a0(18,491 )\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0272,586 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a07,600 \u00a0\u00a0\u00a022,300 \u00a0\nNet cash used in investing activities \u00a0(368,437 )\u00a0\u00a0(6,141,577 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(923,103 )\u00a0\u00a02,216,552 \u00a0\nPurchases of common stock 1 \u00a0(483,704 )\u00a0\u00a0(82,150 )\n25", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,666,540 \u00a0\u00a0$1,544,608 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,176,210 \u00a0\u00a0\u00a0754,656 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,659,525 )\u00a0\u00a0(930,078 )\nInventories \u00a0(665,370 )\u00a0\u00a0(1,116,344 )\nAccounts payable \u00a03,320,725 \u00a0\u00a0\u00a02,049,167 \u00a0\nOther, net \u00a0(1,135,492 )\u00a0\u00a0364,577 \u00a0\nNet cash provided by operating activities \u00a02,703,088 \u00a0\u00a0\u00a02,666,586 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(496,318 )\u00a0\u00a0(438,217 )\nCost of acquired companies, net of cash acquired \u00a0(133,814 )\u00a0\u00a0(5,563,040 )\nCost of equity investments \u00a0(18,491 )\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0272,586 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a07,600 \u00a0\u00a0\u00a022,300 \u00a0\nNet cash used in investing activities \u00a0(368,437 )\u00a0\u00a0(6,141,577 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(923,103 )\u00a0\u00a02,216,552 \u00a0\nPurchases of common stock 1 \u00a0(483,704 )\u00a0\u00a0(82,150 )\n25", "page_label": "25", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e59a7e28-43e4-443e-9f42-04b24dba58b8", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be29c09d5167b3f8d973d95c68ad128715c550d73d321d8c1fd60a3ce5b3ef89", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07584643-a945-44d9-862d-c1bfa42bb778", "node_type": "1", "metadata": {"window": "Total current assets \u00a039,589,758 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,003 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a012,836,623 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0237,571 \u00a0\u00a0290,791\nOther long-term assets \u00a01,761,661 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $56,560,616 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $40,192,890 \u00a0$38,009,954\nOther current liabilities \u00a02,214,592 \u00a0\u00a03,048,474\nShort-term debt \u00a01,070,473 \u00a0\u00a0300,213\nTotal current liabilities \u00a043,477,955 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,632,360 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0320,274 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,620,413 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a0976,583 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,461,758 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a071,273 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $56,560,616 \u00a0$57,337,805\n24", "original_text": "Total current assets \u00a039,589,758 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,003 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a012,836,623 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0237,571 \u00a0\u00a0290,791\nOther long-term assets \u00a01,761,661 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $56,560,616 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $40,192,890 \u00a0$38,009,954\nOther current liabilities \u00a02,214,592 \u00a0\u00a03,048,474\nShort-term debt \u00a01,070,473 \u00a0\u00a0300,213\nTotal current liabilities \u00a043,477,955 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,632,360 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0320,274 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,620,413 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a0976,583 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,461,758 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a071,273 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $56,560,616 \u00a0$57,337,805\n24", "page_label": "24", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7e90906da654898f95358ff7d7f601be1ea12138eb2b298cbb671921b9840bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1e3aca4-0583-40e5-8009-4576f1306aa5", "node_type": "1", "metadata": {"window": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n 2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "original_text": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n"}, "hash": "05be57c2cde3ae6ec14c07d561f23bca6db801a805ddf7b480ecf89f931959fd", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,666,540 \u00a0\u00a0$1,544,608 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,176,210 \u00a0\u00a0\u00a0754,656 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,659,525 )\u00a0\u00a0(930,078 )\nInventories \u00a0(665,370 )\u00a0\u00a0(1,116,344 )\nAccounts payable \u00a03,320,725 \u00a0\u00a0\u00a02,049,167 \u00a0\nOther, net \u00a0(1,135,492 )\u00a0\u00a0364,577 \u00a0\nNet cash provided by operating activities \u00a02,703,088 \u00a0\u00a0\u00a02,666,586 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(496,318 )\u00a0\u00a0(438,217 )\nCost of acquired companies, net of cash acquired \u00a0(133,814 )\u00a0\u00a0(5,563,040 )\nCost of equity investments \u00a0(18,491 )\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0272,586 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a07,600 \u00a0\u00a0\u00a022,300 \u00a0\nNet cash used in investing activities \u00a0(368,437 )\u00a0\u00a0(6,141,577 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(923,103 )\u00a0\u00a02,216,552 \u00a0\nPurchases of common stock 1 \u00a0(483,704 )\u00a0\u00a0(82,150 )\n25", "start_char_idx": 0, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1e3aca4-0583-40e5-8009-4576f1306aa5": {"__data__": {"id_": "a1e3aca4-0583-40e5-8009-4576f1306aa5", "embedding": null, "metadata": {"window": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n 2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "original_text": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n", "page_label": "26", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c26c5325-b2d6-44bd-a9b2-6e959632171d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecfe97d5d06758030a8655b087160d3709600064862cb59911c8a527e9bbb63a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49b2f2eb-7d36-4997-95fd-0d73056d494b", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,666,540 \u00a0\u00a0$1,544,608 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,176,210 \u00a0\u00a0\u00a0754,656 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,659,525 )\u00a0\u00a0(930,078 )\nInventories \u00a0(665,370 )\u00a0\u00a0(1,116,344 )\nAccounts payable \u00a03,320,725 \u00a0\u00a0\u00a02,049,167 \u00a0\nOther, net \u00a0(1,135,492 )\u00a0\u00a0364,577 \u00a0\nNet cash provided by operating activities \u00a02,703,088 \u00a0\u00a0\u00a02,666,586 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(496,318 )\u00a0\u00a0(438,217 )\nCost of acquired companies, net of cash acquired \u00a0(133,814 )\u00a0\u00a0(5,563,040 )\nCost of equity investments \u00a0(18,491 )\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0272,586 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a07,600 \u00a0\u00a0\u00a022,300 \u00a0\nNet cash used in investing activities \u00a0(368,437 )\u00a0\u00a0(6,141,577 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(923,103 )\u00a0\u00a02,216,552 \u00a0\nPurchases of common stock 1 \u00a0(483,704 )\u00a0\u00a0(82,150 )\n25", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,666,540 \u00a0\u00a0$1,544,608 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,176,210 \u00a0\u00a0\u00a0754,656 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,659,525 )\u00a0\u00a0(930,078 )\nInventories \u00a0(665,370 )\u00a0\u00a0(1,116,344 )\nAccounts payable \u00a03,320,725 \u00a0\u00a0\u00a02,049,167 \u00a0\nOther, net \u00a0(1,135,492 )\u00a0\u00a0364,577 \u00a0\nNet cash provided by operating activities \u00a02,703,088 \u00a0\u00a0\u00a02,666,586 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(496,318 )\u00a0\u00a0(438,217 )\nCost of acquired companies, net of cash acquired \u00a0(133,814 )\u00a0\u00a0(5,563,040 )\nCost of equity investments \u00a0(18,491 )\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0272,586 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a07,600 \u00a0\u00a0\u00a022,300 \u00a0\nNet cash used in investing activities \u00a0(368,437 )\u00a0\u00a0(6,141,577 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(923,103 )\u00a0\u00a02,216,552 \u00a0\nPurchases of common stock 1 \u00a0(483,704 )\u00a0\u00a0(82,150 )\n25", "page_label": "25", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a1d971edbbe80a3dedd944173ccc8910d68610e16fe08bb06e1a0fd09937378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4d8f2d7-ec5a-48e3-a868-bd94fa69efa8", "node_type": "1", "metadata": {"window": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n 2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "original_text": "2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26"}, "hash": "43fe7448bc140c1fff8046445328668053014b47610752ae89c186cc04b48754", "class_name": "RelatedNodeInfo"}}, "text": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n", "start_char_idx": 0, "end_char_idx": 971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4d8f2d7-ec5a-48e3-a868-bd94fa69efa8": {"__data__": {"id_": "b4d8f2d7-ec5a-48e3-a868-bd94fa69efa8", "embedding": null, "metadata": {"window": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n 2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "original_text": "2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "page_label": "26", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c26c5325-b2d6-44bd-a9b2-6e959632171d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecfe97d5d06758030a8655b087160d3709600064862cb59911c8a527e9bbb63a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1e3aca4-0583-40e5-8009-4576f1306aa5", "node_type": "1", "metadata": {"window": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n 2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "original_text": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n", "page_label": "26", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69a8d613e52690656f33ffdaf496af5c3025cc6eb751af022dcaa4b91d8f2aa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c69dd6e3-a16d-4ed6-8fc0-0c41bc3c0e1f", "node_type": "1", "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "To supplement the financial measures prepared in accordance with U.S. "}, "hash": "15a2bb8a3922cb4ff576c81aad2d46a059dce7349f7ccbedb62f5088107dde61", "class_name": "RelatedNodeInfo"}}, "text": "2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "start_char_idx": 971, "end_char_idx": 1644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c69dd6e3-a16d-4ed6-8fc0-0c41bc3c0e1f": {"__data__": {"id_": "c69dd6e3-a16d-4ed6-8fc0-0c41bc3c0e1f", "embedding": null, "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "To supplement the financial measures prepared in accordance with U.S. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4d8f2d7-ec5a-48e3-a868-bd94fa69efa8", "node_type": "1", "metadata": {"window": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n 2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "original_text": "2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "page_label": "26", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f1722297a682117fc1581829da4188692263278e481d584d555be42bb59cfee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05a0c248-28fc-4c96-9831-c34db80595e6", "node_type": "1", "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "2819e5b7873af9535d789349f846c5df9b6a88ea80b26ca02a34c3b7862b7a04", "class_name": "RelatedNodeInfo"}}, "text": "To supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 0, "end_char_idx": 70, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05a0c248-28fc-4c96-9831-c34db80595e6": {"__data__": {"id_": "05a0c248-28fc-4c96-9831-c34db80595e6", "embedding": null, "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c69dd6e3-a16d-4ed6-8fc0-0c41bc3c0e1f", "node_type": "1", "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "To supplement the financial measures prepared in accordance with U.S. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0c3f27722b526e17910c04153663166b70794c0ac2996d77b8b0c16d9a3866d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fe3fe99-40ba-4233-a8d6-8e559befbe99", "node_type": "1", "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "ca1b486e69a0942c72ff374fb69cca325f5c2fd265a5d1750541d3c5b938bd40", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 70, "end_char_idx": 185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fe3fe99-40ba-4233-a8d6-8e559befbe99": {"__data__": {"id_": "6fe3fe99-40ba-4233-a8d6-8e559befbe99", "embedding": null, "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05a0c248-28fc-4c96-9831-c34db80595e6", "node_type": "1", "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b631dcc0980e88fbb6dfc427d786e9641fc6238e0988bdcd635298ebb99cbb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bef6d37-35e9-42a1-b639-d98e1b0e098d", "node_type": "1", "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "98333fa49a8ba5a52cad1a14b9df68b5c6d29f7050fa9be3786a90e113be10a6", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 185, "end_char_idx": 325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bef6d37-35e9-42a1-b639-d98e1b0e098d": {"__data__": {"id_": "1bef6d37-35e9-42a1-b639-d98e1b0e098d", "embedding": null, "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fe3fe99-40ba-4233-a8d6-8e559befbe99", "node_type": "1", "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5130c296064d84020d3563ef1b86b72b11b47f384d3c826747196ac1a1b2c9aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94218b4b-a2fb-436b-b3b4-5182c9e73899", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit. ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "6ad02b8a83e51d060831e27d50dd64d87eff0b285073b8db63612b2ac0a74fa0", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 325, "end_char_idx": 444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94218b4b-a2fb-436b-b3b4-5182c9e73899": {"__data__": {"id_": "94218b4b-a2fb-436b-b3b4-5182c9e73899", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit. ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bef6d37-35e9-42a1-b639-d98e1b0e098d", "node_type": "1", "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e296e01a8e0247187e534a854ac6e95f2c4e394b1aecc1001c0c4a8ce3ce7a92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86fc53c2-a868-4d33-a9ed-075d93b87781", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "7908f288cd56d4d45b46fedcbb0915024d844335a546abbc2e5fdbc40c4ab8ef", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 444, "end_char_idx": 663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86fc53c2-a868-4d33-a9ed-075d93b87781": {"__data__": {"id_": "86fc53c2-a868-4d33-a9ed-075d93b87781", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94218b4b-a2fb-436b-b3b4-5182c9e73899", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit. ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54845cde6117b3410c9f007e7f49de68c09c8d75bbbb738ca1e4713f2fd3fc8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a89a1efa-f638-40fe-b992-40c5c58ad062", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "41f132fdd9fa5cfdf6795bb722810949bc7175ffd839297b980ae8b3d9ddb68a", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 663, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a89a1efa-f638-40fe-b992-40c5c58ad062": {"__data__": {"id_": "a89a1efa-f638-40fe-b992-40c5c58ad062", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86fc53c2-a868-4d33-a9ed-075d93b87781", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c69d8d69615a7d34443550f659b5363ac2e1f913efa302e27b6434e6ec3388f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a91a441-cd3f-4550-b9de-d2f4624d74d3", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit. "}, "hash": "a2328ec22566fc1cff1dfb8ebd45676c74a4ce0729a6654a8dfcec732c850a3a", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 845, "end_char_idx": 1126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a91a441-cd3f-4550-b9de-d2f4624d74d3": {"__data__": {"id_": "5a91a441-cd3f-4550-b9de-d2f4624d74d3", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a89a1efa-f638-40fe-b992-40c5c58ad062", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c564d2a569d92bc21a093b4b2649816e76d3e88ccb083e4c153627d565c2a98c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbef6859-369a-4389-ab2d-f91263fd99fd", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. "}, "hash": "f0d787f00b8f8d5a194dc9dcb486c275ea704c0e0dcc94de891abd93ef387018", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit. ", "start_char_idx": 1126, "end_char_idx": 1448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbef6859-369a-4389-ab2d-f91263fd99fd": {"__data__": {"id_": "cbef6859-369a-4389-ab2d-f91263fd99fd", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a91a441-cd3f-4550-b9de-d2f4624d74d3", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74e4336e352eda85685a772d0ed1ec9b5a67bd5df77b57ffd43b2a7ef210b702", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8627cc23-67bd-4cf9-b552-a696df26a01b", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue. "}, "hash": "1f0978b6c290c4a8885198ce06daa4870d3aa216e35a5f5c59a7afce99a5a026", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "start_char_idx": 1448, "end_char_idx": 1648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8627cc23-67bd-4cf9-b552-a696df26a01b": {"__data__": {"id_": "8627cc23-67bd-4cf9-b552-a696df26a01b", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbef6859-369a-4389-ab2d-f91263fd99fd", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7e8c5948fc0f33db72959129b177f35ef8401699176d7abc4bfca25677c6083", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed55b7d9-2b14-4c6a-8b26-dcd4c0a3c7c2", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance. "}, "hash": "86d80ac2267e4a3cc602ca9f567c2aa15bf56271a62c7347831435242f4122d2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue. ", "start_char_idx": 1648, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed55b7d9-2b14-4c6a-8b26-dcd4c0a3c7c2": {"__data__": {"id_": "ed55b7d9-2b14-4c6a-8b26-dcd4c0a3c7c2", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8627cc23-67bd-4cf9-b552-a696df26a01b", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cc81ebc7c14735c402eba0ec66df1cbcaaf3a08c7f96d4fb32f5f1c36832367", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68c459fd-8105-404f-9789-9f772ba21c1e", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. "}, "hash": "f286deca40f17d5230297a61652feda04387a911e1293b189d46d15fba50a7fe", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 1733, "end_char_idx": 1890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68c459fd-8105-404f-9789-9f772ba21c1e": {"__data__": {"id_": "68c459fd-8105-404f-9789-9f772ba21c1e", "embedding": null, "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed55b7d9-2b14-4c6a-8b26-dcd4c0a3c7c2", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense/credit.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0e4036ef5c756580ca0536b7671aa65cc65d9fc5420e009132f3514941f0086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97bd98f5-f331-425e-a350-f56b4be5ad75", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n"}, "hash": "8a2b9b3d1fd3b92a21547f4e54675ea3613b59836c428d09b1fc7819e2e1d755", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "start_char_idx": 1890, "end_char_idx": 2186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97bd98f5-f331-425e-a350-f56b4be5ad75": {"__data__": {"id_": "97bd98f5-f331-425e-a350-f56b4be5ad75", "embedding": null, "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68c459fd-8105-404f-9789-9f772ba21c1e", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense/credit are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87bf38bd172bcac0028107fc40a630d2e7afc280bd5d7d75e5b0a85bb7dd1781", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7401cb7-2c77-4bd6-944a-6e91f21e241c", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets. "}, "hash": "6ab86fecc512ed09dcfaf3f8ce2010313d22cf485ade4826222fd2d378eefc95", "class_name": "RelatedNodeInfo"}}, "text": "LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n", "start_char_idx": 2186, "end_char_idx": 2366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7401cb7-2c77-4bd6-944a-6e91f21e241c": {"__data__": {"id_": "e7401cb7-2c77-4bd6-944a-6e91f21e241c", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97bd98f5-f331-425e-a350-f56b4be5ad75", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to\ntotal revenue.  Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d71a1cbe6e2eceeee9b4ddf9d84e04721d2e2bea420130ee2376de053916f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d380d7e-bae9-4c51-85db-ac61d8bd551e", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "original_text": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. "}, "hash": "45fdbd0fe83f8953593a0342ffb84c7d116ef291d5c51176d0ee292b48f9acc4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets. ", "start_char_idx": 2366, "end_char_idx": 2694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d380d7e-bae9-4c51-85db-ac61d8bd551e": {"__data__": {"id_": "9d380d7e-bae9-4c51-85db-ac61d8bd551e", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "original_text": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7401cb7-2c77-4bd6-944a-6e91f21e241c", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental\nmeasure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7682dccea38f1203f2cad2ef01a19b7d753018f74061c6da2c8b10e8b780311a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6a671e5-6179-421d-90a4-8cc707477971", "node_type": "1", "metadata": {"window": "LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. "}, "hash": "5d6083ec77ff27dc693c5a2269cedf6bf084f3abaceb31df92db5837ecc26894", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "start_char_idx": 2694, "end_char_idx": 2790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6a671e5-6179-421d-90a4-8cc707477971": {"__data__": {"id_": "a6a671e5-6179-421d-90a4-8cc707477971", "embedding": null, "metadata": {"window": "LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d380d7e-bae9-4c51-85db-ac61d8bd551e", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the\nsettlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by\nitself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "original_text": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d41433fa304201c0f912a6d8f58cd5a1a711524e47c44faf5fc6ca0324647ab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "216f7b0a-bf06-45aa-a033-8a1f37150872", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring. "}, "hash": "fd0d2326fab4c68b97fd9493e632bdf05a6e1ea56596572213416c7a6c6f2939", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "start_char_idx": 2790, "end_char_idx": 2951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "216f7b0a-bf06-45aa-a033-8a1f37150872": {"__data__": {"id_": "216f7b0a-bf06-45aa-a033-8a1f37150872", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6a671e5-6179-421d-90a4-8cc707477971", "node_type": "1", "metadata": {"window": "LIFO\nexpense/credit is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718613855b00ebc3b7b17458d5ab81f46fb34da39a04cfcb661eae7d4ff55e9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e16fb5d-b432-43de-8fe9-69d8916f6121", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n"}, "hash": "fe0fa192951fef56a436a708c220ffbc1298e964f9708158b2d4c76fbd4c1743", "class_name": "RelatedNodeInfo"}}, "text": "We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring. ", "start_char_idx": 2951, "end_char_idx": 3060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e16fb5d-b432-43de-8fe9-69d8916f6121": {"__data__": {"id_": "2e16fb5d-b432-43de-8fe9-69d8916f6121", "embedding": null, "metadata": {"window": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "216f7b0a-bf06-45aa-a033-8a1f37150872", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, litigation and opioid-related expenses, acquisition,\nintegration, and restructuring expenses, goodwill impairment, and impairment of assets.  Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98cdd2839473f40d2370cf04348ef118e62d397935e546765ae5be54aef54ed1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9937be4-8422-473a-a9dd-189372ff03d9", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "8e0250338d6435f81dfe7e95fe81dc51acdca8a9682c8a2f70ede58fee9e0cda", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "start_char_idx": 3060, "end_char_idx": 3370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9937be4-8422-473a-a9dd-189372ff03d9": {"__data__": {"id_": "f9937be4-8422-473a-a9dd-189372ff03d9", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e16fb5d-b432-43de-8fe9-69d8916f6121", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin\nis the ratio of adjusted operating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5583a98b5b7bf1674bf97fdf0b76dcd85ae954a293745e49326df891ba9d0bcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "137b4752-a439-4463-895a-c1fe8351a3d5", "node_type": "1", "metadata": {"window": "We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "c755845b7cce29a38bf6a689fef57dfcdc9163843bfbc503d52f9fb1993586ff", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 3370, "end_char_idx": 3619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "137b4752-a439-4463-895a-c1fe8351a3d5": {"__data__": {"id_": "137b4752-a439-4463-895a-c1fe8351a3d5", "embedding": null, "metadata": {"window": "We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9937be4-8422-473a-a9dd-189372ff03d9", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because\nit is a non-cash item and does not reflect the operating performance of the acquired companies.  We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4949119807e74c218e069700925ef46e5a0581d481274c1047bdc54757c373a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f604614-9758-42f2-9b8d-cd8d9d56c48e", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "88ad1087603cb3641f0d99807d107c63fa2cfbbdc2f083e54eb193a883fb4b8f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 3619, "end_char_idx": 3712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f604614-9758-42f2-9b8d-cd8d9d56c48e": {"__data__": {"id_": "6f604614-9758-42f2-9b8d-cd8d9d56c48e", "embedding": null, "metadata": {"window": "We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "137b4752-a439-4463-895a-c1fe8351a3d5", "node_type": "1", "metadata": {"window": "We exclude acquisition,\nintegration, and restructuring expenses that are unpredictable and/or non-recurring.  We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b017a4baec0a8c7f36283680b500d0965becff62c496ff4816a62ff88b533db8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5d27975-9d6c-4f8a-95af-c0db74b714b6", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "62116b64e54201bed0c120d40e6ccc00a969eb6e21bab0228333a6caf080cca4", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 3712, "end_char_idx": 3959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5d27975-9d6c-4f8a-95af-c0db74b714b6": {"__data__": {"id_": "d5d27975-9d6c-4f8a-95af-c0db74b714b6", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f604614-9758-42f2-9b8d-cd8d9d56c48e", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation\nsettlements and other expenses, such as goodwill impairment and the impairment of assets, that are unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing\noperational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38a6d1ef8987ba53c1df64c7b480a460526ab481404c996f07e602084f01e828", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ea9c43d-b8cb-4523-a8dd-5303b2ae258a", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. "}, "hash": "d5ec659f54423388e59a271578590ac11a49d58f729452c06a7e9ad5ad7df1c5", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 3959, "end_char_idx": 4164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ea9c43d-b8cb-4523-a8dd-5303b2ae258a": {"__data__": {"id_": "2ea9c43d-b8cb-4523-a8dd-5303b2ae258a", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5d27975-9d6c-4f8a-95af-c0db74b714b6", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c96f3d822aac0820b4bf4b453d6cea6e839577a40e4eb15ac4cbc1708d7ff7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f998c9f1-27dc-45fb-b1d9-adfbe2d137c5", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n"}, "hash": "3e89a07c5e28132f8351f8907a6b31023f60e46b649763bbf8d96f0fc6096c04", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "start_char_idx": 4164, "end_char_idx": 4564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f998c9f1-27dc-45fb-b1d9-adfbe2d137c5": {"__data__": {"id_": "f998c9f1-27dc-45fb-b1d9-adfbe2d137c5", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ea9c43d-b8cb-4523-a8dd-5303b2ae258a", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "947863c451e0a64ffe33f86c484a8ae7514827ce88c25621376cafcc7f9b29ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "520c0582-c677-4545-97fe-2d6be2132742", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "dbb186e6998f91114da9d628b48071ef6d2b921c7fb995164f6269a9c2b4d561", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "start_char_idx": 4564, "end_char_idx": 4729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "520c0582-c677-4545-97fe-2d6be2132742": {"__data__": {"id_": "520c0582-c677-4545-97fe-2d6be2132742", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f998c9f1-27dc-45fb-b1d9-adfbe2d137c5", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4fb41b19782890ea0bd9d03dc0eade4036e554b0bbe4a08aca11c23a1003139", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "624f03f0-fe03-4d9a-aad5-e185b8f9cd3d", "node_type": "1", "metadata": {"window": "In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "40398ff9f84a4c1964c17c22e28eb5dac5278ecc86f1add7099f89a4e69d5a7e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 4729, "end_char_idx": 4926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "624f03f0-fe03-4d9a-aad5-e185b8f9cd3d": {"__data__": {"id_": "624f03f0-fe03-4d9a-aad5-e185b8f9cd3d", "embedding": null, "metadata": {"window": "In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "520c0582-c677-4545-97fe-2d6be2132742", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eba8795f385fc668fa658f74ca7af2890e3865da10b98650e5fca4f50e56f63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f987ae6b-8e91-4d14-a3c1-f07f37334c31", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27"}, "hash": "472e0e4e79a38195e23498c289a8d40d8054209fa097b56b2cc3e19f67fe1e4b", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 4926, "end_char_idx": 5198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f987ae6b-8e91-4d14-a3c1-f07f37334c31": {"__data__": {"id_": "f987ae6b-8e91-4d14-a3c1-f07f37334c31", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07de28c8862fb482035898af86ad7fe5b1efa8e1ea4c443859f977ef3bc9356a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "624f03f0-fe03-4d9a-aad5-e185b8f9cd3d", "node_type": "1", "metadata": {"window": "In addition, the gain on the\nremeasurement of an equity investment, impairment of a non-customer note receivable, as well as the gain/loss on the sale\nof non-core businesses and the gain/loss on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98e06190d0b0d87a4f5b121e9808e6807297fc1b80d2338db80e854b3207948", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "134504d0-72a0-4105-a971-06879b7bb8fd", "node_type": "1", "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "8c3fc6a71fc0425731a0abb3bf642f84bc42bbfdfbf642bc6d3187405e081656", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "start_char_idx": 5198, "end_char_idx": 5319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "134504d0-72a0-4105-a971-06879b7bb8fd": {"__data__": {"id_": "134504d0-72a0-4105-a971-06879b7bb8fd", "embedding": null, "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f987ae6b-8e91-4d14-a3c1-f07f37334c31", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\n27", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80d4c96b10e83486ea4ad3762bd920b55b038b0041269f162db2c4cb7cd87494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2262d33b-2578-4896-b25c-60b328eade6e", "node_type": "1", "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense. "}, "hash": "2f7465b3a260d6b0f1a8a5f7bfe5ccc67b33c0a2d22842bfadc85b3e346a5a5c", "class_name": "RelatedNodeInfo"}}, "text": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 0, "end_char_idx": 119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2262d33b-2578-4896-b25c-60b328eade6e": {"__data__": {"id_": "2262d33b-2578-4896-b25c-60b328eade6e", "embedding": null, "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "134504d0-72a0-4105-a971-06879b7bb8fd", "node_type": "1", "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d62146453ab296d6e56dd62718a41b3bb9f8eadfb99d6e4ad03d640bc6fe7b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c00e58af-7584-4fc8-9ec2-60b890bf8654", "node_type": "1", "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n", "original_text": "Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022. "}, "hash": "abf17cbff3490a8bb41aeb2cb6cfb3141f2082ac4e30c7f3ce8403cb79fb429b", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense. ", "start_char_idx": 119, "end_char_idx": 319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c00e58af-7584-4fc8-9ec2-60b890bf8654": {"__data__": {"id_": "c00e58af-7584-4fc8-9ec2-60b890bf8654", "embedding": null, "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n", "original_text": "Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2262d33b-2578-4896-b25c-60b328eade6e", "node_type": "1", "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41edf95dcd3958412b63de6c7d14d127307009e93c19ce6295a2bd10e03b78d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "591b06b4-8515-4c8e-8acf-894859120871", "node_type": "1", "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "ad5bcc3cad4328826c5e1ba99c571be05e40ddc1a16e7ccbf500d7c6b85a3dd6", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022. ", "start_char_idx": 319, "end_char_idx": 577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "591b06b4-8515-4c8e-8acf-894859120871": {"__data__": {"id_": "591b06b4-8515-4c8e-8acf-894859120871", "embedding": null, "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c00e58af-7584-4fc8-9ec2-60b890bf8654", "node_type": "1", "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n", "original_text": "Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ecfe0730bc808cb9d265faf1bdbdf170604af0d8b34d3e9afab9ca5baec285f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78c89f36-4e4e-4dc9-92e7-3abbf0389e02", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses. "}, "hash": "b18e9f4bb7faf537e7969c2a71632424444cfc2ad8332e998d94d709db432e66", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 577, "end_char_idx": 821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78c89f36-4e4e-4dc9-92e7-3abbf0389e02": {"__data__": {"id_": "78c89f36-4e4e-4dc9-92e7-3abbf0389e02", "embedding": null, "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "591b06b4-8515-4c8e-8acf-894859120871", "node_type": "1", "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99a6d4975155651b324a4a5401baab088896f18b1e1f0641349a386473e38dbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7614b7ed-2da1-4929-a54b-a864e794e79c", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n"}, "hash": "2f70dba55e574799c77a7d066146e6b15898b3757e9c4b9e5ea46fec3d3e0234", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses. ", "start_char_idx": 821, "end_char_idx": 1114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7614b7ed-2da1-4929-a54b-a864e794e79c": {"__data__": {"id_": "7614b7ed-2da1-4929-a54b-a864e794e79c", "embedding": null, "metadata": {"window": "Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78c89f36-4e4e-4dc9-92e7-3abbf0389e02", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87d5ba4a3c4a155ff48a1fc4aa075173ddec13f5b4576dc4ce7090472959e83e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a955e1f-bbb2-4ec8-b93a-76e7ffa5400b", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share. ", "original_text": "Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above. "}, "hash": "029a14c97d4f5bf7cfb1de4abe9b43180bd7d8afd481a0109faa27aaaefd3e4d", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n", "start_char_idx": 1114, "end_char_idx": 1291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a955e1f-bbb2-4ec8-b93a-76e7ffa5400b": {"__data__": {"id_": "2a955e1f-bbb2-4ec8-b93a-76e7ffa5400b", "embedding": null, "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share. ", "original_text": "Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7614b7ed-2da1-4929-a54b-a864e794e79c", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62dd97ca005f7329e3a0ae2715d8d617abbf0d4116927d74452723100c75317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af545af1-ca7c-44cb-9c62-0030fe80d3a0", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "389744aa3869aecbf304a0df89629e6b427ba1314b5ca088f11520c91065864f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above. ", "start_char_idx": 1291, "end_char_idx": 1489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af545af1-ca7c-44cb-9c62-0030fe80d3a0": {"__data__": {"id_": "af545af1-ca7c-44cb-9c62-0030fe80d3a0", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a955e1f-bbb2-4ec8-b93a-76e7ffa5400b", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share. ", "original_text": "Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0ec6d5ae8b3e1a645305cb132fdc29e202ede78902b0dac69a8bee366e0b594", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1461c2da-1b80-45b4-bde3-5402989501a8", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. "}, "hash": "fb67ccf8dbfdc35290bab31fbbc58b7b73d13a11205210b43905e18bfe47882d", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 1489, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1461c2da-1b80-45b4-bde3-5402989501a8": {"__data__": {"id_": "1461c2da-1b80-45b4-bde3-5402989501a8", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af545af1-ca7c-44cb-9c62-0030fe80d3a0", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization, goodwill impairment,\nand gain/loss on sale of non-core businesses.  Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf32922ba67d865e31bb1ec10aad37e59b3be9490b29f0c8aa39221d305d5c47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d949d34f-7fa1-4853-bb99-c5a6974877b6", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share. "}, "hash": "6fbdaafb4b20bacf4394456566230de21cc451a0041f2a58963fe89d99f53943", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "start_char_idx": 1733, "end_char_idx": 2375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d949d34f-7fa1-4853-bb99-c5a6974877b6": {"__data__": {"id_": "d949d34f-7fa1-4853-bb99-c5a6974877b6", "embedding": null, "metadata": {"window": "Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1461c2da-1b80-45b4-bde3-5402989501a8", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors because it facilitates the calculation of adjusted net income attributable to AmerisourceBergen.\n Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c11525bc3f7285b8b660dfe943b5a2cfcb95d16a2e363df1157f79986d9d256", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22b120f3-29f1-4254-a168-a94e24086e09", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n"}, "hash": "dc9aeeb1c82dc664f409d148359356d84dfe0298e5ac51e6cd130c5f49aca4b5", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share. ", "start_char_idx": 2375, "end_char_idx": 2735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22b120f3-29f1-4254-a168-a94e24086e09": {"__data__": {"id_": "22b120f3-29f1-4254-a168-a94e24086e09", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d949d34f-7fa1-4853-bb99-c5a6974877b6", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to AmerisourceBergen:  Adjusted net income attributable to AmerisourceBergen is a non-\nGAAP financial measure that excludes the same items that are described above.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7378af63b9ef9f8eb2cfbc6fb8da7b31f741f259ae0553931e4d547d5c8807c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6df2a390-54bc-40b6-a76c-97e16ece3660", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. "}, "hash": "304ce6ab35c23cba4ee67fdb9fbdbd4bb742e8d90be428a392eacc70c90945fe", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "start_char_idx": 2735, "end_char_idx": 3089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6df2a390-54bc-40b6-a76c-97e16ece3660": {"__data__": {"id_": "6df2a390-54bc-40b6-a76c-97e16ece3660", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22b120f3-29f1-4254-a168-a94e24086e09", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company's performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcef5755d6df1dfa659e51654efecf7a4f7711d1e3b84e54cccda2caba40f1a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa6cddf6-2635-4130-a633-d88d57e8c3a4", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. "}, "hash": "3ac4c5f3b423c853f53f49767ac106de9d307f7710fbeb3691fe0e35e1880e30", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "start_char_idx": 3089, "end_char_idx": 3362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa6cddf6-2635-4130-a633-d88d57e8c3a4": {"__data__": {"id_": "fa6cddf6-2635-4130-a633-d88d57e8c3a4", "embedding": null, "metadata": {"window": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6df2a390-54bc-40b6-a76c-97e16ece3660", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense/credit; acquisition-related\nintangibles amortization; litigation and opioid expenses; acquisition, integration and restructuring expenses; gain on\nremeasurement of equity investment; gain/loss on sale of non-core businesses; impairment of a non-customer note\nreceivable; goodwill impairment; and impairment of assets, in each case net of the tax effect calculated using the applicable\neffective tax rate for those items.  In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed111b6281fc3055db89d70a63517a3c3169d371605ec65f7562249f727bab10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2077b57-8c0f-48bd-830c-940df2174bd6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S. ", "original_text": "For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n"}, "hash": "a615ac154a37c666b52bda8482cc650f6fac17367df3a8781cacf79062170abe", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "start_char_idx": 3362, "end_char_idx": 3600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2077b57-8c0f-48bd-830c-940df2174bd6": {"__data__": {"id_": "e2077b57-8c0f-48bd-830c-940df2174bd6", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S. ", "original_text": "For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa6cddf6-2635-4130-a633-d88d57e8c3a4", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete tax benefits primarily attributable to the\nincome tax deduction recognized in connection with the permanent shutdown of PharMEDium as well as the per share\nimpact of certain benefits and expenses relating to tax reforms in Switzerland and the UK are also excluded from adjusted\ndiluted earnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29670cb0d6a0ce51c6b9ecacbdcc7d23d7cfb6af621cc905693e877a35b733f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96d7a2be-43e4-4ce0-ad6e-c3067fd317eb", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n", "original_text": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n"}, "hash": "d054712ab6c7dd2f23bdad23dcf0f86272c87c68435a54c0cb2904ae6c16fb63", "class_name": "RelatedNodeInfo"}}, "text": "For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n", "start_char_idx": 3600, "end_char_idx": 3930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96d7a2be-43e4-4ce0-ad6e-c3067fd317eb": {"__data__": {"id_": "96d7a2be-43e4-4ce0-ad6e-c3067fd317eb", "embedding": null, "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n", "original_text": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2077b57-8c0f-48bd-830c-940df2174bd6", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\neliminates the per share impact of the items that are outside the control of the Company or that we consider to not be\nindicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring,\nor non-cash nature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S. ", "original_text": "For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95a1a61040cc988535b700069e43532d5719e5f0396c372d5a8251fc2e63b2c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31718ee0-aedd-4a31-abce-42f0aa1a2bc4", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. "}, "hash": "1a2d69623761e39e616f4a7678260eff42cb257c92adcee5114bf3fa2a136266", "class_name": "RelatedNodeInfo"}}, "text": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "start_char_idx": 3930, "end_char_idx": 4056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31718ee0-aedd-4a31-abce-42f0aa1a2bc4": {"__data__": {"id_": "31718ee0-aedd-4a31-abce-42f0aa1a2bc4", "embedding": null, "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96d7a2be-43e4-4ce0-ad6e-c3067fd317eb", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n", "original_text": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f54923958d2c633fafe363089116d86c021efc3b1313cd68c4c7470f162d2c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e4ea2f0-9248-4f48-a6ff-c8e97a4789b4", "node_type": "1", "metadata": {"window": "For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S. "}, "hash": "acf686d23fefc2f37eb03d72fe3d404e0418020a66de211b0ffa5aa003bac236", "class_name": "RelatedNodeInfo"}}, "text": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "start_char_idx": 4056, "end_char_idx": 4216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e4ea2f0-9248-4f48-a6ff-c8e97a4789b4": {"__data__": {"id_": "1e4ea2f0-9248-4f48-a6ff-c8e97a4789b4", "embedding": null, "metadata": {"window": "For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31718ee0-aedd-4a31-abce-42f0aa1a2bc4", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97b53d09f1c8797cf9e898c1a0352f85413dc82710f167e361ed191b20475d48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17f72d41-f5aa-4dfd-8441-72c6f967a184", "node_type": "1", "metadata": {"window": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n"}, "hash": "1fead601e1de85233694637b8ff779715871a23e9584be7129fb91b3e216ab67", "class_name": "RelatedNodeInfo"}}, "text": "The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S. ", "start_char_idx": 4216, "end_char_idx": 4393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17f72d41-f5aa-4dfd-8441-72c6f967a184": {"__data__": {"id_": "17f72d41-f5aa-4dfd-8441-72c6f967a184", "embedding": null, "metadata": {"window": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e4ea2f0-9248-4f48-a6ff-c8e97a4789b4", "node_type": "1", "metadata": {"window": "For the fiscal year ended September 30, 2022, adjusted free cash flow of $2,977.8 million consisted of net cash\nprovided by operating activities of $2,703.1 million, minus capital expenditures of $496.3 million and the gains from antitrust\nlitigation settlements of $1.8 million, plus legal settlement payments of $772.9 million.\n The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54027d66e9d95109269d8d882b10b6fe94d24826e118e9e3cd32706a3ee2dc44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36982700-3884-4951-b74f-fb85b85f40e0", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "2fe1962283e9d14246656f078e10556db4c7cf312559a9440d6a66821710d867", "class_name": "RelatedNodeInfo"}}, "text": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n", "start_char_idx": 4393, "end_char_idx": 4574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36982700-3884-4951-b74f-fb85b85f40e0": {"__data__": {"id_": "36982700-3884-4951-b74f-fb85b85f40e0", "embedding": null, "metadata": {"window": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17f72d41-f5aa-4dfd-8441-72c6f967a184", "node_type": "1", "metadata": {"window": "The Company also presents revenue and operating income on a \u201cconstant currency\u201d basis, which are non-GAAP financial measures.\n These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "564ce9c27d5e1f486045580b4dccbf1798d494f32975e57ce029caa0bf1af53f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db5af48d-bc51-41ce-b850-da948982a586", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. "}, "hash": "ba677954702f4a23eeac68b21c65afbed072ea40cd7d729a789850c4ef4e9c10", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 4574, "end_char_idx": 5022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db5af48d-bc51-41ce-b850-da948982a586": {"__data__": {"id_": "db5af48d-bc51-41ce-b850-da948982a586", "embedding": null, "metadata": {"window": "The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36982700-3884-4951-b74f-fb85b85f40e0", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period GAAP results at the foreign currency exchange rates used in the\ncomparable period in the prior year.  The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79575d925b91441b80002bc6a99fad3a683dfacfefaa6edcdc76346e9a342293", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2eff4c6-ce3e-4868-a308-e2e8da14b93d", "node_type": "1", "metadata": {"window": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "07d96ab38deec9a4fccc66df7f3f2e446ba65261f37b99fd3fdaee1f93886a17", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "start_char_idx": 5022, "end_char_idx": 5258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2eff4c6-ce3e-4868-a308-e2e8da14b93d": {"__data__": {"id_": "f2eff4c6-ce3e-4868-a308-e2e8da14b93d", "embedding": null, "metadata": {"window": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db5af48d-bc51-41ce-b850-da948982a586", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has significant\noperations outside of the United States reporting in currencies other than the U.S.  dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7837ab89ecfafdd5c5499b28105bd625fd6b189ef9e0fdd544f870b4b4a93e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97ac83a3-ceca-4043-8d89-028fddc32bc5", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28"}, "hash": "4ba93ec77ec6e9f6a400de2f9b6f7273e1b34eed70309e79a4aa3f50d477c0f0", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 5258, "end_char_idx": 5572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97ac83a3-ceca-4043-8d89-028fddc32bc5": {"__data__": {"id_": "97ac83a3-ceca-4043-8d89-028fddc32bc5", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8c873a7a1cc32ac05b8bb9913a3ffa5a17a5301c87493b78cc94f138477f60", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2eff4c6-ce3e-4868-a308-e2e8da14b93d", "node_type": "1", "metadata": {"window": "dollar and management believes that this\npresentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate\nfluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c26eadcf3d3b3f6ae6e84f94db494c5ad8c8e29e5338e7f16c8d3ab4bdc441eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ec8cca9-a3f5-403c-8605-1431054280e6", "node_type": "1", "metadata": {"window": "and cannot be reasonably estimated.\n Bennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "and cannot be reasonably estimated.\n"}, "hash": "48e17a0e243069e090a01d100b89dc2b3ddc2acc284d6304117dc77c434eab50", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "start_char_idx": 5572, "end_char_idx": 5722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ec8cca9-a3f5-403c-8605-1431054280e6": {"__data__": {"id_": "7ec8cca9-a3f5-403c-8605-1431054280e6", "embedding": null, "metadata": {"window": "and cannot be reasonably estimated.\n Bennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "and cannot be reasonably estimated.\n", "page_label": "29", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa5146df-bba4-46dc-ac09-81e1f3545705", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bd7dbac620c2d5afa8f0f5ae502fbc0e4fb2be56156a01e827a6604875dbaa5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97ac83a3-ceca-4043-8d89-028fddc32bc5", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate and free cash flow that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense/credit is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\n28", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5b7f3f92b3b20982240311e1329a8cde2908e5f479da7abc5282b26c506657b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea54393a-9105-4001-b15f-759684ef4046", "node_type": "1", "metadata": {"window": "and cannot be reasonably estimated.\n Bennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "Bennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n29"}, "hash": "914f001118467828c993ba85dd0a073be59bbab917f62f6219474fe53e6a6357", "class_name": "RelatedNodeInfo"}}, "text": "and cannot be reasonably estimated.\n", "start_char_idx": 0, "end_char_idx": 36, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea54393a-9105-4001-b15f-759684ef4046": {"__data__": {"id_": "ea54393a-9105-4001-b15f-759684ef4046", "embedding": null, "metadata": {"window": "and cannot be reasonably estimated.\n Bennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "Bennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n29", "page_label": "29", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa5146df-bba4-46dc-ac09-81e1f3545705", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bd7dbac620c2d5afa8f0f5ae502fbc0e4fb2be56156a01e827a6604875dbaa5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ec8cca9-a3f5-403c-8605-1431054280e6", "node_type": "1", "metadata": {"window": "and cannot be reasonably estimated.\n Bennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "and cannot be reasonably estimated.\n", "page_label": "29", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5b1e69194bab4c910ccf72af7b46148df01ac612cdfaef4409ff6e0e20abdba", "class_name": "RelatedNodeInfo"}}, "text": "Bennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n29", "start_char_idx": 36, "end_char_idx": 185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"ee6ae5b2-2503-4fa2-8ba9-6ea67573ab57": {"doc_hash": "45b1bfdd2faa9b0ca48a4fdcaae7a8109bb57279f344f2717aa2baa0d76fcc46", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "db1ed0e1-54e2-4c2d-b916-d6ccd9fc9832": {"doc_hash": "3782513879486e4eee5bfbd2c781ee74dbb4f3b6af3b43686bef8a5def0856b5", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "92e0c04e-820d-4eee-9f56-c43faab2865a": {"doc_hash": "2bc05839f261343d10b6e604b86fbcdbfdaceff2afc59ae3ffe858134131737e", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "128f7cbb-d598-4dc1-8ffd-d3aaea15774e": {"doc_hash": "c5d7055b5efc37370f3e38dafb9aab29c2bec9bf2a48584f193ac00b2a15e9cd", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "32724e6c-0ce1-4427-a280-7dfd48e92f53": {"doc_hash": "caedc040e576ea15450f5aaacb8500dbbfb2f33fa280811ff364d062fe20fa6c", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "b7f5f27c-031e-45ee-9e94-9e99cb14d96e": {"doc_hash": "7c57c2f0e071ecd233a82f58f680988d92c16fd9c49ade7b61b70be811710933", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "adc2b52c-56f7-48be-8a87-d7b23ef59198": {"doc_hash": "94d213c509ba6f9d7ead72434a8921cc77663c37728ce1547290fad1b0f126c5", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "1f099b2c-5412-43a8-9ac2-cf4e10bdc597": {"doc_hash": "2a5a18287f2a1b534d57a787eb34b58cdb07ba669432bfe1869fc9ab5d1944d0", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "90b6d25b-e13b-424b-96cb-324c4eaf5a23": {"doc_hash": "d20dde9d5fe2e7d6f4ca4426710b67913cd739a6e8e9fcb9506f5b4dd8580168", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "c1475d67-ae7e-4bf7-aea2-874a11740043": {"doc_hash": "d055e3867ef86ccfb8b432c3b209ad02987519d305854126fdf6cefcc3832bd6", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "48ea8a4b-3ea1-4c22-a21b-72354b56689c": {"doc_hash": "b25b662cb993e38613dadbbe49647b55e465633ed532079e9c120f7b43e39b93", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "4cb60628-419c-4fab-a98d-cebc8ba02ede": {"doc_hash": "f805fe836cfab2b4669685bb58a0d17f34a5a6b17d5df01215638b7a09e856be", "ref_doc_id": "b968c78e-ae4d-4b99-b6bb-c62bbf697e98"}, "efce9afa-ac43-4b39-9f8e-0c01557da49e": {"doc_hash": "28c11b5011b94891090eb379687f4e94f1af407245888194f75d5da40d39db1f", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "4fa95183-63cb-40a9-a312-713ecdc9ed66": {"doc_hash": "7e26f12f6b1f369524a133b4289989a195cc8de801ea1dd9d0e3e8b276f0575d", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "06151153-aab5-42e3-87b3-9bb31a3bc800": {"doc_hash": "31343e9134c1fe7da6b2e9d8e595bc576b10215000806c51020aaa09cd1c1d1a", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "e77d2d38-e641-4add-8904-d9549d74e747": {"doc_hash": "5746ff87851dab93084024312d24982c207efb9b265ef89cb6d27bab0c3d3d71", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "8098cf5e-f5bf-43f9-81f1-a86f1861194a": {"doc_hash": "9bdd3f0fd673f6ec217d26c5ae6aaf17bbfc4ec74e0f0b78ad196c6a7edd53a3", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "1d08a53c-9fb5-4543-8912-b9ab034c0f3f": {"doc_hash": "2ddeded1911e8c5a3f43669e555097bc936bdef70d454b82f1217c0773c3fb3b", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "6b03e6d8-60fa-4842-91d5-926e5ebf2d5f": {"doc_hash": "98ff43716cba39c3ec9a43f86c59aa7c5ff145f8708d67bdb80be59ae1e58d5f", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "a9b6cc8e-8090-407a-ab57-4d44dce365f7": {"doc_hash": "8da61ee323cb4f942d1eba0a9572645c33860d07a93b06d2460ce2081551c4cc", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "13ba6ed1-5f06-44cb-a2d0-876d2f7b09a3": {"doc_hash": "10d74efc18614eda560ee6d0157ff7c79e8f092428dd23444b2b8b2a233c62e9", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "565b5fd3-f266-40df-a747-ed3b80e794a7": {"doc_hash": "d16e9d97cb29d6643dd1e14a6103b4149c03a934f1a90db45775ef070c06ea7d", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "1facaba3-fe33-4505-bb60-97b89257a541": {"doc_hash": "1ee1389278d88a10961810fee7581fb82670ce5a21cd9cda1358a785fecde997", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "8c1aa6fc-e4e2-4e6e-8f94-9164d7847bbe": {"doc_hash": "a1bd7f3e3c322a2598dac7faf02174b054a2a65711f799f5d80589c180e47453", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "e2c95d30-2727-4c02-b486-472baed2028e": {"doc_hash": "a4aabaa964e49ca26b0fa4e6bf26a0115f00133d7792ffd57bb30f7dfb171246", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "09b25521-bc96-4f9e-bacf-a98c9566121c": {"doc_hash": "50419551fe5b2480ccefe400d12f6686369b3ca50e330aa8187c2a2b6ae8bad3", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "566b8bd0-bb9c-478d-86b2-9e8240a51012": {"doc_hash": "4dd5a5d04e055e162b8b3ec90a4e0a0599058ca0768586a149344253739d787e", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "55a21817-ccc6-4ac7-b9a5-f8d87fd09841": {"doc_hash": "c42c8aa653e1ad7667fb3b5e6fc9824dc42ec4b846b3aa7f7d6cac112949deba", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "bbaa7845-620c-44ec-918e-8a66d9412d1e": {"doc_hash": "7a2d569d34b43007ee5acca82f4db3782cd11a36ca7f4958b9d478d2dec4a973", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "d361b967-ea7e-4eba-bf48-9db31743d9f4": {"doc_hash": "48ab6e7bf62b8022396f7d0c9f4d3b78ccaf506067fc4fd1348ab3ecbf56ff91", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "c4658214-60b0-43b8-a5db-bf38c407ef86": {"doc_hash": "1878b3c1dc1b23d083711219998dcb1f3bf823fc935e4fa97b9b949bacbf8405", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "fa9e5732-c343-4196-b2b8-13012845a233": {"doc_hash": "82680ecdccbec02b4d17a4e7406d0f53b832bd94dbc0c263d36087b956129d78", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "934cc17c-05d9-4e76-83ee-99e10ee7f1e1": {"doc_hash": "92b4c60a01d559ab1027ed8fed135ace331b677b2e14d31f6c12c7c63d144b9d", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "56d12f6e-9f64-4fca-9783-23b8b04dcde5": {"doc_hash": "18510a3420f2141563b98dfb808e3ed06b262336388eb3f82dea3348707c7fb7", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "ee6d63cf-fb6c-4d1f-b849-5f1d50339264": {"doc_hash": "e9bd929356210fcab2a3296e0713ad1a8173e6bd2f6bcf6e1c6b2519d1fe1c9b", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "de7b98fc-7c4d-4cc8-a5dc-81e7f2b1455e": {"doc_hash": "8459b009a0f3b21479aaf693fcc95d97a70dac332aec8892243daa313883dc30", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "bfda1178-e301-4ae3-a628-be03c2a6375f": {"doc_hash": "bc31abec3d9b3ca1aad39cdff05572a4b36b2f55ee34b8a8d14664d525c73b45", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "6eb0c918-36cc-4c04-89fa-ed32d28a6ae1": {"doc_hash": "915710563053621c46593931f14e796b7b246d7d17c2574065176a133ef8bf90", "ref_doc_id": "14bb0de0-a72e-45c4-a47c-c04d9c1e0707"}, "caeca9e1-6294-4aa2-8cab-a110a16f3167": {"doc_hash": "ccbd2dec721ec4a648dea424d23e7d491e00dfae3384f2dc634339c1bcaac0cf", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "2bc5add5-e9ba-4615-8ec2-93db69a5800e": {"doc_hash": "59a128933a9c130d0de63e6ee361f9410bae3666f535235a58770020d9fa55ba", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "9ccacf68-1e22-4e7c-a204-005c835df1a6": {"doc_hash": "d0bb328606e1850623ad76f62b27847bd11defde0ebc65325f84992f3cb7f04a", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "794266ea-a583-4b91-ab65-09bebafab231": {"doc_hash": "ee664dd9eda597f9954ddf097b6ba6c4db2a73f3c8fd99049cbf703834043be2", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "8754192d-95a4-4f82-924d-6e8140df1749": {"doc_hash": "940ec0db63fd9dca639d1d5b29b5899a3e4ffc726f9d3583b53d316457470307", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "37e93c2e-287a-4442-9562-3650ef14946a": {"doc_hash": "2e6e7757b4053f91147dc612bc85c245de8f02e296f085e67c02374047ef2cd9", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "ac201113-5bc7-4fc9-bc16-9794d8e6c3d0": {"doc_hash": "fd80a5d57a769313878e28801d47ee312e3b4aec00fdc51c3e1d461debd4368a", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "9bc5cbe8-f3e0-4a20-bcf7-50ede04b68b2": {"doc_hash": "e8f397845e428f3f3676016d79ef390151c6bf8ff3b45fe8b59aae031b64d4a5", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "9c9c84be-5c4e-4b58-b3e5-2aa10e83c049": {"doc_hash": "4f5ae6cef8bdb7d0eea0b222f629e3fbafa4a1a7a8aeba216c5fab47fcec3766", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "ae0caca5-c84c-48c9-8387-d19e4d1b0849": {"doc_hash": "c600a24a80475e97e703fb71d2803960f29022d542fc2e3b173bd9ad5e98139a", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "421517db-7461-4d7a-a7c1-a4e4142b4d51": {"doc_hash": "4f25c1c3309b94c7f0c8033cbccdd4fe5355e5ae213dca1a947dcb855de8cc31", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "796c0af1-813a-42a8-8a55-51ee1534bb1a": {"doc_hash": "4ae0ab2d763b79a26d0b56c67f67bee7d8b0d9e0d69743c1a562b9f7cabf2bd9", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "453131fb-cd5f-4e89-bb21-55e64c1dcdd6": {"doc_hash": "27b0fc1c788aded64e94b7bbe3dd55a26c6253d801aa8252b74da9c35167ed2d", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "46dec6cb-8854-4abf-9a54-8795832d1a67": {"doc_hash": "5bcc060c76c94cd479e8d669cf7bb63f966372ef16332ec6ae0630fab78d17b4", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "6c9f07f5-8b92-4dcb-a701-c48061ba7645": {"doc_hash": "4031bb99eadba7f145f61929c0dc487d63f45246f88ff66c7e413f025278b029", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "b772a7aa-b684-4e44-aa63-f1509d549a08": {"doc_hash": "55e1487d4a3b0b245582e8ff361e86187e9fe4fcbca2965a5733b5eebda1408e", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "81c8d2ce-97df-43a5-98a9-bf808f29c580": {"doc_hash": "6be0ad64d310eb99c59ee77889a7816a4cccdf660dfc0edd6e68d8b23e1d4664", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "d2479e0b-7cc0-42a4-afca-be404f62dbd1": {"doc_hash": "112266817f43c01f3e9a46b745ad381abaed9d02fa0b95c5f1119fe7109e4a5c", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "fff9e945-7bb8-4b0f-9775-7532303b3016": {"doc_hash": "99688f03dc840c77ea321c7fdf38e237ba77ce5abb8837a9cbf325b3c16ec3ca", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "a7977de3-bb55-4c68-9919-2924ade42cad": {"doc_hash": "6f94c0cd7454bca6410d053fe824aa140e7df8468d90f48f2d59853a2765a420", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "6e475589-75a6-499a-b7a8-dc4c4ab00442": {"doc_hash": "06235f3aa14bb8e99c0bcc771a897d758220587f0760381842e5b867e173d897", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "162079fa-64ab-46f9-a359-f18682016f7b": {"doc_hash": "824edf2bc901314aed2dde8ec6873a47d8e643ab58c2f44a3425a5e8f67b7b5b", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "28f9653b-44ba-484b-9771-c28dd872882a": {"doc_hash": "b27b7a6b3c8794e9a30446e292c7ebd7e45c6f4317df5e3119b68ace3818b3ab", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "8d86ff64-b35b-4a82-9f8d-781c15f5dc10": {"doc_hash": "3187d41b2116129b35143d08f0dc0100980085cf08fc95ce66073535ae2e8fec", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "bf5db6ee-2a3c-429e-a0ca-c24ca6799f4c": {"doc_hash": "233fd500e5c12bae5691512f28171c848a7e54badb645b4ef85288dbb84cd2db", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "5cf2a41b-d4fd-4f94-a520-27163255dc7c": {"doc_hash": "9759958ae3056c5ef4d323ca1ec67dfce1503ce5d865f575143e7d9731488c5c", "ref_doc_id": "4f956f19-6a30-4459-99fb-dd262cafd1ac"}, "5c012ccd-c899-43e4-acd4-43383bae0e12": {"doc_hash": "e4309395dcdd3d78793bc8ecbe9cec8e1db1033b48c582164305afe730b6a0ae", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "f37dc250-60fc-404f-a2f2-26f15443da1f": {"doc_hash": "a606a5a229f15d02f7f2c680f489326baddee7167703c189d873647717ece525", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "3b262889-23be-4c2d-b258-17b9da251aea": {"doc_hash": "f5a9424993c36167c8fa4d3ee2833d8f0deb087746ba974a7ccbc3b4e9067b95", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "99398746-9c8a-42c4-bc38-54274b13365a": {"doc_hash": "1b189ae81c0596fb3d10f6007577a6aa641baad2b01c3015ced22aabcae2bd28", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "93ee77d7-7edd-4890-99b5-ab74f6d209d2": {"doc_hash": "1e0c3ad6a8ac9b05b37fb969b0e0052e8b9ff5c4071a5e7b577e8a4613ec3a1d", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "b86b146d-f5a4-47dc-b6f8-5f3bbd31baa1": {"doc_hash": "0a602a0e49642415b72a3790c481dc1be6f4071834f713585ae2625f32f7d4e9", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "fd054673-0e63-43d2-8098-8a16df09ebdf": {"doc_hash": "6cca96f1aa54df1266d55af190d5b59a1d391bdf63e9b3161ab02c6403e637fb", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "8379db79-9565-45e6-9e7b-535e90fcfae4": {"doc_hash": "9d2e80b1bb9dc4a198a75684d5fe2acd7eccbda67a7447d96ce2c80318036c01", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "c63f97e2-e32a-4274-a2d5-c2006b863803": {"doc_hash": "4aeefa4ee5031c00b19feadf5921ed4b4a4072f78f9c428359aa3f76d40ee71d", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "4b2b8ba9-816a-47de-8e91-d70f4f115952": {"doc_hash": "b425d00f794f2a569250ea200559880abc20c9338ac23b92617b518e4f41593e", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "ffca696c-79c8-4936-b88f-72c1feb9c5eb": {"doc_hash": "fd6fee8e2fdccef80f823ec5376d308081e4e76dba6256dd48e0c804232a5fde", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "76eb3b28-1dd0-49f1-baac-0fad5c893d77": {"doc_hash": "b3a80b30c958929c65d40c4f0ec6b7a48c7c9aad4050621ad3b2eb9215dd635d", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "63377ddc-e1b6-4e01-bc3a-47127f123eeb": {"doc_hash": "550e3f59203b944fe13089f959350e8d1621153f7631a2e356782e9d01d12d01", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "2787444d-cd35-488d-bd45-633b3d16788e": {"doc_hash": "95ee30a926084e177eeb5b6c9273aa4e6e401e45b5752d660d4e58e568c33d9c", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "42ab8791-5f9c-462b-b498-78929c6e080e": {"doc_hash": "b5eff1b542dba9e530576ddcdd965af3a3b847b757d1140ebe2739d64457d7a6", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "b27fd88a-0cfa-4c40-886f-7a039d83ca2b": {"doc_hash": "188f19cb760de96733c33a27c61b89a541fed25c28ec7e5de041a47d2216eccc", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "3d63d00b-09d1-4df1-a913-eb6b7214c4c4": {"doc_hash": "fb5f1e79fadf1694666db5560df54e70d2e98e74ea08071ccb7e61c556f73773", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "417317ff-a630-4980-aeea-e37c811f58bf": {"doc_hash": "34e5d2774623dcba8b48e98ff2014533c86c2810a3c841e63fe8b173c013b1f0", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "51776c10-44af-4cad-8a9f-0f218c852431": {"doc_hash": "23a6130468c27e6dfa0be0b367effc03b065d7bf442fd7dc41ca8673720d1b2a", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "09786442-2438-4122-95b1-bf9d66a9393b": {"doc_hash": "7adfdb4367ed5109ef4e38a498b6e8bac0bb3ba8b9d9ba87fb0a1688df7ca108", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "e80b8a70-6af7-4ef2-9ea2-10e5a935f643": {"doc_hash": "32e8272a6283e059330ad697db0b168e57e6cd575e7bb4ffd21e9954ef0818e9", "ref_doc_id": "d67dee92-0ce2-4274-9b8f-6d45fb28b953"}, "085869d4-6044-471a-bb88-faec787b50c2": {"doc_hash": "7013fb006ea7eb7ab0331bf5ed456184d056e431ec41be1c9556ddf224994919", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "ae902c71-23c9-4988-99f1-f78c12eecb8b": {"doc_hash": "9c6943058a7a47d8078f1bcff2cb34eed98a2e66db6b7673753696372624a61b", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "b6023283-52aa-49a5-a699-99be191d6d84": {"doc_hash": "ba4edb06ad102ac50251adf8f1451e9d4d8d507f764922950ec59da09ae4ee17", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "2d81ef30-1268-42b3-81a2-f2163dbe5f86": {"doc_hash": "1aa31449d4eb4fbbb2b99b84cdc44478acdc20ea2df08d7fb88b1053ca3f5e1e", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "0f034437-825f-4fa4-b630-c145866ec56d": {"doc_hash": "692f9e229c011cd45f2931150c178229eabfe16b38969f4091d9999488fb9567", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "93515638-f16d-4c3e-b046-85208f424f11": {"doc_hash": "a5d1595228bdba71e639165b6e1dc216ef6f5d242770afa19b8d21e460187783", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "384887b7-2218-4902-9994-d069f02d71f4": {"doc_hash": "cf4745846678cb09e677a338e90ff8f436c17f9f101ffd3557ebecc530702992", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "5f17dc73-ab39-439c-8d2d-1454dfd9c77b": {"doc_hash": "386e8c086cae9466193b72595d7f4e21755cc3fb4990249ef38c7d9d0ae3e66b", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "db4a5346-ad96-4a30-ac92-8bc5cd221ee7": {"doc_hash": "94049658bc68fcd26e7b4bf16d97278d86e1b11388b5d1352cb662f9122ba209", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "cce00488-3d75-41b2-9056-c5723da91fc9": {"doc_hash": "7bef010db383b3d6c496779edccd117ddfcf79eab608fa089ab63cbded283b77", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "a744504c-f365-4601-88ff-a25f41921f80": {"doc_hash": "3d6b194ca347233025b2a4b00e0ccbfd4bde8d166c455e292b8ebf94a71eb2d9", "ref_doc_id": "4a112dff-31f2-4cad-a9a7-e59cebf37ea7"}, "983613b6-d66f-45fd-9c31-6822e2ea4256": {"doc_hash": "6d3a4eca27cf23d505b7da24619cf0d0930159f41325a95f4c56c8edee632391", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "d3d60933-81fe-4f51-a016-5f4be0c27849": {"doc_hash": "9160a178d7c0fe113ee23bf7866fe150e99641b53aae5112981df3c09f6d15f8", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "e602a727-786b-449f-8215-b820f699548f": {"doc_hash": "7f5e3f519bf0806114f9dd2f15b04f27b1617472e6bf006748963e80cab4bc1d", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "09068d98-3f8a-49ce-a2d3-4cdcae16170b": {"doc_hash": "73f463532cdc079ec87cbb92836fd107968936e3d5bfcd69f67d2f7d226f9b7a", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "39169849-65da-4142-9d86-f33cc6c537f7": {"doc_hash": "aa139a0829dce518a2a7b3e8c09ebeb7323063ff7b7cf3cb42ea782c728210f2", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "69fcbc78-1783-49e8-b444-2b77b6f486fe": {"doc_hash": "0d618379a9c111c83060801074da7dae1ff64a0979fb256af253893f96e11112", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "84682d56-6d77-4dc4-a947-bdaaad64e0e6": {"doc_hash": "d3a3a0cb36deb47a68092a7425763a9c5f0c1f6710b97a5586c5718f06a30cd9", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "8c03ce97-66db-4e76-9f94-fbb19aeb8d86": {"doc_hash": "a7d16bb64c29699a613452d1913a4f20e02eed29278be6712196c43c2e97da68", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "b189b90b-62dd-45c2-bd4a-f7c7c9585057": {"doc_hash": "51189bab5e736a3a75d649518474ca1a0efa2e8eb80a8ae4d9be06a129bf4895", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "ed9bab14-3043-4aa5-9a1f-93b70a1a29f3": {"doc_hash": "d1e2d559eaec36c686f5b6f2847cf716ac34c358f07a690aee806d0b4cd2035d", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "50e84f97-cd05-42f4-bf75-58191d20d156": {"doc_hash": "9e0b685a5076c33b5d8ce4f0b04d9a655bca34f34672530d672055161f50227a", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "53356fac-8c8a-4e43-80d7-f661ddd8d150": {"doc_hash": "7b1c04f0536c592e40beacf321aa8c8d0b94f35d3592c3c99bfe18c44cb797b6", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "8b89874f-3ee0-4e72-aba4-5b490dfec1c4": {"doc_hash": "9715151ec48761ba5f15c4ee8a7864910838675d49d3d68788394a77c8b109c1", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "c0bc1075-274a-4c9c-8325-37dfdaac9804": {"doc_hash": "51f9e556708ce336067e28de9b34917885f4dd0cdb0b9aee4df336e015cea189", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "2cfd7e93-fa6a-4d00-8174-c64ef3a29902": {"doc_hash": "8fe11a16c98ae3514c2eeeb1a2e2546f47dff77ed89939b416b6e0beecd686e1", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "9545b10f-2f3c-4a78-8fac-878ee957a41f": {"doc_hash": "aac69f738b8426bf432dce791dd2608020e714f2eb50d9b7b699ce6cbe27c891", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "2e9d8bca-9a65-431c-a894-778e48fc90ad": {"doc_hash": "a34d9bb1b49acea69ba295070bc7c2e368c44680dbe57896ad307df437d1938a", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "d8226164-c034-475d-b562-4c4d8b285ba4": {"doc_hash": "586cda7e4acc553b18ff47ac1c7c9f392613880589400708936aeb7898dc0dab", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "dc8cb903-75d5-4edc-a1e7-46d0612c6c6a": {"doc_hash": "741ef2d19ececeadbaf5c2ca811c6a8f85139f95ba27c4feb4b046f94cae51ba", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "2a85f1d7-b0dc-498f-b623-62d0f2f83018": {"doc_hash": "3c62857f31880f3cf0c012d193ebc0f4fc77aad6f211be078c16ee78cfe64420", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "e86fa7da-8421-4f88-8a82-e016bd0ccf9b": {"doc_hash": "4f410e33bb1866c158e57a045468afc4a0210fd0fec70851539be3c5ee3463b5", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "430005e8-b05b-4071-9d08-4787237e2ca6": {"doc_hash": "f2e5f9f140faacc71a30da7735d44372e98c0f51dd29689276f771b410e8d8dc", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "7c09c9cc-abea-4ead-bc49-00251edd7fab": {"doc_hash": "d8bf3d6719659bba5febcb3ff5c6137d4af224bff71954165379760d8182e56c", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "71a8cad6-948d-4155-954c-97f0311f0f0c": {"doc_hash": "55525c2db218b192cf3b7a12d4354642b3ea628e35a7fbf6eeae434d35c9c0f6", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "eb1bd276-5ecd-4322-81e7-2b048c30d3a7": {"doc_hash": "9db5f0b7dfc4304d584c01da95c576491423868842ea8e6d2e06b9c230390b64", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "8fb4a642-a52b-47b3-8de0-ed7f5a55d98a": {"doc_hash": "f0e641d5f14afd61b0ec6f447daed9f39f57d31502cf02f6822fc10a7c82f44a", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "6ea7b245-413e-494b-a65d-3e049cf8f9ee": {"doc_hash": "d35e7c90336e8af1f31ace0368bc17fb4a8f92fbcbcc296dbf04fb3d11210682", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "26b7256b-97f5-410b-b548-3473605bd39c": {"doc_hash": "58687230f1a6960a947930a3cd984b058829535bd3dae1d379b5c1e6b82794ef", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "3117a402-5c07-4088-b8e5-8c96082ccc5b": {"doc_hash": "f0c321422aa55eacda0cc701ec05a7837331c1a90ec0886065a32cbf7d6836ff", "ref_doc_id": "6992a1ae-ddce-4057-9717-e74ff527ad43"}, "0ffaa400-3c20-4848-aa03-7d5205a26089": {"doc_hash": "2da5cc23a5d29053239262d75db25a836cbad928790a8381d1599903f44bc6fe", "ref_doc_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f"}, "d0aae783-7b6e-439b-88cf-a5f8a33728e0": {"doc_hash": "6129dc55a45983499c05956e3ee7260bd1cde374fdd46b50a5e1bb4ddca93a08", "ref_doc_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f"}, "013745d6-b250-4019-b172-4d3ec30d489d": {"doc_hash": "98ec2c4e429edfd78115f50e00a8216b3b3398f33a7a67d53bbd8c28a65b7af0", "ref_doc_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f"}, "ee7f9945-f7bd-46ed-a90a-6361a8e3ea58": {"doc_hash": "866ce8e3ab63dbea04162ca8352bd52b58253e83cbd1b0d0bdc2f6e5949ff80d", "ref_doc_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f"}, "965a8e3b-d85d-45a1-bf23-80d91571a15f": {"doc_hash": "f82b7f03888313d0e1afda456d3a28eba1ba760ce404243f147dd6806a3e5b1e", "ref_doc_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f"}, "f892e518-be5c-4685-b2e5-1a0cba42d6b7": {"doc_hash": "46319dcd90022933783135ae1fa789d9af8c8a380b2f717153e3ff88e6949b87", "ref_doc_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f"}, "814e7ba7-d166-4dc0-b641-fad8cfd04452": {"doc_hash": "9eeeca33641354d1ddc57c360a22386feea07980277309351f189b76d73efa3a", "ref_doc_id": "d39920ec-37f3-4277-93e5-33b4341f9e5f"}, "dc454161-9825-4277-9f0a-70e20fa32242": {"doc_hash": "ff63db0848c3ceb8dd542fa5da873cb3e78c7e8afda3624e85ef6259c880322b", "ref_doc_id": "e1149a58-9120-4328-8ded-2fd5ae3e7f68"}, "35117da4-e247-4b9f-9eaf-31256f098c41": {"doc_hash": "b403aeaded55dfadfd793cafb079fb9dae764e25068bc9574d6be0edcfd25d3e", "ref_doc_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7"}, "21fd5879-28b5-4f14-8ea5-6c57bc27f652": {"doc_hash": "ce0faf2f9dfcf0037cdb41ec65b4c598ea7c7e75bb24cada55114f0af1fef1e1", "ref_doc_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7"}, "d68a3fec-2571-4a10-8f1e-9aa6acbceec0": {"doc_hash": "e9e45407043c8b00b8cf8a32a103c165a1fc8a80ad229e2247b7b968f66ae5c9", "ref_doc_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7"}, "9ca2f1e8-9c32-4350-b926-bde0da1516b4": {"doc_hash": "4d5e74e0a384b9122d7114f13775a156d007b3a33adde85d29c7cb51aafdf6df", "ref_doc_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7"}, "734d6a59-d8c9-4628-9408-41370d5b95e5": {"doc_hash": "5b0daf64ed70e4d7439c0561d7af2f7749fb11ae3109e127dcc8852c312e3baa", "ref_doc_id": "a0882c34-d65f-45fd-9fcd-92a230b74df7"}, "fc632b4f-6379-4fee-8a53-97c1b3e91152": {"doc_hash": "af195127efac4e6fdef59a6421d45dd554b27e1acce378875a751a823a93c9bc", "ref_doc_id": "8a94cd0c-cd36-4d4d-8bac-0dd7accd2040"}, "bf21c2a0-2b5d-4872-a92a-5db23c692665": {"doc_hash": "f9415889256acea9bf2423dbf20a3146f2bee156f93c23dd3acd5386b3d12521", "ref_doc_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90"}, "50548cc3-2908-4040-886d-bad174a64657": {"doc_hash": "2744dbc46a7b3b4857bf0acda0b289917a07501ab1d91173e29df025206d17d2", "ref_doc_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90"}, "a4d0d221-016e-428d-a1c6-c111ecf928bf": {"doc_hash": "f4bcdfe760f3e4c6d4acf1693360c7c74808c14c990b3bbf750444031cc2643e", "ref_doc_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90"}, "cbcd44ad-fea7-4116-a485-7e62bd46faa8": {"doc_hash": "332b71478d3fd48f7ee6f576dba03ed5f9c5e6ecfd5dfb55a768a8f8769699d3", "ref_doc_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90"}, "a71e440d-0bf9-4c52-9800-6fbc8a2e6817": {"doc_hash": "48fea89d4cf51a2aaa4221b795243cf1020935463822005f281c1c6da034b228", "ref_doc_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90"}, "90e779a3-e4a2-4312-8d4a-916dddd57c6b": {"doc_hash": "985b540bce36fb09aa638309680706e4fb96ebd0d48480fdc1f6038cc32f76c1", "ref_doc_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90"}, "1753da94-41de-4fc0-9542-b5f41e7a4ecb": {"doc_hash": "37623488db9cc66e5870c474e456190b523b611dd2052ff7d21ec84f1aab242f", "ref_doc_id": "1816d15c-8d8e-478a-994e-952ee0b7ee90"}, "8d2d1ef6-4b5e-4fc9-ae4e-82ffe65f5748": {"doc_hash": "16216f0c08e1caa1533d882cd5f279cc3ec02186b3277462bd86c017764f4346", "ref_doc_id": "643c5de3-bf96-41f7-ab20-836813ab4085"}, "b014156f-c852-4d11-987f-91bbca1155cd": {"doc_hash": "7c5b696634170840c12a45c82dca2b2d2518effbdf006abd1a78f4d062e097e0", "ref_doc_id": "61f14a0f-0815-4592-af87-d8fb20bb8d9f"}, "62b66616-5f91-4aaa-97b6-8a4e0647a75f": {"doc_hash": "a79b5c80fefe94f32cd09733f466e7ad10573cc96a6c33a5b306e309f023efb5", "ref_doc_id": "61f14a0f-0815-4592-af87-d8fb20bb8d9f"}, "40baa716-cb56-42fa-b564-b61131464dbf": {"doc_hash": "9f1e4b681333fe00e60a01b60d2c3e925f7bddeefa4a4295c04cb305b8437802", "ref_doc_id": "61f14a0f-0815-4592-af87-d8fb20bb8d9f"}, "a81dbff1-2a3e-46db-90fa-d9cd2c9b961c": {"doc_hash": "1384f1a0d891b8c5e2ca7865ce66137adc28a998debccfd55adb8e8100602c0a", "ref_doc_id": "61f14a0f-0815-4592-af87-d8fb20bb8d9f"}, "6b57f805-671b-4f3d-bf2c-83d9a34b7299": {"doc_hash": "7895a6f618f264f6728adcbfddb3130e0ccafe5b33e0b69caeebe72494018195", "ref_doc_id": "5ce78148-080b-4415-842a-92e7402300a6"}, "15866567-8c1f-4b0e-8df1-b634856d10e0": {"doc_hash": "aa37199c1bc2b6a08f73e76e11de173e1402f85203fbad471799c12ab867d6b9", "ref_doc_id": "ab64f157-079e-46a0-9ad1-6d073684e00e"}, "9aa031bd-5f30-4032-96fb-283b87c607da": {"doc_hash": "231d6aee6553cfbd855e24ef82dbc738e64eea48edf48d56f19d633e50692b6b", "ref_doc_id": "ab64f157-079e-46a0-9ad1-6d073684e00e"}, "86712c93-ed13-4a14-8216-c2d608b4bc53": {"doc_hash": "2d7f15a80954d55f8be61effcae8fee5f3e2e21acb1d1e5e09386ac231527240", "ref_doc_id": "ab64f157-079e-46a0-9ad1-6d073684e00e"}, "1f95fc91-b011-46d1-880f-02d56ad4f146": {"doc_hash": "1f0d41a88dec0fea47a2f93ba8097c5f1907eab27025a8b9f6520c6d5a3ad193", "ref_doc_id": "ab64f157-079e-46a0-9ad1-6d073684e00e"}, "d1dffebf-1082-411e-9dd6-dda4e3375938": {"doc_hash": "220322b45e55fb9936da8e3e9cfce9a1f555466d7ccc1ac044c6c58605e338b6", "ref_doc_id": "65fe3ce5-de37-4ebc-bd71-9bfe9e54f708"}, "fe0fcd7e-abf8-44d3-bbaa-3a971a984c8e": {"doc_hash": "0a09ceaa863ef1e72485accf485d5d4be5a2ab672e0f15108dea1af5a6e9808d", "ref_doc_id": "b8319279-d7f5-4758-99a9-1ab39219839d"}, "97bc5cb2-38d8-4f00-a7eb-e0a9bca9ace5": {"doc_hash": "08f32579906c6f56e903ff26d05e5ea40040ab240fbe96556d89538cf53de402", "ref_doc_id": "b8319279-d7f5-4758-99a9-1ab39219839d"}, "01b2d000-ee8e-48d3-8fc4-f9b5d083447a": {"doc_hash": "7b8ab2df919248510b06eb06c3e0164a346a68de923cff2ed40909629ca6fd92", "ref_doc_id": "b8319279-d7f5-4758-99a9-1ab39219839d"}, "02e4c9c9-206c-4f6a-a3f9-14cf7f8da3aa": {"doc_hash": "d7bd6f876a4e87e4a5b8b44e82b2a7e03843f3037c0932e13aa524d0ff4451ff", "ref_doc_id": "b8319279-d7f5-4758-99a9-1ab39219839d"}, "31c0fcf2-5ce2-4e0a-82f6-860a515d20db": {"doc_hash": "ebe5788c238f1bc136f66dab52de83b3d7ce3106f6103d20a62f919bb89661f1", "ref_doc_id": "b8319279-d7f5-4758-99a9-1ab39219839d"}, "d76c12a0-f2a8-4141-8b13-654626f216a4": {"doc_hash": "eaa783d78615c6726ee116dcea03efa1e2cc275e28f8d6a7d9b8369f74feb20f", "ref_doc_id": "5050269a-d340-4cc9-abc1-4dc55fbe0f9d"}, "9d803435-382b-410d-a6df-a941311e8a56": {"doc_hash": "22b2dac800f691eb8244ea54a02052cd4b4db65af7a288ca1f26428f148b84b3", "ref_doc_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f"}, "2594edb9-b0d8-4d50-a9fb-18209c3029f6": {"doc_hash": "f9d975a4aebcb10c0f35d0b2f217f4241410cc55293a968dd7fd20387de5bbfd", "ref_doc_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f"}, "b3001d95-73af-493d-9582-446603dd874a": {"doc_hash": "f49a53b5a24ce14e93c36f8037e7290bb8015989eb17569f08c106f42f0d0b53", "ref_doc_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f"}, "c6555165-d0c2-4689-9173-633b58b8f3fc": {"doc_hash": "85a6f8f58f678d7e3d06e22fa4a5697a5edb28b7ee49e4ad6e9dea1389535b55", "ref_doc_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f"}, "499c8f1e-54d9-44f3-8f33-40fe9a554778": {"doc_hash": "adeda5f6f24ae142237f3bba732f8809f905e89c7e84154e5ec16f9f40b4bcfc", "ref_doc_id": "ff47ab50-4dda-43f7-afb6-c648607b3a2f"}, "5e110c59-a06f-4e3b-88de-5cf74f261109": {"doc_hash": "42be30f300b0a3e96b8fe65b82b1b2e05e5140d4bc44342148c2a8f1da940dd5", "ref_doc_id": "afcc3826-a4b0-4087-90ec-de9cc9b180d8"}, "0452d29a-b32f-4d92-8e5e-f02d22550777": {"doc_hash": "a1dee62453d3347b7e5d1ed023273cc7181714f05c6f0520c688f656c20099fa", "ref_doc_id": "afcc3826-a4b0-4087-90ec-de9cc9b180d8"}, "c0e58ed2-59c0-4b11-8bd8-456666ee7475": {"doc_hash": "f77e144669412a20afc4bfe343065e59ead1bbcc8eccf0d5b223b0e44e36b2be", "ref_doc_id": "afcc3826-a4b0-4087-90ec-de9cc9b180d8"}, "d4cb7e74-ba4a-43da-9a17-bacec4d4c976": {"doc_hash": "15bde3d76dfb08c37372444c6af5bd8c1a0d65bbe0130b9245de73b1f3bafcf1", "ref_doc_id": "b3262805-6b48-4a9b-98ba-48044b9da8d5"}, "e2a5d8c7-81d4-4051-b2ab-bc388748af9d": {"doc_hash": "955ffd26947e8e8dfa38a4a21eb370f8a0b5068aafcf9fa44877108b179fdf03", "ref_doc_id": "b3262805-6b48-4a9b-98ba-48044b9da8d5"}, "c4d0d37c-9065-4517-9ee1-f11ea04a1ef9": {"doc_hash": "abf4227c7b3c50f6cf02203f70fa59b4f0723b7f0b98680af41756fc7fad2d2a", "ref_doc_id": "b3262805-6b48-4a9b-98ba-48044b9da8d5"}, "672a5eb2-6413-4b50-bb65-c8dafd41a2ba": {"doc_hash": "635a582c202e7d7718ebaf6de8c785c94373471dcc8d30ed14604d1efffe3beb", "ref_doc_id": "2318ecbc-dea3-4801-b07e-f006195958ad"}, "b4dfe92c-2eb0-4563-8b69-784d09d72b41": {"doc_hash": "bc5da103bf6856c02a4e812b2bfa18a6ceeb8ec89e6a2d8e65ce35bd06531cdf", "ref_doc_id": "2318ecbc-dea3-4801-b07e-f006195958ad"}, "95cb331c-bbbd-4f9f-af33-f8200daae153": {"doc_hash": "1e32d6f108d1a25b1caddc4609c10f67cd91e76b4aa6ddb43ac91ccbb260bb4e", "ref_doc_id": "2318ecbc-dea3-4801-b07e-f006195958ad"}, "9116171c-75d8-4141-bd39-61fd58b9731e": {"doc_hash": "5964110d3ac9798ad312fe569f6238524724de93f44cfca5aabc4387b9c3bb84", "ref_doc_id": "0995082e-f5f9-4a7e-ac46-943fd94c69fe"}, "e4d7afbe-c740-4fda-9ff2-c39b783a906f": {"doc_hash": "1e78b462df5bb7cff03a51066fa9fe0fcddb855f8598f360656c8f72a5c82245", "ref_doc_id": "0995082e-f5f9-4a7e-ac46-943fd94c69fe"}, "07584643-a945-44d9-862d-c1bfa42bb778": {"doc_hash": "b7e90906da654898f95358ff7d7f601be1ea12138eb2b298cbb671921b9840bb", "ref_doc_id": "7f513770-0913-43ba-9ec8-09122efc9214"}, "49b2f2eb-7d36-4997-95fd-0d73056d494b": {"doc_hash": "2a1d971edbbe80a3dedd944173ccc8910d68610e16fe08bb06e1a0fd09937378", "ref_doc_id": "e59a7e28-43e4-443e-9f42-04b24dba58b8"}, "a1e3aca4-0583-40e5-8009-4576f1306aa5": {"doc_hash": "69a8d613e52690656f33ffdaf496af5c3025cc6eb751af022dcaa4b91d8f2aa5", "ref_doc_id": "c26c5325-b2d6-44bd-a9b2-6e959632171d"}, "b4d8f2d7-ec5a-48e3-a868-bd94fa69efa8": {"doc_hash": "3f1722297a682117fc1581829da4188692263278e481d584d555be42bb59cfee", "ref_doc_id": "c26c5325-b2d6-44bd-a9b2-6e959632171d"}, "c69dd6e3-a16d-4ed6-8fc0-0c41bc3c0e1f": {"doc_hash": "d0c3f27722b526e17910c04153663166b70794c0ac2996d77b8b0c16d9a3866d", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "05a0c248-28fc-4c96-9831-c34db80595e6": {"doc_hash": "5b631dcc0980e88fbb6dfc427d786e9641fc6238e0988bdcd635298ebb99cbb1", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "6fe3fe99-40ba-4233-a8d6-8e559befbe99": {"doc_hash": "5130c296064d84020d3563ef1b86b72b11b47f384d3c826747196ac1a1b2c9aa", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "1bef6d37-35e9-42a1-b639-d98e1b0e098d": {"doc_hash": "e296e01a8e0247187e534a854ac6e95f2c4e394b1aecc1001c0c4a8ce3ce7a92", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "94218b4b-a2fb-436b-b3b4-5182c9e73899": {"doc_hash": "54845cde6117b3410c9f007e7f49de68c09c8d75bbbb738ca1e4713f2fd3fc8b", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "86fc53c2-a868-4d33-a9ed-075d93b87781": {"doc_hash": "2c69d8d69615a7d34443550f659b5363ac2e1f913efa302e27b6434e6ec3388f", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "a89a1efa-f638-40fe-b992-40c5c58ad062": {"doc_hash": "c564d2a569d92bc21a093b4b2649816e76d3e88ccb083e4c153627d565c2a98c", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "5a91a441-cd3f-4550-b9de-d2f4624d74d3": {"doc_hash": "74e4336e352eda85685a772d0ed1ec9b5a67bd5df77b57ffd43b2a7ef210b702", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "cbef6859-369a-4389-ab2d-f91263fd99fd": {"doc_hash": "c7e8c5948fc0f33db72959129b177f35ef8401699176d7abc4bfca25677c6083", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "8627cc23-67bd-4cf9-b552-a696df26a01b": {"doc_hash": "5cc81ebc7c14735c402eba0ec66df1cbcaaf3a08c7f96d4fb32f5f1c36832367", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "ed55b7d9-2b14-4c6a-8b26-dcd4c0a3c7c2": {"doc_hash": "c0e4036ef5c756580ca0536b7671aa65cc65d9fc5420e009132f3514941f0086", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "68c459fd-8105-404f-9789-9f772ba21c1e": {"doc_hash": "87bf38bd172bcac0028107fc40a630d2e7afc280bd5d7d75e5b0a85bb7dd1781", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "97bd98f5-f331-425e-a350-f56b4be5ad75": {"doc_hash": "c3d71a1cbe6e2eceeee9b4ddf9d84e04721d2e2bea420130ee2376de053916f9", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "e7401cb7-2c77-4bd6-944a-6e91f21e241c": {"doc_hash": "7682dccea38f1203f2cad2ef01a19b7d753018f74061c6da2c8b10e8b780311a", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "9d380d7e-bae9-4c51-85db-ac61d8bd551e": {"doc_hash": "d41433fa304201c0f912a6d8f58cd5a1a711524e47c44faf5fc6ca0324647ab6", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "a6a671e5-6179-421d-90a4-8cc707477971": {"doc_hash": "718613855b00ebc3b7b17458d5ab81f46fb34da39a04cfcb661eae7d4ff55e9f", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "216f7b0a-bf06-45aa-a033-8a1f37150872": {"doc_hash": "98cdd2839473f40d2370cf04348ef118e62d397935e546765ae5be54aef54ed1", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "2e16fb5d-b432-43de-8fe9-69d8916f6121": {"doc_hash": "5583a98b5b7bf1674bf97fdf0b76dcd85ae954a293745e49326df891ba9d0bcf", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "f9937be4-8422-473a-a9dd-189372ff03d9": {"doc_hash": "c4949119807e74c218e069700925ef46e5a0581d481274c1047bdc54757c373a", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "137b4752-a439-4463-895a-c1fe8351a3d5": {"doc_hash": "b017a4baec0a8c7f36283680b500d0965becff62c496ff4816a62ff88b533db8", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "6f604614-9758-42f2-9b8d-cd8d9d56c48e": {"doc_hash": "38a6d1ef8987ba53c1df64c7b480a460526ab481404c996f07e602084f01e828", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "d5d27975-9d6c-4f8a-95af-c0db74b714b6": {"doc_hash": "6c96f3d822aac0820b4bf4b453d6cea6e839577a40e4eb15ac4cbc1708d7ff7a", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "2ea9c43d-b8cb-4523-a8dd-5303b2ae258a": {"doc_hash": "947863c451e0a64ffe33f86c484a8ae7514827ce88c25621376cafcc7f9b29ee", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "f998c9f1-27dc-45fb-b1d9-adfbe2d137c5": {"doc_hash": "e4fb41b19782890ea0bd9d03dc0eade4036e554b0bbe4a08aca11c23a1003139", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "520c0582-c677-4545-97fe-2d6be2132742": {"doc_hash": "4eba8795f385fc668fa658f74ca7af2890e3865da10b98650e5fca4f50e56f63", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "624f03f0-fe03-4d9a-aad5-e185b8f9cd3d": {"doc_hash": "f98e06190d0b0d87a4f5b121e9808e6807297fc1b80d2338db80e854b3207948", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "f987ae6b-8e91-4d14-a3c1-f07f37334c31": {"doc_hash": "80d4c96b10e83486ea4ad3762bd920b55b038b0041269f162db2c4cb7cd87494", "ref_doc_id": "ba152fb8-ca4c-4e64-9abc-d13464df4cab"}, "134504d0-72a0-4105-a971-06879b7bb8fd": {"doc_hash": "9d62146453ab296d6e56dd62718a41b3bb9f8eadfb99d6e4ad03d640bc6fe7b3", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "2262d33b-2578-4896-b25c-60b328eade6e": {"doc_hash": "e41edf95dcd3958412b63de6c7d14d127307009e93c19ce6295a2bd10e03b78d", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "c00e58af-7584-4fc8-9ec2-60b890bf8654": {"doc_hash": "9ecfe0730bc808cb9d265faf1bdbdf170604af0d8b34d3e9afab9ca5baec285f", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "591b06b4-8515-4c8e-8acf-894859120871": {"doc_hash": "99a6d4975155651b324a4a5401baab088896f18b1e1f0641349a386473e38dbd", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "78c89f36-4e4e-4dc9-92e7-3abbf0389e02": {"doc_hash": "87d5ba4a3c4a155ff48a1fc4aa075173ddec13f5b4576dc4ce7090472959e83e", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "7614b7ed-2da1-4929-a54b-a864e794e79c": {"doc_hash": "a62dd97ca005f7329e3a0ae2715d8d617abbf0d4116927d74452723100c75317", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "2a955e1f-bbb2-4ec8-b93a-76e7ffa5400b": {"doc_hash": "e0ec6d5ae8b3e1a645305cb132fdc29e202ede78902b0dac69a8bee366e0b594", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "af545af1-ca7c-44cb-9c62-0030fe80d3a0": {"doc_hash": "cf32922ba67d865e31bb1ec10aad37e59b3be9490b29f0c8aa39221d305d5c47", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "1461c2da-1b80-45b4-bde3-5402989501a8": {"doc_hash": "9c11525bc3f7285b8b660dfe943b5a2cfcb95d16a2e363df1157f79986d9d256", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "d949d34f-7fa1-4853-bb99-c5a6974877b6": {"doc_hash": "e7378af63b9ef9f8eb2cfbc6fb8da7b31f741f259ae0553931e4d547d5c8807c", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "22b120f3-29f1-4254-a168-a94e24086e09": {"doc_hash": "fcef5755d6df1dfa659e51654efecf7a4f7711d1e3b84e54cccda2caba40f1a4", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "6df2a390-54bc-40b6-a76c-97e16ece3660": {"doc_hash": "ed111b6281fc3055db89d70a63517a3c3169d371605ec65f7562249f727bab10", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "fa6cddf6-2635-4130-a633-d88d57e8c3a4": {"doc_hash": "29670cb0d6a0ce51c6b9ecacbdcc7d23d7cfb6af621cc905693e877a35b733f7", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "e2077b57-8c0f-48bd-830c-940df2174bd6": {"doc_hash": "95a1a61040cc988535b700069e43532d5719e5f0396c372d5a8251fc2e63b2c8", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "96d7a2be-43e4-4ce0-ad6e-c3067fd317eb": {"doc_hash": "8f54923958d2c633fafe363089116d86c021efc3b1313cd68c4c7470f162d2c2", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "31718ee0-aedd-4a31-abce-42f0aa1a2bc4": {"doc_hash": "97b53d09f1c8797cf9e898c1a0352f85413dc82710f167e361ed191b20475d48", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "1e4ea2f0-9248-4f48-a6ff-c8e97a4789b4": {"doc_hash": "54027d66e9d95109269d8d882b10b6fe94d24826e118e9e3cd32706a3ee2dc44", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "17f72d41-f5aa-4dfd-8441-72c6f967a184": {"doc_hash": "564ce9c27d5e1f486045580b4dccbf1798d494f32975e57ce029caa0bf1af53f", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "36982700-3884-4951-b74f-fb85b85f40e0": {"doc_hash": "79575d925b91441b80002bc6a99fad3a683dfacfefaa6edcdc76346e9a342293", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "db5af48d-bc51-41ce-b850-da948982a586": {"doc_hash": "d7837ab89ecfafdd5c5499b28105bd625fd6b189ef9e0fdd544f870b4b4a93e1", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "f2eff4c6-ce3e-4868-a308-e2e8da14b93d": {"doc_hash": "c26eadcf3d3b3f6ae6e84f94db494c5ad8c8e29e5338e7f16c8d3ab4bdc441eb", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "97ac83a3-ceca-4043-8d89-028fddc32bc5": {"doc_hash": "f5b7f3f92b3b20982240311e1329a8cde2908e5f479da7abc5282b26c506657b", "ref_doc_id": "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2"}, "7ec8cca9-a3f5-403c-8605-1431054280e6": {"doc_hash": "a5b1e69194bab4c910ccf72af7b46148df01ac612cdfaef4409ff6e0e20abdba", "ref_doc_id": "fa5146df-bba4-46dc-ac09-81e1f3545705"}, "ea54393a-9105-4001-b15f-759684ef4046": {"doc_hash": "70feb8b013a96e3b4a81ab37c039fe9a8051da5b34d78be85d7a8465603ce587", "ref_doc_id": "fa5146df-bba4-46dc-ac09-81e1f3545705"}}, "docstore/ref_doc_info": {"b968c78e-ae4d-4b99-b6bb-c62bbf697e98": {"node_ids": ["ee6ae5b2-2503-4fa2-8ba9-6ea67573ab57", "db1ed0e1-54e2-4c2d-b916-d6ccd9fc9832", "92e0c04e-820d-4eee-9f56-c43faab2865a", "128f7cbb-d598-4dc1-8ffd-d3aaea15774e", "32724e6c-0ce1-4427-a280-7dfd48e92f53", "b7f5f27c-031e-45ee-9e94-9e99cb14d96e", "adc2b52c-56f7-48be-8a87-d7b23ef59198", "1f099b2c-5412-43a8-9ac2-cf4e10bdc597", "90b6d25b-e13b-424b-96cb-324c4eaf5a23", "c1475d67-ae7e-4bf7-aea2-874a11740043", "48ea8a4b-3ea1-4c22-a21b-72354b56689c", "4cb60628-419c-4fab-a98d-cebc8ba02ede"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion.  Revenue increased 11.5 percent to $238.6\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$1.40 for the September quarter of fiscal 2022, compared to $2.08 in the prior year quarter. ", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2022 Four th Quar ter and Y ear End R esults\n11/3/2022\nRevenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase \n Fourth  Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 \n Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase \n Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nfourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "14bb0de0-a72e-45c4-a47c-c04d9c1e0707": {"node_ids": ["efce9afa-ac43-4b39-9f8e-0c01557da49e", "4fa95183-63cb-40a9-a312-713ecdc9ed66", "06151153-aab5-42e3-87b3-9bb31a3bc800", "e77d2d38-e641-4add-8904-d9549d74e747", "8098cf5e-f5bf-43f9-81f1-a86f1861194a", "1d08a53c-9fb5-4543-8912-b9ab034c0f3f", "6b03e6d8-60fa-4842-91d5-926e5ebf2d5f", "a9b6cc8e-8090-407a-ab57-4d44dce365f7", "13ba6ed1-5f06-44cb-a2d0-876d2f7b09a3", "565b5fd3-f266-40df-a747-ed3b80e794a7", "1facaba3-fe33-4505-bb60-97b89257a541", "8c1aa6fc-e4e2-4e6e-8f94-9164d7847bbe", "e2c95d30-2727-4c02-b486-472baed2028e", "09b25521-bc96-4f9e-bacf-a98c9566121c", "566b8bd0-bb9c-478d-86b2-9e8240a51012", "55a21817-ccc6-4ac7-b9a5-f8d87fd09841", "bbaa7845-620c-44ec-918e-8a66d9412d1e", "d361b967-ea7e-4eba-bf48-9db31743d9f4", "c4658214-60b0-43b8-a5db-bf38c407ef86", "fa9e5732-c343-4196-b2b8-13012845a233", "934cc17c-05d9-4e76-83ee-99e10ee7f1e1", "56d12f6e-9f64-4fca-9783-23b8b04dcde5", "ee6d63cf-fb6c-4d1f-b849-5f1d50339264", "de7b98fc-7c4d-4cc8-a5dc-81e7f2b1455e", "bfda1178-e301-4ae3-a628-be03c2a6375f", "6eb0c918-36cc-4c04-89fa-ed32d28a6ae1"], "metadata": {"window": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2022, revenue was $61.2 billion, up 3.8 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 4.7 percent increase in U.S. ", "original_text": "Dilut ed Shar es Outstanding 210.0M 210.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "page_label": "2", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4f956f19-6a30-4459-99fb-dd262cafd1ac": {"node_ids": ["caeca9e1-6294-4aa2-8cab-a110a16f3167", "2bc5add5-e9ba-4615-8ec2-93db69a5800e", "9ccacf68-1e22-4e7c-a204-005c835df1a6", "794266ea-a583-4b91-ab65-09bebafab231", "8754192d-95a4-4f82-924d-6e8140df1749", "37e93c2e-287a-4442-9562-3650ef14946a", "ac201113-5bc7-4fc9-bc16-9794d8e6c3d0", "9bc5cbe8-f3e0-4a20-bcf7-50ede04b68b2", "9c9c84be-5c4e-4b58-b3e5-2aa10e83c049", "ae0caca5-c84c-48c9-8387-d19e4d1b0849", "421517db-7461-4d7a-a7c1-a4e4142b4d51", "796c0af1-813a-42a8-8a55-51ee1534bb1a", "453131fb-cd5f-4e89-bb21-55e64c1dcdd6", "46dec6cb-8854-4abf-9a54-8795832d1a67", "6c9f07f5-8b92-4dcb-a701-c48061ba7645", "b772a7aa-b684-4e44-aa63-f1509d549a08", "81c8d2ce-97df-43a5-98a9-bf808f29c580", "d2479e0b-7cc0-42a4-afca-be404f62dbd1", "fff9e945-7bb8-4b0f-9775-7532303b3016", "a7977de3-bb55-4c68-9919-2924ade42cad", "6e475589-75a6-499a-b7a8-dc4c4ab00442", "162079fa-64ab-46f9-a359-f18682016f7b", "28f9653b-44ba-484b-9771-c28dd872882a", "8d86ff64-b35b-4a82-9f8d-781c15f5dc10", "bf5db6ee-2a3c-429e-a0ca-c24ca6799f4c", "5cf2a41b-d4fd-4f94-a520-27163255dc7c"], "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter.  Adjusted operating expenses as a percentage of revenue in the\nfiscal 2022 fourth quarter was 2.23 percent, flat when compared to the prior year quarter.\n Adjusted Operating Income:  In the fiscal 2022 fourth quarter, adjusted operating income of $741.5 million increased 6.8\npercent from the prior year quarter due to a 14.0 percent increase in U.S.  Healthcare Solutions' operating income, partially\noffset by a 12.6 percent decrease in operating income within International Healthcare Solutions due to the negative impact of\nforeign currency translation. ", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2022, adjusted operating expenses were $1.4 billion, an increase\nof 3.8 percent compared to the same period in the previous fiscal year primarily due to an increase in distribution, selling, and\nadministrative expenses compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d67dee92-0ce2-4274-9b8f-6d45fb28b953": {"node_ids": ["5c012ccd-c899-43e4-acd4-43383bae0e12", "f37dc250-60fc-404f-a2f2-26f15443da1f", "3b262889-23be-4c2d-b258-17b9da251aea", "99398746-9c8a-42c4-bc38-54274b13365a", "93ee77d7-7edd-4890-99b5-ab74f6d209d2", "b86b146d-f5a4-47dc-b6f8-5f3bbd31baa1", "fd054673-0e63-43d2-8098-8a16df09ebdf", "8379db79-9565-45e6-9e7b-535e90fcfae4", "c63f97e2-e32a-4274-a2d5-c2006b863803", "4b2b8ba9-816a-47de-8e91-d70f4f115952", "ffca696c-79c8-4936-b88f-72c1feb9c5eb", "76eb3b28-1dd0-49f1-baac-0fad5c893d77", "63377ddc-e1b6-4e01-bc3a-47127f123eeb", "2787444d-cd35-488d-bd45-633b3d16788e", "42ab8791-5f9c-462b-b498-78929c6e080e", "b27fd88a-0cfa-4c40-886f-7a039d83ca2b", "3d63d00b-09d1-4df1-a913-eb6b7214c4c4", "417317ff-a630-4980-aeea-e37c811f58bf", "51776c10-44af-4cad-8a9f-0f218c852431", "09786442-2438-4122-95b1-bf9d66a9393b", "e80b8a70-6af7-4ef2-9ea2-10e5a935f643"], "metadata": {"window": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year.  Revenue increased 11.5 percent from last\nfiscal year to $238.6 billion.  Gross profit increased 19.5 percent to $8.3 billion primarily due to increases in gross profit within\nInternational Healthcare Solutions, including the full year impact of the June 2021 Alliance Healthcare acquisition, and within U.S.\n Healthcare Solutions, partially offset by a LIFO expense in the current year versus a credit in the previous fiscal year and less\nfavorable gains from antitrust litigation settlements. ", "original_text": "\u00a0 GAAP Adjust ed (non-GAAP)\nRevenue $238.6B $238.6B\nGross Pr ofit $8.3B $8.4B\nOperating Expenses $5.9B $5.2B\nOperating Income $2.4B $3.2B\nInterest Expense, Net $211M $211M\nEffectiv e Tax Rat e 23.7% 20.6%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $1.7B $2.3B\nDilut ed Earnings P er Shar e $8.04 $11.03\nDilut ed Shar es Outstanding 211.2M 211.2M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2022, GAAP diluted EPS was $8.04 compared to $7.39 in the prior fiscal year. ", "page_label": "4", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4a112dff-31f2-4cad-a9a7-e59cebf37ea7": {"node_ids": ["085869d4-6044-471a-bb88-faec787b50c2", "ae902c71-23c9-4988-99f1-f78c12eecb8b", "b6023283-52aa-49a5-a699-99be191d6d84", "2d81ef30-1268-42b3-81a2-f2163dbe5f86", "0f034437-825f-4fa4-b630-c145866ec56d", "93515638-f16d-4c3e-b046-85208f424f11", "384887b7-2218-4902-9994-d069f02d71f4", "5f17dc73-ab39-439c-8d2d-1454dfd9c77b", "db4a5346-ad96-4a30-ac92-8bc5cd221ee7", "cce00488-3d75-41b2-9056-c5723da91fc9", "a744504c-f365-4601-88ff-a25f41921f80"], "metadata": {"window": "health equity in cancer care.\n Dividend Declaration\nOn November 2, 2022, the Company's Board of Directors declared a quarterly dividend of $0.485 per common share, an increase in\nits quarterly dividend rate from $0.46 per common share.  The quarterly dividend of $0.485 per common share will be payable\nNovember 28, 2022, to stockholders of record at the close of business on November 14, 2022.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "health equity in cancer care.\n", "page_label": "5", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6992a1ae-ddce-4057-9717-e74ff527ad43": {"node_ids": ["983613b6-d66f-45fd-9c31-6822e2ea4256", "d3d60933-81fe-4f51-a016-5f4be0c27849", "e602a727-786b-449f-8215-b820f699548f", "09068d98-3f8a-49ce-a2d3-4cdcae16170b", "39169849-65da-4142-9d86-f33cc6c537f7", "69fcbc78-1783-49e8-b444-2b77b6f486fe", "84682d56-6d77-4dc4-a947-bdaaad64e0e6", "8c03ce97-66db-4e76-9f94-fbb19aeb8d86", "b189b90b-62dd-45c2-bd4a-f7c7c9585057", "ed9bab14-3043-4aa5-9a1f-93b70a1a29f3", "50e84f97-cd05-42f4-bf75-58191d20d156", "53356fac-8c8a-4e43-80d7-f661ddd8d150", "8b89874f-3ee0-4e72-aba4-5b490dfec1c4", "c0bc1075-274a-4c9c-8325-37dfdaac9804", "2cfd7e93-fa6a-4d00-8174-c64ef3a29902", "9545b10f-2f3c-4a78-8fac-878ee957a41f", "2e9d8bca-9a65-431c-a894-778e48fc90ad", "d8226164-c034-475d-b562-4c4d8b285ba4", "dc8cb903-75d5-4edc-a1e7-46d0612c6c6a", "2a85f1d7-b0dc-498f-b623-62d0f2f83018", "e86fa7da-8421-4f88-8a82-e016bd0ccf9b", "430005e8-b05b-4071-9d08-4787237e2ca6", "7c09c9cc-abea-4ead-bc49-00251edd7fab", "71a8cad6-948d-4155-954c-97f0311f0f0c", "eb1bd276-5ecd-4322-81e7-2b048c30d3a7", "8fb4a642-a52b-47b3-8de0-ed7f5a55d98a", "6ea7b245-413e-494b-a65d-3e049cf8f9ee", "26b7256b-97f5-410b-b548-3473605bd39c", "3117a402-5c07-4088-b8e5-8c96082ccc5b"], "metadata": {"window": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 3, 2022.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com. ", "original_text": "Adjusted effective tax rate to be approximately 20 percent to 21 percent;\nAdjusted free cash flow to be approximately $2 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 207 to 209 million for the fiscal year.\n", "page_label": "6", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d39920ec-37f3-4277-93e5-33b4341f9e5f": {"node_ids": ["0ffaa400-3c20-4848-aa03-7d5205a26089", "d0aae783-7b6e-439b-88cf-a5f8a33728e0", "013745d6-b250-4019-b172-4d3ec30d489d", "ee7f9945-f7bd-46ed-a90a-6361a8e3ea58", "965a8e3b-d85d-45a1-bf23-80d91571a15f", "f892e518-be5c-4685-b2e5-1a0cba42d6b7", "814e7ba7-d166-4dc0-b641-fad8cfd04452"], "metadata": {"window": "actual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or\nthat their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;\nunexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance Healthcare and\nPharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the Company\u2019s, Alliance\nHealthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance and results; the\neffects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance\nHealthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to\nestablish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including\nthe acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s tax\npositions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss, bankruptcy or\ninsolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or\ninsolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial and other\nimpacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or\nbreach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks generally\nassociated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "original_text": "actual results to vary materially from those indicated. ", "page_label": "7", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e1149a58-9120-4328-8ded-2fd5ae3e7f68": {"node_ids": ["dc454161-9825-4277-9f0a-70e20fa32242"], "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a03.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a0\u00a056,843,010 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a0\u00a02,069,411 \u00a0\u00a03.51 %\u00a0(4.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a0\u00a01,215,688 \u00a0\u00a02.06 %\u00a03.9 %\nDepreciation and amortization \u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a0\u00a0177,721 \u00a0\u00a00.30 %\u00a0(4.0 )%\nLitigation and opioid-related expenses \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a045,348 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a081,992 \u00a0\u00a0\u00a0 \u00a0\u00a051,062 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a0\u00a01,507,516 \u00a0\u00a02.56 %\u00a01.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a0\u00a0561,895 \u00a0\u00a00.95 %\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 2 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0(46,637 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a0\u00a054,596 \u00a0\u00a0\u00a0 \u00a0(5.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a0\u00a0553,936 \u00a0\u00a00.94 %\u00a0(31.0 )%\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$61,174,149 \u00a0\u00a0\u00a0 \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a03.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a059,188,590 \u00a0\u00a0\u00a0 \u00a0\u00a056,843,010 \u00a0\u00a0\u00a0 \u00a04.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a01,985,559 \u00a0\u00a03.25 %\u00a0\u00a02,069,411 \u00a0\u00a03.51 %\u00a0(4.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,263,462 \u00a0\u00a02.07 %\u00a0\u00a01,215,688 \u00a0\u00a02.06 %\u00a03.9 %\nDepreciation and amortization \u00a0\u00a0170,562 \u00a0\u00a00.28 %\u00a0\u00a0177,721 \u00a0\u00a00.30 %\u00a0(4.0 )%\nLitigation and opioid-related expenses \u00a0\u00a015,024 \u00a0\u00a0\u00a0 \u00a0\u00a045,348 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a081,992 \u00a0\u00a0\u00a0 \u00a0\u00a051,062 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,531,040 \u00a0\u00a02.50 %\u00a0\u00a01,507,516 \u00a0\u00a02.56 %\u00a01.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0454,519 \u00a0\u00a00.74 %\u00a0\u00a0561,895 \u00a0\u00a00.95 %\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income), net 2 \u00a0\u00a020,656 \u00a0\u00a0\u00a0 \u00a0\u00a0(46,637 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a051,523 \u00a0\u00a0\u00a0 \u00a0\u00a054,596 \u00a0\u00a0\u00a0 \u00a0(5.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0382,340 \u00a0\u00a00.63 %\u00a0\u00a0553,936 \u00a0\u00a00.94 %\u00a0(31.0 )%\n8", "page_label": "8", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a0882c34-d65f-45fd-9fcd-92a230b74df7": {"node_ids": ["35117da4-e247-4b9f-9eaf-31256f098c41", "21fd5879-28b5-4f14-8ea5-6c57bc27f652", "d68a3fec-2571-4a10-8f1e-9aa6acbceec0", "9ca2f1e8-9c32-4350-b926-bde0da1516b4", "734d6a59-d8c9-4628-9408-41370d5b95e5"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022.  Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the\nthree months ended September 30, 2021.\n 2 Includes an $8.1 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform, Turkey foreign\nexchange remeasurement expense of $6.1 million, a $4.8 million gain on the remeasurement of an equity investment, and a $3.7\nmillion reduction to the previously recognized gain on the sale of businesses in the three months September 30, 2022.  Includes a\n$64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable,\nand a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three months ended\nSeptember 30, 2021.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a083,664 \u00a0\u00a0\u00a0 \u00a0\u00a0117,488 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0298,676 \u00a0\u00a00.49 %\u00a0\u00a0436,448 \u00a0\u00a00.74 %\u00a0(31.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling\ninterests \u00a0\u00a0(3,939 )\u00a0\u00a0 \u00a0\u00a01,250 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$294,737 \u00a0\u00a00.48 %\u00a0$437,698 \u00a0\u00a00.74 %\u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0 \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0(32.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0207,222 \u00a0\u00a0\u00a0 \u00a0\u00a0207,900 \u00a0\u00a0\u00a0 \u00a0(0.3 )%\nDiluted \u00a0\u00a0209,961 \u00a0\u00a0\u00a0 \u00a0\u00a0210,810 \u00a0\u00a0\u00a0 \u00a0(0.4 )%\n________________________________________\n1 Includes a $104.8 million LIFO expense and Turkey foreign exchange remeasurement expense of $12.4 million in the three months\nended September 30, 2022. ", "page_label": "9", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8a94cd0c-cd36-4d4d-8bac-0dd7accd2040": {"node_ids": ["fc632b4f-6379-4fee-8a53-97c1b3e91152"], "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Fiscal Y ear Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a0\u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a011.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a0\u00a06,943,228 \u00a0\u00a03.24 %\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a0\u00a03,594,251 \u00a0\u00a01.68 %\u00a034.9 %\nDepreciation and amortization \u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a0\u00a0505,172 \u00a0\u00a00.24 %\u00a037.4 %\nLitigation and opioid-related expenses \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0272,623 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0183,059 \u00a0\u00a0\u00a0 \u00a0\u00a0199,288 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 2 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a0\u00a04,589,031 \u00a0\u00a02.14 %\u00a029.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0\u00a02,354,197 \u00a0\u00a01.10 %\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  3 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0(41,736 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a0\u00a0174,074 \u00a0\u00a0\u00a0 \u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0\u00a02,221,859 \u00a0\u00a01.04 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0677,251 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a0\u00a01,544,608 \u00a0\u00a00.72 %\u00a07.9 %\n10", "original_text": "\u00a0 \u00a0Fiscal Y ear Ended \nSeptember 30,\n2022 \u00a0% of\nRevenue \u00a0Fiscal Y ear Ended \nSeptember 30,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$238,587,006 \u00a0\u00a0\u00a0 \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a011.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0230,290,639 \u00a0\u00a0\u00a0 \u00a0\u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a011.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a08,296,367 \u00a0\u00a03.48 %\u00a0\u00a06,943,228 \u00a0\u00a03.24 %\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a04,848,962 \u00a0\u00a02.03 %\u00a0\u00a03,594,251 \u00a0\u00a01.68 %\u00a034.9 %\nDepreciation and amortization \u00a0\u00a0693,895 \u00a0\u00a00.29 %\u00a0\u00a0505,172 \u00a0\u00a00.24 %\u00a037.4 %\nLitigation and opioid-related expenses \u00a0\u00a0123,191 \u00a0\u00a0\u00a0 \u00a0\u00a0272,623 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0183,059 \u00a0\u00a0\u00a0 \u00a0\u00a0199,288 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment 2 \u00a0\u00a075,936 \u00a0\u00a0\u00a0 \u00a0\u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a05,929,989 \u00a0\u00a02.49 %\u00a0\u00a04,589,031 \u00a0\u00a02.14 %\u00a029.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a02,366,378 \u00a0\u00a00.99 %\u00a0\u00a02,354,197 \u00a0\u00a01.10 %\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  3 \u00a0\u00a0(27,352 )\u00a0\u00a0 \u00a0\u00a0(41,736 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0210,673 \u00a0\u00a0\u00a0 \u00a0\u00a0174,074 \u00a0\u00a0\u00a0 \u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a02,183,057 \u00a0\u00a00.91 %\u00a0\u00a02,221,859 \u00a0\u00a01.04 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 4 \u00a0\u00a0516,517 \u00a0\u00a0\u00a0 \u00a0\u00a0677,251 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,666,540 \u00a0\u00a00.70 %\u00a0\u00a01,544,608 \u00a0\u00a00.72 %\u00a07.9 %\n10", "page_label": "10", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1816d15c-8d8e-478a-994e-952ee0b7ee90": {"node_ids": ["bf21c2a0-2b5d-4872-a92a-5db23c692665", "50548cc3-2908-4040-886d-bad174a64657", "a4d0d221-016e-428d-a1c6-c111ecf928bf", "cbcd44ad-fea7-4116-a485-7e62bd46faa8", "a71e440d-0bf9-4c52-9800-6fbc8a2e6817", "90e779a3-e4a2-4312-8d4a-916dddd57c6b", "1753da94-41de-4fc0-9542-b5f41e7a4ecb"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022.  Includes a $203.0 million LIFO credit and $168.8\nmillion of gains from antitrust litigation settlements in the fiscal year ended September 30, 2021.\n 2 The goodwill impairments related to the Company's non-wholly-owned subsidiary in Brazil.\n 3 Includes a $56.2 million gain on the sale of non-core businesses, a $14.4 million loss on the currency remeasurement of deferred\ntax assets relating to Swiss tax reform, Turkey foreign exchange remeasurement expense of $11.9 million, and a $4.8 million gain on\nthe remeasurement of an equity investment in the fiscal year ended September 30, 2022. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a032,280 \u00a0\u00a0\u00a0 \u00a0\u00a0(4,676 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$1,698,820 \u00a0\u00a00.71 %\u00a0$1,539,932 \u00a0\u00a00.72 %\u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$8.15 \u00a0\u00a0\u00a0 \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a09.0 %\nDiluted \u00a0$8.04 \u00a0\u00a0\u00a0 \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a08.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,472 \u00a0\u00a0\u00a0 \u00a0\u00a0205,919 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0\u00a0211,210 \u00a0\u00a0\u00a0 \u00a0\u00a0208,465 \u00a0\u00a0\u00a0 \u00a01.3 %\n________________________________________\n1 Includes a $67.2 million LIFO expense, Turkey foreign exchange remeasurement expense of $40.0 million, and a $1.8 million gain\nfrom antitrust litigation settlements in the fiscal year ended September 30, 2022. ", "page_label": "11", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "643c5de3-bf96-41f7-ab20-836813ab4085": {"node_ids": ["8d2d1ef6-4b5e-4fc9-ae4e-82ffe65f5748"], "metadata": {"window": "\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0\u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0\u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a012,415 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a0\u00a015,024 \u00a0\u00a0\u00a02,184 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,840 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,992 )\u00a0\u00a081,992 \u00a0\u00a0\u00a081,992 \u00a0\u00a0\u00a011,920 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a070,072 \u00a0\u00a0\u00a00.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n12", "original_text": "\u00a0 \u00a0Three Months Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,985,559 \u00a0\u00a0$1,531,040 \u00a0\u00a0$454,519 \u00a0\u00a0$382,340 \u00a0\u00a0$83,664 \u00a0\u00a0$(3,939 )\u00a0$294,737 \u00a0\u00a0$1.40 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79 )\u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a012,415 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,415 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a018,543 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a0104,839 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a0104,839 \u00a0\u00a0\u00a024,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a079,896 \u00a0\u00a0\u00a00.38 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(72,685 )\u00a0\u00a072,685 \u00a0\u00a0\u00a072,685 \u00a0\u00a0\u00a06,194 \u00a0\u00a0\u00a0(1,127 )\u00a0\u00a065,364 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,024 )\u00a0\u00a015,024 \u00a0\u00a0\u00a015,024 \u00a0\u00a0\u00a02,184 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,840 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,992 )\u00a0\u00a081,992 \u00a0\u00a0\u00a081,992 \u00a0\u00a0\u00a011,920 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a070,072 \u00a0\u00a0\u00a00.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,745 \u00a0\u00a0\u00a02,821 \u00a0\u00a0\u00a03,618 \u00a0\u00a0\u00a04,542 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "61f14a0f-0815-4592-af87-d8fb20bb8d9f": {"node_ids": ["b014156f-c852-4d11-987f-91bbca1155cd", "62b66616-5f91-4aaa-97b6-8a4e0647a75f", "40baa716-cb56-42fa-b564-b61131464dbf", "a81dbff1-2a3e-46db-90fa-d9cd2c9b961c"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a0\u00a04.8 %\u00a0\u00a03.8 %\u00a0\u00a06.8 %\u00a0\u00a07.0 %\u00a0\u00a04.3 %\u00a0\u00a0 \u00a0\u00a08.4 %\u00a0\u00a08.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.25% \u00a03.44%\nOperating expenses \u00a02.50% \u00a02.23%\nOperating income \u00a00.74% \u00a01.21%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\nIncome\nBefor e IncomeNet Loss\n(Income)\nAttributable to NetIncomeDilut ed \nEarnings\n13", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,302 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,302 )\u00a0\u00a0(0.04 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a08,127 \u00a0\u00a0\u00a0(5,951 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,078 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,102,813 \u00a0\u00a0$1,361,339 \u00a0\u00a0$741,474 \u00a0\u00a0$682,461 \u00a0\u00a0$135,156 \u00a0\u00a0$(1,448 )\u00a0$545,857 \u00a0\u00a0$2.60 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5ce78148-080b-4415-842a-92e7402300a6": {"node_ids": ["6b57f805-671b-4f3d-bf2c-83d9a34b7299"], "metadata": {"window": "\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Befor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(21,362 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,362 )\u00a0\u00a0(21,362 )\u00a0\u00a0(32,251 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,889 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(42,463 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(42,463 )\u00a0\u00a0(42,463 )\u00a0\u00a0(40,529 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,934 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,932 )\u00a0\u00a081,932 \u00a0\u00a0\u00a081,932 \u00a0\u00a0\u00a043,830 \u00a0\u00a0\u00a0(5,734 )\u00a0\u00a032,368 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(45,348 )\u00a0\u00a045,348 \u00a0\u00a0\u00a045,348 \u00a0\u00a0\u00a023,896 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,452 \u00a0\u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(51,062 )\u00a0\u00a051,062 \u00a0\u00a0\u00a051,062 \u00a0\u00a0\u00a026,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,156 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n14", "original_text": "\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Befor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u00a0(21,362 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(21,362 )\u00a0\u00a0(21,362 )\u00a0\u00a0(32,251 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a010,889 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(42,463 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(42,463 )\u00a0\u00a0(42,463 )\u00a0\u00a0(40,529 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,934 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(81,932 )\u00a0\u00a081,932 \u00a0\u00a0\u00a081,932 \u00a0\u00a0\u00a043,830 \u00a0\u00a0\u00a0(5,734 )\u00a0\u00a032,368 \u00a0\u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(45,348 )\u00a0\u00a045,348 \u00a0\u00a0\u00a045,348 \u00a0\u00a0\u00a023,896 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,452 \u00a0\u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(51,062 )\u00a0\u00a051,062 \u00a0\u00a0\u00a051,062 \u00a0\u00a0\u00a026,906 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,156 \u00a0\u00a0\u00a00.11 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ab64f157-079e-46a0-9ad1-6d073684e00e": {"node_ids": ["15866567-8c1f-4b0e-8df1-b634856d10e0", "9aa031bd-5f30-4032-96fb-283b87c607da", "86712c93-ed13-4a14-8216-c2d608b4bc53", "1f95fc91-b011-46d1-880f-02d56ad4f146"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss\n(Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$8,296,367 \u00a0\u00a0$5,929,989 \u00a0\u00a0$2,366,378 \u00a0\u00a0$2,183,057 \u00a0\u00a0$516,517 \u00a0\u00a0$32,280 \u00a0\u00a0$1,698,820 \u00a0\u00a0$8.04 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(408 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,427 )\u00a0\u00a0(0.01 )\u00a0\n15", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a02,276 \u00a0\u00a0\u00a0(9,784 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a012,060 \u00a0\u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484 )\u00a0$503,665 \u00a0\u00a0$2.39 \u00a02\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Loss (Income), Net.\n", "page_label": "15", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "65fe3ce5-de37-4ebc-bd71-9bfe9e54f708": {"node_ids": ["d1dffebf-1082-411e-9dd6-dda4e3375938"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,059 )\u00a0\u00a0183,059 \u00a0\u00a0\u00a0183,059 \u00a0\u00a0\u00a035,829 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,230 \u00a0\u00a0\u00a00.70 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n16", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a040,033 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a040,033 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a051,966 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a067,171 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a067,171 \u00a0\u00a0\u00a014,943 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a052,228 \u00a0\u00a0\u00a00.25 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(304,551 )\u00a0\u00a0304,551 \u00a0\u00a0\u00a0304,551 \u00a0\u00a0\u00a067,749 \u00a0\u00a0\u00a0(5,219 )\u00a0\u00a0231,583 \u00a0\u00a0\u00a01.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(123,191 )\u00a0\u00a0123,191 \u00a0\u00a0\u00a0123,191 \u00a0\u00a0\u00a024,111 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a099,080 \u00a0\u00a0\u00a00.47 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration,\nand\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(183,059 )\u00a0\u00a0183,059 \u00a0\u00a0\u00a0183,059 \u00a0\u00a0\u00a035,829 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0147,230 \u00a0\u00a0\u00a00.70 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,834 )\u00a0\u00a0(0.02 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(75,936 )\u00a0\u00a075,936 \u00a0\u00a0\u00a075,936 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(47,004 )\u00a0\u00a028,932 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nnon-core\nbusinesses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(56,228 )\u00a0\u00a0(10,372 )\u00a0\u00a03,618 \u00a0\u00a0\u00a0(42,238 )\u00a0\u00a0(0.20 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(9,677 )\u00a0\u00a06,840 \u00a0\u00a0\u00a016,517 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b8319279-d7f5-4758-99a9-1ab39219839d": {"node_ids": ["fe0fcd7e-abf8-44d3-bbaa-3a971a984c8e", "97bc5cb2-38d8-4f00-a7eb-e0a9bca9ace5", "01b2d000-ee8e-48d3-8fc4-f9b5d083447a", "02e4c9c9-206c-4f6a-a3f9-14cf7f8da3aa", "31c0fcf2-5ce2-4e0a-82f6-860a515d20db"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a0\u00a027.9 %\u00a0\u00a033.5 %\u00a0\u00a019.5 %\u00a0\u00a019.3 %\u00a0\u00a015.4 %\u00a0\u00a0 \u00a0\u00a020.7 %\u00a0\u00a019.1 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.48% \u00a03.52%\nOperating expenses \u00a02.49% \u00a02.20%\nOperating income \u00a00.99% \u00a01.33%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n 2 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,443 \u00a0\u00a0\u00a0(32,109 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,552 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$8,401,736 \u00a0\u00a0$5,238,306 \u00a0\u00a0$3,163,430 \u00a0\u00a0$2,945,423 \u00a0\u00a0$606,583 \u00a0\u00a0$(9,485 )\u00a0$2,329,355 \u00a0\u00a0$11.03 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "17", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5050269a-d340-4cc9-abc1-4dc55fbe0f9d": {"node_ids": ["d76c12a0-f2a8-4141-8b13-654626f216a4"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,794 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,794 )\u00a0\u00a0(168,794 )\u00a0\u00a0(47,517 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(121,277 )\u00a0\u00a0(0.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(203,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(203,028 )\u00a0\u00a0(203,028 )\u00a0\u00a0(57,154 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(145,874 )\u00a0\u00a0(0.70 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(176,221 )\u00a0\u00a0176,221 \u00a0\u00a0\u00a0176,221 \u00a0\u00a0\u00a046,873 \u00a0\u00a0\u00a0(7,498 )\u00a0\u00a0121,850 \u00a0\u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(272,623 )\u00a0\u00a0272,623 \u00a0\u00a0\u00a0272,623 \u00a0\u00a0\u00a050,436 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222,187 \u00a0\u00a0\u00a01.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(199,288 )\u00a0\u00a0199,288 \u00a0\u00a0\u00a0199,288 \u00a0\u00a0\u00a036,868 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0162,420 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\n f\n18", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(168,794 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(168,794 )\u00a0\u00a0(168,794 )\u00a0\u00a0(47,517 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(121,277 )\u00a0\u00a0(0.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(203,028 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(203,028 )\u00a0\u00a0(203,028 )\u00a0\u00a0(57,154 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(145,874 )\u00a0\u00a0(0.70 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(176,221 )\u00a0\u00a0176,221 \u00a0\u00a0\u00a0176,221 \u00a0\u00a0\u00a046,873 \u00a0\u00a0\u00a0(7,498 )\u00a0\u00a0121,850 \u00a0\u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(272,623 )\u00a0\u00a0272,623 \u00a0\u00a0\u00a0272,623 \u00a0\u00a0\u00a050,436 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0222,187 \u00a0\u00a0\u00a01.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(199,288 )\u00a0\u00a0199,288 \u00a0\u00a0\u00a0199,288 \u00a0\u00a0\u00a036,868 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0162,420 \u00a0\u00a0\u00a00.78 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,000 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(64,721 )\u00a0\u00a0(0.31 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a06,373 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a06,373 \u00a0\u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a011,324 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,324 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\n f\n18", "page_label": "18", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ff47ab50-4dda-43f7-afb6-c648607b3a2f": {"node_ids": ["9d803435-382b-410d-a6df-a941311e8a56", "2594edb9-b0d8-4d50-a9fb-18209c3029f6", "b3001d95-73af-493d-9582-446603dd874a", "c6555165-d0c2-4689-9173-633b58b8f3fc", "499c8f1e-54d9-44f3-8f33-40fe9a554778"], "metadata": {"window": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 2 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, the latter of which is recorded within Other Income,\nNet.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "original_text": "tax benefits 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a020,425 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,425 )\u00a0\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,362 \u00a0\u00a0\u00a0(201,391 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0204,753 \u00a0\u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174 )\u00a0$1,930,542 \u00a0\u00a0$9.26 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "page_label": "19", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "afcc3826-a4b0-4087-90ec-de9cc9b180d8": {"node_ids": ["5e110c59-a06f-4e3b-88de-5cf74f261109", "0452d29a-b32f-4d92-8e5e-f02d22550777", "c0e58ed2-59c0-4b11-8bd8-456666ee7475"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$578,416 \u00a0\u00a0$507,486 \u00a0\u00a014.0 %\nInternational Healthcare Solutions \u00a0\u00a0163,058 \u00a0\u00a0\u00a0186,623 \u00a0\u00a0(12.6 )%\nTotal segment operating income \u00a0\u00a0741,474 \u00a0\u00a0\u00a0694,109 \u00a0\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,362 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(104,839 )\u00a0\u00a042,463 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(12,415 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(72,685 )\u00a0\u00a0(81,932 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(15,024 )\u00a0\u00a0(45,348 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(81,992 )\u00a0\u00a0(51,062 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$454,519 \u00a0\u00a0$561,895 \u00a0\u00a0(19.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.53 %\u00a0\u00a02.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.47 %\u00a0\u00a01.41 %\u00a0\u00a0\nOperating income \u00a0\u00a01.06 %\u00a0\u00a00.97 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$61,174,149 \u00a0\u00a0$58,912,421 \u00a0\u00a03.8 %\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "20", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b3262805-6b48-4a9b-98ba-48044b9da8d5": {"node_ids": ["d4cb7e74-ba4a-43da-9a17-bacec4d4c976", "e2a5d8c7-81d4-4051-b2ab-bc388748af9d", "c4d0d37c-9065-4517-9ee1-f11ea04a1ef9"], "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$212,100,202 \u00a0\u00a0$202,461,545 \u00a0\u00a04.8 %\nInternational Healthcare Solutions \u00a0\u00a026,491,673 \u00a0\u00a0\u00a011,529,629 \u00a0\u00a0129.8 %\nIntersegment eliminations \u00a0\u00a0(4,869 )\u00a0\u00a0(2,331 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$238,587,006 \u00a0\u00a0$213,988,843 \u00a0\u00a011.5 %\n21", "original_text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.22 %\u00a0\u00a011.54 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.67 %\u00a0\u00a08.69 %\u00a0\u00a0\nOperating income \u00a0\u00a02.55 %\u00a0\u00a02.84 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.25 %\u00a0\u00a03.51 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.50 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating income \u00a0\u00a00.74 %\u00a0\u00a00.95 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.44 %\u00a0\u00a03.40 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.23 %\u00a0\u00a02.23 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.21 %\u00a0\u00a01.18 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "21", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2318ecbc-dea3-4801-b07e-f006195958ad": {"node_ids": ["672a5eb2-6413-4b50-bb65-c8dafd41a2ba", "b4dfe92c-2eb0-4563-8b69-784d09d72b41", "95cb331c-bbbd-4f9f-af33-f8200daae153"], "metadata": {"window": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$2,456,972 \u00a0\u00a0$2,257,918 \u00a0\u00a08.8 %\nInternational Healthcare Solutions \u00a0\u00a0706,458 \u00a0\u00a0\u00a0390,286 \u00a0\u00a081.0 %\nTotal segment operating income \u00a0\u00a03,163,430 \u00a0\u00a0\u00a02,648,204 \u00a0\u00a019.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0168,794 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(67,171 )\u00a0\u00a0203,028 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(40,033 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(304,551 )\u00a0\u00a0(176,221 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(123,191 )\u00a0\u00a0(272,623 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(183,059 )\u00a0\u00a0(199,288 )\u00a0\u00a0\nGoodwill impairment \u00a0\u00a0(75,936 )\u00a0\u00a0(6,373 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0(11,324 )\u00a0\u00a0\nOperating income \u00a0$2,366,378 \u00a0\u00a0$2,354,197 \u00a0\u00a00.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.57 %\u00a0\u00a02.48 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.41 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.16 %\u00a0\u00a01.12 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a013.38 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.46 %\u00a0\u00a09.99 %\u00a0\u00a0\n22", "original_text": "\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "22", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0995082e-f5f9-4a7e-ac46-943fd94c69fe": {"node_ids": ["9116171c-75d8-4141-bd39-61fd58b9731e", "e4d7afbe-c740-4fda-9ff2-c39b783a906f"], "metadata": {"window": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 \u00a02022 \u00a0\u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,388,189 \u00a0$2,547,142\nAccounts receivable, net \u00a018,452,675 \u00a0\u00a018,167,175\nInventories \u00a015,556,394 \u00a0\u00a015,368,352\nRight to recover asset \u00a01,532,061 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a0660,439 \u00a0\u00a01,448,383\n23", "original_text": "Operating income \u00a0\u00a02.67 %\u00a0\u00a03.39 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.48 %\u00a0\u00a03.24 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.49 %\u00a0\u00a02.14 %\u00a0\u00a0\nOperating income \u00a0\u00a00.99 %\u00a0\u00a01.10 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.52 %\u00a0\u00a03.07 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.20 %\u00a0\u00a01.83 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.33 %\u00a0\u00a01.24 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "23", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7f513770-0913-43ba-9ec8-09122efc9214": {"node_ids": ["07584643-a945-44d9-862d-c1bfa42bb778"], "metadata": {"window": "Total current assets \u00a039,589,758 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,003 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a012,836,623 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0237,571 \u00a0\u00a0290,791\nOther long-term assets \u00a01,761,661 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $56,560,616 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $40,192,890 \u00a0$38,009,954\nOther current liabilities \u00a02,214,592 \u00a0\u00a03,048,474\nShort-term debt \u00a01,070,473 \u00a0\u00a0300,213\nTotal current liabilities \u00a043,477,955 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,632,360 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0320,274 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,620,413 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a0976,583 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,461,758 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a071,273 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $56,560,616 \u00a0$57,337,805\n24", "original_text": "Total current assets \u00a039,589,758 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,135,003 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a012,836,623 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0237,571 \u00a0\u00a0290,791\nOther long-term assets \u00a01,761,661 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $56,560,616 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $40,192,890 \u00a0$38,009,954\nOther current liabilities \u00a02,214,592 \u00a0\u00a03,048,474\nShort-term debt \u00a01,070,473 \u00a0\u00a0300,213\nTotal current liabilities \u00a043,477,955 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,632,360 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0320,274 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,620,413 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a0976,583 \u00a0\u00a01,082,723\nAccrued litigation liability \u00a05,461,758 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a071,273 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $56,560,616 \u00a0$57,337,805\n24", "page_label": "24", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e59a7e28-43e4-443e-9f42-04b24dba58b8": {"node_ids": ["49b2f2eb-7d36-4997-95fd-0d73056d494b"], "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,666,540 \u00a0\u00a0$1,544,608 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,176,210 \u00a0\u00a0\u00a0754,656 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,659,525 )\u00a0\u00a0(930,078 )\nInventories \u00a0(665,370 )\u00a0\u00a0(1,116,344 )\nAccounts payable \u00a03,320,725 \u00a0\u00a0\u00a02,049,167 \u00a0\nOther, net \u00a0(1,135,492 )\u00a0\u00a0364,577 \u00a0\nNet cash provided by operating activities \u00a02,703,088 \u00a0\u00a0\u00a02,666,586 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(496,318 )\u00a0\u00a0(438,217 )\nCost of acquired companies, net of cash acquired \u00a0(133,814 )\u00a0\u00a0(5,563,040 )\nCost of equity investments \u00a0(18,491 )\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0272,586 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a07,600 \u00a0\u00a0\u00a022,300 \u00a0\nNet cash used in investing activities \u00a0(368,437 )\u00a0\u00a0(6,141,577 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(923,103 )\u00a0\u00a02,216,552 \u00a0\nPurchases of common stock 1 \u00a0(483,704 )\u00a0\u00a0(82,150 )\n25", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,666,540 \u00a0\u00a0$1,544,608 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a01,176,210 \u00a0\u00a0\u00a0754,656 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions and divestitures: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(1,659,525 )\u00a0\u00a0(930,078 )\nInventories \u00a0(665,370 )\u00a0\u00a0(1,116,344 )\nAccounts payable \u00a03,320,725 \u00a0\u00a0\u00a02,049,167 \u00a0\nOther, net \u00a0(1,135,492 )\u00a0\u00a0364,577 \u00a0\nNet cash provided by operating activities \u00a02,703,088 \u00a0\u00a0\u00a02,666,586 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(496,318 )\u00a0\u00a0(438,217 )\nCost of acquired companies, net of cash acquired \u00a0(133,814 )\u00a0\u00a0(5,563,040 )\nCost of equity investments \u00a0(18,491 )\u00a0\u00a0(162,620 )\nProceeds from the sale of businesses \u00a0272,586 \u00a0\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a07,600 \u00a0\u00a0\u00a022,300 \u00a0\nNet cash used in investing activities \u00a0(368,437 )\u00a0\u00a0(6,141,577 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(923,103 )\u00a0\u00a02,216,552 \u00a0\nPurchases of common stock 1 \u00a0(483,704 )\u00a0\u00a0(82,150 )\n25", "page_label": "25", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c26c5325-b2d6-44bd-a9b2-6e959632171d": {"node_ids": ["a1e3aca4-0583-40e5-8009-4576f1306aa5", "b4d8f2d7-ec5a-48e3-a868-bd94fa69efa8"], "metadata": {"window": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n 2 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n(amounts in thousands) \u00a0September 30, \n2022 \u00a0September 30, \n2021 \u00a0September 30, \n2020\nCash and cash equivalents \u00a0$3,388,189 \u00a0$2,547,142 \u00a0$4,597,746\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0144,980 \u00a0\u00a0462,986 \u00a0\u00a0\u2014\nRestricted cash (included in Other Assets) \u00a0\u00a060,370 \u00a0\u00a060,000 \u00a0\u00a0\u2014\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,593,539 \u00a0$3,070,128 \u00a0$4,597,746\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\n26", "original_text": "Exercises of stock options \u00a093,912 \u00a0\u00a0\u00a0198,750 \u00a0\nCash dividends on common stock \u00a0(391,687 )\u00a0\u00a0(366,648 )\nOther, net \u00a0(48,198 )\u00a0\u00a0(13,655 )\nNet cash (used in) provided by financing activities \u00a0(1,752,780 )\u00a0\u00a01,952,849 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(57,850 )\u00a0\u00a0(3,725 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease (decrease) in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0524,021 \u00a0\u00a0\u00a0(1,525,867 )\nLess: Increase in cash classified within assets held for sale \u00a0(610 )\u00a0\u00a0(1,751 )\nIncrease (decrease) in cash, cash equivalents, and restricted cash \u00a0523,411 \u00a0\u00a0\u00a0(1,527,618 )\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 2 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 2 $3,593,539 \u00a0\u00a0$3,070,128 \u00a0\n________________________________________\n1 Excludes $28.4 million of September 2022 purchases that cash settled in October 2022.\n", "page_label": "26", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ba152fb8-ca4c-4e64-9abc-d13464df4cab": {"node_ids": ["c69dd6e3-a16d-4ed6-8fc0-0c41bc3c0e1f", "05a0c248-28fc-4c96-9831-c34db80595e6", "6fe3fe99-40ba-4233-a8d6-8e559befbe99", "1bef6d37-35e9-42a1-b639-d98e1b0e098d", "94218b4b-a2fb-436b-b3b4-5182c9e73899", "86fc53c2-a868-4d33-a9ed-075d93b87781", "a89a1efa-f638-40fe-b992-40c5c58ad062", "5a91a441-cd3f-4550-b9de-d2f4624d74d3", "cbef6859-369a-4389-ab2d-f91263fd99fd", "8627cc23-67bd-4cf9-b552-a696df26a01b", "ed55b7d9-2b14-4c6a-8b26-dcd4c0a3c7c2", "68c459fd-8105-404f-9789-9f772ba21c1e", "97bd98f5-f331-425e-a350-f56b4be5ad75", "e7401cb7-2c77-4bd6-944a-6e91f21e241c", "9d380d7e-bae9-4c51-85db-ac61d8bd551e", "a6a671e5-6179-421d-90a4-8cc707477971", "216f7b0a-bf06-45aa-a033-8a1f37150872", "2e16fb5d-b432-43de-8fe9-69d8916f6121", "f9937be4-8422-473a-a9dd-189372ff03d9", "137b4752-a439-4463-895a-c1fe8351a3d5", "6f604614-9758-42f2-9b8d-cd8d9d56c48e", "d5d27975-9d6c-4f8a-95af-c0db74b714b6", "2ea9c43d-b8cb-4523-a8dd-5303b2ae258a", "f998c9f1-27dc-45fb-b1d9-adfbe2d137c5", "520c0582-c677-4545-97fe-2d6be2132742", "624f03f0-fe03-4d9a-aad5-e185b8f9cd3d", "f987ae6b-8e91-4d14-a3c1-f07f37334c31"], "metadata": {"window": "To supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "To supplement the financial measures prepared in accordance with U.S. ", "page_label": "27", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3d6e0b73-cc92-4d68-bc7b-355227c4c0a2": {"node_ids": ["134504d0-72a0-4105-a971-06879b7bb8fd", "2262d33b-2578-4896-b25c-60b328eade6e", "c00e58af-7584-4fc8-9ec2-60b890bf8654", "591b06b4-8515-4c8e-8acf-894859120871", "78c89f36-4e4e-4dc9-92e7-3abbf0389e02", "7614b7ed-2da1-4929-a54b-a864e794e79c", "2a955e1f-bbb2-4ec8-b93a-76e7ffa5400b", "af545af1-ca7c-44cb-9c62-0030fe80d3a0", "1461c2da-1b80-45b4-bde3-5402989501a8", "d949d34f-7fa1-4853-bb99-c5a6974877b6", "22b120f3-29f1-4254-a168-a94e24086e09", "6df2a390-54bc-40b6-a76c-97e16ece3660", "fa6cddf6-2635-4130-a633-d88d57e8c3a4", "e2077b57-8c0f-48bd-830c-940df2174bd6", "96d7a2be-43e4-4ce0-ad6e-c3067fd317eb", "31718ee0-aedd-4a31-abce-42f0aa1a2bc4", "1e4ea2f0-9248-4f48-a6ff-c8e97a4789b4", "17f72d41-f5aa-4dfd-8441-72c6f967a184", "36982700-3884-4951-b74f-fb85b85f40e0", "db5af48d-bc51-41ce-b850-da948982a586", "f2eff4c6-ce3e-4868-a308-e2e8da14b93d", "97ac83a3-ceca-4043-8d89-028fddc32bc5"], "metadata": {"window": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreforms in the UK and Switzerland are excluded from adjusted income tax expense in fiscal 2021 and certain benefits relating\nto tax reform in Switzerland are excluded from adjusted income tax expense in fiscal 2022.  Management believes that this\nnon-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because\nthe adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "expense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "28", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "fa5146df-bba4-46dc-ac09-81e1f3545705": {"node_ids": ["7ec8cca9-a3f5-403c-8605-1431054280e6", "ea54393a-9105-4001-b15f-759684ef4046"], "metadata": {"window": "and cannot be reasonably estimated.\n Bennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n29", "original_text": "and cannot be reasonably estimated.\n", "page_label": "29", "file_name": "CEN-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 998710, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}